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PREFACE 
 
 The present thesis work is undertaken to develop reliable, precise and 
reproducible analytical methods for quantification of certain drugs from its single dosage 
form as well as combination dosage forms. The data is carefully analyzed and expressed 
in assorted sections. 
 
 The first section explains the importance of drug analysis for health care industry 
while the second section explains about used separation technique and process of 
analytical method validation for the same. Third section outlines the name of drugs which 
are undertaken in the present work.  
 
 The fourth section includes the work done on analytical method development, 
analytical method determination and analytical method validation for an analytical 
method which is develop for quantification purpose of Ezetimibe through assay and 
content uniformity determination. 
 
 The fifth section considers analytical method development and analytical method 
determination of the quantification methods of combination dosage forms of Ezetimibe 
with Statins (Rosuvastatin, Atorvastatin and Simvastatin) & Fibrate (Fenofibrate). The 
evaluation of the preciseness of these quantification methods is also included in this 
section. 
 
 The sixth section provides conclusion on the performed work. The seventh section 
represents the references of the current work and the eighth section provides publication 
details of the performed work.   
 
 Hence the work, in a nutshell, is an attempt to evolve analytical methods that are 
acceptable to quantify the drugs from the pharmaceutical formulations of the recent 
global market.  
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Synopsis 
 
 
1  
AIM OF WORK: 
 
The aim of the work of the thesis entitled “Studies on HPLC profile of some 
pharmaceutical compounds” is to develop analytical methods for drug quantification. It 
has been distinguish in three divisions as under: 
  
1. Selection of analytical technique for drug quantification 
2. HPLC method development,  method determination and method validation of 
dosage form of Ezetimibe 
3. HPLC method development & method determination of several combination 
dosage forms of Ezetimibe with Statins and Fibrate and precision evaluation for 
the same 
 
The research work preformed in above divisions mainly addresses development of 
stability indicating HPLC methods for drug quantification followed by validating 
method. Validation activity is carried out according to ICH guidelines with pre-defined 
acceptance criteria. The strategy for drug quantification is applicable to dosage form and 
combination dosage forms of drugs. 
 
EXPERIMENTAL WORK: 
 
  
In the present thesis, HPLC technique is used to develop analytical methods for 
drug quantification. The experimental work is performed according to following 
approach: 
 
(A) Analytical Method Development  
(B) Analytical Method Determination 
(C) Analytical Method Validation 
 
Synopsis 
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The completion of above approach is described as under: 
 
(A) Analytical Method Development 
 
The development process of an analytical method is followed systemically. It 
involves selection of various chromatographic parameters which are as under: 
 
• Selection of mobile phase   
• Selection of stationary phase 
• Selection of flow-mode  
• Optimization of flow rate 
• Choice of detection method  
• Optimization of Injection volume  
• Selection of diluent  
• Extraction process 
 
(B) Analytical Method Determination 
 
Analytical method determination is harmonized through documentation of 
Standard Testing Procedure. The parameters which are included in Standard Testing 
Procedure are as under: 
    
• Aim 
• Instrument 
• Reagents  
• Chromatographic parameters 
• Blank preparation 
• Standard preparation 
• Test preparation 
• System suitability 
• Procedure 
• Calculation   
Synopsis 
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(C)       Analytical Method Validation 
  
Analytical method validation is performed according to ICH guidelines and 
involves following parameters: 
  
• Specificity study  
• Limit of detection and Limit of quantification study 
• Linearity and range study  
• Precision study 
• Accuracy study 
• Robustness study 
• Solution stability study 
• System suitability  
 
SELECTION OF DOSAGE FORMS AND DETERMINATION METHOD: 
 
The pharmaceutical formulations undertaken for the present work are dosage form 
and combination dosage forms which are as under: 
 
• Ezetimibe 
• Ezetimibe and Rosuvastatin 
• Ezetimibe and Atorvastatin 
• Ezetimibe and Simvastatin 
• Ezetimibe, Atorvastatin and Fenofibrate  
 
The quantification of Ezetimibe is developed by means of assay and content 
uniformity determination for single dosage form (tablet).  The developed procedures has 
been evaluated over the specificity, limit of detection & limit of quantification, linearity, 
precision, accuracy, robustness, solution stability and system suitability in order to 
ascertain the validity of the analytical method. It has been proved that the developed 
procedures for assay & content uniformity quantification of Ezetimibe from its tablet 
Synopsis 
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dosage form is specific, linear, precise, accurate, robust and hence stability indicating. 
The developed method is recommended for quality control analysis to pharmaceutical 
industry. 
 
The quantification of Ezetimibe with Statins and Fibrates is also developed by 
means of assay determination of the drugs from combination dosage forms (tablet) for the 
same. In order to ascertain the preciseness of the developed methods, the same are 
evaluated for the method precision and system suitability. The developed method is 
found accurate for the quantification of Ezetimibe with Statins and Fibrates from their 
pharmaceutical formulations. The developed method is recommended for quality control 
analysis of Ezetimibe with Statins (Rosuvastatin, Atorvastatin, Simvastatin and 
Fenofibrate) to pharmaceutical industry. 
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1.0 Importance of drug analysis 
 
 
‘Health is wealth’. It is vital fact that a healthy body is desire of every 
human being. Good health is first condition to enjoy the life and all other things 
which mankind is having. Nowadays peoples are more concentrating towards 
health. Even governmental bodies of different countries and World health 
organization (WHO) are also focusing for health of human being. Health care is 
prevention, treatment and management of illness and preservation of mental and 
physical well being. Health care embraces all the goods and services designed to 
promote health including preventive, curative and palliative in interventions. The 
Health care industry is considered an industry or profession which includes 
people’s exercise of skill or judgment or providing of a service related to the 
prevention or improvement of the health of the individuals or the treatment or 
care of individuals who are injured, sick, disabled or infirm. The delivery of 
modern health care depends on an Interdisciplinary Team. 
 
The medical model of health focuses on the eradication of illness through 
diagnosis and effective treatment. A traditional view is that improvement in health 
results from advancements in medical science. Advancements in medical science 
bring varieties of medicines. Medicines are key part of the health care system. 
The numerous medicines are introducing into the world-market and also, that is 
increasing every year. These medicines are being either new entities or partial 
structural modification of the existing one. So, to evaluate quality and  efficacy of 
these medicines is also important factor. Right from the beginning of discovery of 
any medicine quality and efficacy of the same are checked by quantification 
means. Quality and efficacy are checked by either observing effect of drug on 
various animal models or analytical means. The option of animal models is not 
practically suitable for every batch of medicine as it’s require long time, high cost 
and more man-power. Later option of analytical way is more suitable, highly 
precise, safe and selective.   
 
Section-1: Importance of… 
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The analytical way deals with quality standards which are assigned for 
products to have desirable efficacy of the medicines. Sample representing any 
batch are analyzed for these standards and it is assumed that drug/medicine which 
is having such standards are having desire effect on use. Quality control is a 
concept, which strives to produce a perfect product by series of measures 
designed to prevent and eliminate errors at different stage of production. The 
decision to release or reject a product is based on one or more type of control 
action.  
 
Due to rapid growth of pharmaceutical industry during last several years, 
number of pharmaceutical formulations are enter as a part of health care system 
and thus, there has been rapid progress in the field of pharmaceutical analysis. 
Developing analytical method for newly introduced pharmaceutical formulation is 
a matter of most importance because drug or drug combination may not be 
official in any pharmacopoeias and thus, no analytical method for quantification is 
available. To check the quality standards of the medicine various analytical 
methods are used. Modern analytical techniques are playing key role in assessing 
chemical quality standards of medicine. Thus analytical techniques are required 
for fixing standards of medicines and its regular checking.  Out of all analytical 
techniques, the technique which is widely used to check the quality of drug is 
known as ‘CHROMATOGRAPHY’.       
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2.0 Chromatography 
 
In 1906, the Russian botanist M.S. Tswett reported separation of different 
colored constituents of extract of green leaves into a series of colored bands by 
allowing a solvent to percolate through column bed of powdered calcium 
carbonate1. He termed this technique as ‘chromatography’ from the Greek words 
meaning ‘color (chroma)’ and ‘writing (graphy)’. As a matter of above fact, 
chromatography owes its origin to the efforts of him. Tswett’s this technique was 
virtually unnoticed in the literature until the early 1940s, when the well-known 
paper of Martin and Synge was published2. They reported the discovery of liquid-
liquid partition chromatography, both on columns and on paper. They also 
provided a theoretical frame work for the basic chromatographic process, and they 
received the Nobel Prize in chemistry in 1952 for their work. The next major step 
that led to progress in this field was the development of gas-liquid 
chromatography by James and Martin3. The success of modern chromatography is 
greatly due to the excellent extensive treatment of chromatographic theory by 
Giddings in 1965 through his book entitled Dynamics of Chromatography4.  
Afterwards, a number of well-known scientists whose contributions are too 
numerous to be recounted here, and their work has led to the development of 
modern liquid chromatography, which is often called high-pressure or high-
performance liquid chromatography. This technique is also called as HPLC, or 
simply LC. 
General classification of chromatographic methods is as below5: 
1) Column chromatography 
2) Paper chromatography 
3) Thin-layer chromatography 
4) Gas chromatography 
5) High pressure liquid chromatography 
6) Ion-exchange chromatography 
7) Gel filtration chromatography 
8) Supercritical fluid chromatography 
Section-2: Chromatography 
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2.1 High-Performance Liquid Chromatography6,7 
 
Based on the preceding discussion, chromatography can be simply defined 
as: ‘Chromatography is the technique in which the components of a mixture are 
separated based upon the rates at which they are distributed through two phases, 
one of which does not move (stationary phase) and the other that moves (mobile 
phase)’. When mobile phase is liquid, this technique is known as ‘liquid 
chromatography’. Liquid chromatography (LC) is a method of chromatographic 
separation based on the difference in the distribution of species between two non-
miscible phases, in which the mobile phase is a liquid which percolates through a 
stationary phase contained in a column. It is mainly based on mechanisms of 
adsorption, mass distribution, ion exchange, size exclusion or stereochemical 
interaction. Early liquid chromatography is carried out in long glass columns with 
wide diameter. Now days with the help of advent of latest technology, the particle 
diameters were reduced as small as to below 10 µm with replacement of glass 
columns to steel ones. The flow rate of the mobile phase was improved by 
applying high pressure to the column using pumps and hence the performance 
was improved. This development led to be mostly called as ‘high-performance 
liquid chromatography’ or ‘high-pressure liquid chromatography’ (HPLC). 
 
HPLC is most widely used analytical separation technique that offers 
major improvements over the old chromatography.  The technique is more 
popular because it is non-destructive and may be applied to thermally liable 
compounds (unlike GC). HPLC is ideally suitable for the separation of 
macromolecules and ionic species of biomedical interest, liable natural products, 
and diverse less stable and/or high molecular weight compounds. The   majority 
of difficult separations are often more readily attained by HPLC because both 
phases used in HPLC participate in the chromatographic process (as opposed to 
only one in GC) to increase more selective interactions with the sample molecule. 
Short, small-bore columns containing densely packed particles of stationary phase 
provide for the rapid exchange of compounds between the mobile and stationary 
Section-2: Chromatography 
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phases. A large variety of unique column packings (stationary phase) provide a 
wide range of selectivity to separation through HPLC. HPLC also offers wide 
choice of detection methods as number of unique detectors are available. HPLC 
can easily be extended to trace determination of compounds which do not usually 
provide adequate detector response with the use of post-column derivatization 
methods that improve selectivity and detection limits. Facility to arrange gradient 
flow of mobile phase is often use during method development and it is also 
provide the possibility to achieve difficult separation in reduced run-time. HPLC 
contains automatic instrumentation and calculation which is carried out by 
integrator itself that offers saving of manual labor. In addition to receiving and 
reporting detector output, computers are used to control chromatographic settings 
and operations, thus providing for long periods of unattended operation. All these 
advantages make HPLC more efficient over the all remaining chromatographic 
techniques in case of separation, speed, sensitivity, easy sample recovery, 
automation, integration, handling and maintenance. The wide applicability of 
HPLC makes it as a most important separation tool in scientific the field of 
analysis. 
 
 
2.1.1    Instrumentation of HPLC 
 
A schematic instrumentation of HPLC is given through figure-1 as under: 
 
Figure-1: A schematic instrumentation of HPLC equipment 
 
 
Section-2: Chromatography 
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A liquid chromatograph consists of a reservoir containing the mobile 
phase, a pump to force the mobile phase through the system at high pressure, an 
injector to introduce the sample into the mobile phase, a chromatographic column 
(a column temperature controller may be also used) to attain retention, a detector 
to detect analyte response, and a data collection device such as a computer, 
integrator, or recorder. Further, in some cases, degasser with vacuum pump and 
pre-column facility can implement in the modern HPLC; represented as figure-2: 
 
Figure-2: Designing of HPLC path 
 
 
A brief introduction of HPLC components is given as under: 
 
(a) Pumping Systems 
 
HPLC pumping system delivers measured amounts of mobile phase from 
the solvent reservoirs to the column through high-pressure tubing and fittings. 
Operating pressures up to 5000 psi or higher, with delivery rates up to about 10 
ml/minute is typical. Pumps used for quantitative analysis should be constructed 
of materials that inert to corrosive mobile phase components and be capable of 
delivering the mobile phase at a constant rate with minimal fluctuations over 
Section-2: Chromatography 
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extended periods of time. Modern systems consist of microprocessor controlled 
metering pumps that can be programmed to deliver either constant (isocratic) flow 
of mobile phase or vary the ratio of mobile phase components, as is required for 
gradient run. Advanced pumping system is equipped with a degasser to remove 
dissolved air and other gases from the solvent through solvent delivery system.  
 
(b) Injectors 
 
After dissolution in mobile phase or suitable diluent, compounds to be 
chromatographed are injected into the mobile phase, either manually by 
syringe/loop injectors or automatically by autosampler. Autosampler consist of a 
carousel or rack to hold sample vials with tops that have a pierceable septum or 
stopper and an injection device to transfer sample from the vials to a loop from 
which it is loaded into the chromatograph. Autosampler can be programmed to 
control sample volume, the number of injections, the interval between injections 
and rinse cycles.  
 
(c) Columns8-16 
 
The column is usually made up of stainless steel to withstand high 
pressure. Columns used for analytical separations usually have 10-30 cm length 
and 4-10 mm inside diameter containing stationary phase having particle diameter 
of 3-10 µm. Particles may range up to 50 µm or more for preparative columns. 
Stationary phases for modern, reverse-phase liquid chromatography typically 
consist of an organic phase chemically bound to silica or other materials. Small 
particles thinly coated with organic phase provide for low mass transfer resistance 
and, hence, rapid transfer of compounds between the stationary and mobile 
phases. Columns may be heated to give more efficient separations, but only rarely 
are they used at temperatures above 60° C. Unmodified silica, porous graphite or 
polar chemically modified silica, e.g. cyanopropyl or diol, used as the stationary 
phase for normal-phase liquid chromatography. 
Section-2: Chromatography 
 
                                                                    
12 
Most of separations for reversed-phase liquid chromatography are based 
upon partition mechanisms that utilize chemically modified silica as the stationary 
phase and polar solvents as the mobile phase. The surface of the support, e.g. the 
silanol groups of silica, is reacted with various silane reagents to produce 
covalently bound silyl derivatives covering a varying number of active sites on 
the surface of the support. The nature of the bonded phase is an important 
parameter for determining the separation properties of the chromatographic 
system.  
 
Commonly used bonded phases are shown below:  
 
Octyl (C8)  = Si-[CH2]7-CH3     
Octadecyl (C18) = Si-[CH2]17-CH3     
Phenyl (C6H5)  = Si-[CH2] n -C6H5     
Cyanopropyl (CN) = Si-[CH2]3-CN     
Aminopropyl (NH2) = Si-[CH2]3-NH2     
Diol (OH)  = Si-[CH2]3-O-CH(OH)-CH2-OH   
 
In ion-exchange chromatography, the stationary phases are usually 
synthetic organic resins; cation-exchange resins contain negatively charged active 
sites and is used to separate basic substances, while anion-exchange resins have 
positively charged active sites for separation of compounds with negatively 
charged groups. Water-soluble ionic or ionizable compounds are attracted to the 
resins, and differences in affinity bring about the chromatographic separation.  
 
In size-exclusion chromatography, columns are packed with a porous 
stationary phase. Smaller molecules enter the pores and are increasingly retained 
as molecular size decreases. These columns are typically used to measure 
aggregation and degradation of large molecules. 
 
Section-2: Chromatography 
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For chiral chromatography, special chemically modified stationary phases, 
e.g. cellulose or amylose derivatives, proteins or peptides, cyclodextrins etc., use 
for the separation of enantiomers. 
 
(d) Detectors17-22   
 
UV/Vis spectrophotometers, including diode array detectors, are the most 
commonly employed detectors. Fluorescence spectrophotometers, differential 
refractometers, electrochemical detectors, mass spectrometers, light scattering 
detectors, radioactivity detectors or other special detectors may also be used. 
 
Detector consists of a flow-through cell mounted at the end of the column. 
A beam of UV radiation passes through the flow cell and into the detector. As 
compounds elute from the column, they pass through the cell and absorb the 
radiation, resulting in measurable energy level changes. Fixed (mercury lamp), 
variable (deuterium or high-pressure xenon lamp), and multi-wavelength 
detectors are widely available. Modern variable wavelength detectors can be 
programmed to change wavelength while an analysis is in progress. Multi-
wavelength detectors measure absorbance at two or more wavelengths 
simultaneously. In diode array multi-wavelength detectors, continuous radiation is 
passed through the sample cell, and then resolved into its constituent wavelengths, 
which are individually detected by the photodiode array. These detectors acquire 
absorbance data over the entire UV-visible range, thus providing the analyst with 
chromatograms at multiple, selectable wavelengths, spectra of the eluting peaks 
and also peak purity.  
 
Differential refractometer detectors measure the difference between the 
refractive index of the mobile phase alone and that of the mobile phase containing 
chromatographed compounds as it emerges from the column. Refractive index 
detectors are used to detect non-UV absorbing compounds. 
Section-2: Chromatography 
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Fluorometric detectors are sensitive to compounds that are inherently 
fluorescent or that can be converted to fluorescent derivatives either by chemical 
transformation of the compound or by coupling with fluorescent reagents at 
specific functional groups.  
 
Potentiometric, voltametric, or polarographic electrochemical detectors are 
useful for the quantitation of species that can be oxidized or reduced at a working 
electrode. These detectors are selective, sensitive, and reliable, but require 
conducting mobile phases free of dissolved oxygen and reducible metal ions. 
Electrochemical detectors with carbon-paste electrodes may be used 
advantageously to measure nanogram quantities of easily oxidized compounds, 
notably phenols and catechols.  
 
(e) Data Collection Devices 
 
Modern data stations receive and store detector output and print out 
chromatograms complete with peak heights, peak areas, sample identification, and 
method variables. They are also used to program the liquid chromatograph, 
controlling most of variables and providing for long periods of unattended 
operation. 
 
2.1.2 Mode of HPLC 
 
Various modes of HPLC utilized to separate compounds are classified as follows: 
 
1) Adsorption chromatography 
2) Normal-phase chromatography 
3) Reversed-phase chromatography 
4) Ion-pair chromatography 
5) Ion-exchange chromatography 
6) Size exclusion chromatography 
Section-2: Chromatography 
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1. Adsorption chromatography 
 
Adsorption chromatography uses polar stationary phases with relatively 
nonpolar mobile phases. Separations in adsorption chromatography result to a 
great extent from the interaction of sample polar functional groups with discrete 
adsorption sites on the stationary phase. Adsorption chromatography is usually 
considered appropriate for the separation of nonionic molecules that are soluble in 
organic solvents. 
 
2.   Normal-phase chromatography 
 
In HPLC, if stationary phase is more polar than the mobile phase, it is 
termed as normal-phase liquid chromatography. Polar bonded phases that have a 
diol, cyano, diethylamino, amino, or diamino functional groups are used as 
stationary phase in normal-phase chromatography. Due to lower affinity of 
nonpolar compounds to the stationary phases used, nonpolar compounds are elute 
first while polar compounds are retained for longer time. Normal-phase 
chromatography is widely applied for chiral separations. 
 
3.   Reversed-phase chromatography 
  
In HPLC, if stationary phase is less polar than the mobile phase, it is 
termed as reversed-phase liquid chromatography. In this technique, C18, C8, 
Phenyl, and cyano-propyl functional groups that chemically bonded to 
microporous silica particles are used as stationary phase. Retention in reversed-
phase chromatography occurs by nonspecific hydrophobic interactions of the 
solute with stationary phase. The ubiquitous application of reversed-phase 
chromatography arise from the fact that practically all organic molecules have 
hydrophobic regions in their structures and effectively interact with the stationary 
phase. It is estimated that over 65% (possibly as high as 90%) of all HPLC 
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separations are executed in the reversed-phase mode. The rationale for this 
includes the simplicity, versatility, and scope of the reversed-phase method23.  
 
4.   Ion-pair chromatography 
 
Ionic or partially ionic compounds can be chromatographed on reversed-
phase columns by using ion-pairing reagents. These reagents are typically long-
chain alkyl anions or cations that, when used in dilute concentrations, can increase 
the retention of analyte ions. C-5 to C-10 alkylsulfonates are commonly used for 
cationic compounds while C-5 to C-8 alkyl ammonium salts are generally used in 
the cases of anionic solutes.  
 
5.   Ion-exchange chromatography 
 
Ion-exchange chromatography is an adaptable technique used primarily 
for the separation of ionic or easily ionizable species. The stationary phase is 
characterized by the presence of charged centers having exchangeable 
counterions. Both anions and cations can be separated by choosing the suitable 
ion-exchange medium. Ion-exchange chromatography employs the dynamic 
interactions between charged solute ions and stationary phases that have 
oppositely charged groups.   
 
6.   Size exclusion chromatography 
  
 Size exclusion chromatography separates molecules according to their 
molecular mass. In Size exclusion chromatography, column is filled with material 
having precisely controlled pore sizes and the sample is simply screened or 
filtered according to its solvated molecular size. Largest molecules are eluted first 
and the smallest molecules last. This method is generally used when a mixture 
contains compounds with a molecular mass difference of at least 10%. This mode 
can be further subdivided into gel permeation chromatography (with organic 
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solvents) and gel filtration chromatography (with aqueous solvents).    
 
2.1.3  HPLC method development: 
 
A variety of patterns have been used to develop analytical separations. The 
discussion here is limited to conventional chromatographic approaches. These 
approaches are advanced and often based on intuitive judgment and the 
knowledge of the chromatographer. Where as individual approaches may exhibit 
considerable diversity, method development often follows the series of steps 
summarized below. 
 
Before starting the method development, it is need to review what is 
known about the sample. The aim of method development should also define at 
separation stage. The kinds of sample-related information that can be important 
that are nature of the sample, number of compounds present, chemical structure 
and molecular weight of the analytes, pKa values of the compounds, sample 
solubility and sample type (ionic or non-ioinic).      
 
The choice of the mode of HPLC method should be made principally from 
the properties of the sample that has been determined about molecular weight 
(MW). On the basis of the solubility of the sample in polar or nonpolar solvents, 
mode of HPLC can be select as per below flow-chart: 
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After selecting mode of HPLC, the choice of the column (stationary 
phase) should be made after thorough consideration of mode of chromatography, 
column-to-column variability, and a number of other considerations. The silica 
particles may be acquired in a variety of sizes, shapes, and degrees of porosity. In 
addition, various functional groups or polymeric layers can easily be attached to 
the silica surface, extending the usefulness of these particles for applications to 
any specific HPLC method. Sufficient time is also allowed for column 
equilibration before starting the analysis. 
 
The selection of mobile phase is very important parameter in HPLC 
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Solvent: 
Organic 
Solvent: 
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exchange
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Ion-pair
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method development as the selectivity is altered by changing the mobile phase. 
When selecting organic solvents for use in mobile phases, various physical and 
chemical properties of the solvent should be consider. Selected solvent will have 
low viscosity, be compatible with the detection system, be easily available in pure 
form, and, if possible, have low flammability and toxicity. UV cutoff values of 
solvents are also important consideration from the standpoint of detection.  
 
The term polarity concerns the ability of a sample or solvent molecule to 
interact by combination of dispersion, dipole, hydrogen boding, and dielectric 
interactions. The combination of these four intermolecular attractive forces 
constitutes the solvent polarity. Polarity is measure strength of solvent that 
affected selectivity. The changes in selectivity may be affected by making use of 
the following solvent properties: 
 
Proton acceptors: amines, ethers, sulfoxides, amides, esters, and alcohols 
Proton donors: alcohols, carboxylic acids, phenols, and chloroform 
Large dipole solvents: methylene chloride, nitrites, sulfoxides, and ketones 
 
Application of reagents such as buffers, ion-pairing reagents, or other 
modifiers (such as triethylamine) to the mobile phase is carried out to improve 
reproducibility, selectivity, or peak shape. Buffers are used primarily to regulate 
the pH and the acid-base equilibrium of the solute in the mobile phase. They may 
also be utilized to affect the retention times of ionizable compounds. The buffer 
capacity should be at maximum and should not vary in the pH range of 2 to 8 
commonly used in HPLC. The buffers should be soluble, stable, inert to analytes 
and compatible to the detector.   
 
By employing gradient elution mode, required % of the organic phase can 
be estimated rapidly. For aqueous sample mixtures, the best way to start is with 
gradient reversed phase chromatography. Gradient run can be started with 5 to 
10% organic phase (acetonitile or methanol) in the mobile phase and can be 
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increased up to 90% within 30 to 40 minutes. Separation can then be optimized by 
changing the initial mobile phase composition and the slope of the gradient 
according to the chromatogram obtained from the preliminary run. The initial 
mobile phase composition can be estimated on the basis of where the compounds 
of interest were eluted at what proportion of organic and aqueous component of 
the mobile phase. 
 
For each samples, good analytical results will be obtained by careful 
selection of the wavelength used for detection. This choice requires known UV 
spectra of the sample. If analyte standards are available, their UV spectra can be 
measured prior to HPLC method development. Alternatively, PDA detector 
permits the acquisition of UV spectra for all sample components during method 
development. The wavelength chosen for detection must provide acceptable 
response by the various analytes in the sample and there is no interference of 
baseline noise. In most cases HPLC method development is carried out with UV 
detector. Alterative detectors are required when sample have low or no UV 
absorbance.  
 
Diluent for test preparation shall be selected at initial stage of 
development on the basis of solubility of the drug. However, optimization of the 
diluent is based on its extraction efficiency, effect on peak symmetry, peak 
interference in estimation and stability of analyte in diluent. Test concentration 
and injection volume shall be set according to suitability with extraction process 
and detector response. Wherever it is necessary to filter the test preparation, filter 
compatibility shall be check for selection of proper type of filter.  
 
To finalize HPLC method development, optimization can be started only 
after obtaining preliminary chromatogram that means with more or less 
symmetrical peaks of all analytes detected in the chromatogram. By slight change 
of the mobile phase composition, the position of the peaks can be predicted within 
the range of investigation. A finalized chromatographic condition is that one in 
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which all the peaks having good theoretical plates are symmetrical and well 
separated in less run time in the produced chromatogram. With application of 
more specific column, good symmetry and resolution can be achieved. The 
parameters that are considered for good chromatographic condition and being 
optimized are:  
 
1) Resolution (R) 
2) Theoretical plates (N)  
3) Tailing factor (T) 
4) Capacity factor (k’) 
5) Selectivity (α) 
 
All above terms are explain according to figure-3 and figure-4 as below: 
 
Figure-3: Explanation for resolution, theoretical plates, capacity factor and 
selectivity 
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Figure-4: Explanation for tailing factor  
 
 
1. Resolution (R): 
 
Resolution expresses the separation of two components in a mixture that 
determined by the following equation: 
 
R = 
12
12
W+W
)t-t(2
 
 
Where by t2 and t1 are the retention times of the two components, and W2 
and W1 are the corresponding widths at the bases of the peaks obtained by 
extrapolating the relatively straight sides of the peaks to the baseline. 
 
Where electronic integrators are used, it may be convenient to determine 
the resolution, R, by the following equation: 
 
R = 
)W+W(70.1
)t-t(2
2/h2/h 12
12
 
 
Where by h/2 1W  and h/2 2W  are the width at half-height of corresponding 
peaks. For better separation, the ideal value of R is 1.5 
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2. Theoretical plates (N) 
  
The number of theoretical plates is a measure of column efficiency. It is 
expressed by following equation: 
 
N = ( )
W
t 2
16  =  ( )
2/hW
t 2
54.5  
 
Where t is retention time of the peak and W is the with for the peak. Wh/2 
is width at half-height of the peak. Value of theoretical plates, higher than 4000 is 
indicating good column performance. 
 
3. Tailing factor (T) 
 
The tailing factor (T) is a measure of peak symmetry. It is unity for 
perfectly symmetrical peak to value of 1.0 and its value increases as tailing 
becomes more pronounced. It is determined by following formula: 
 
T = 
f2
W 05.0
 
 
Where by W0.05 is width of the peak at 5% height and f is distance from 
the peak maximum to the leading edge of the peak which being measured at a 
point of 5% of the peak height from the baseline. In general, value of tailing 
factor should be less than 2.0 
 
       4. Capacity Factor (k’) 
 
 Capacity factor is the ratio of the reduced retention volume to the dead 
volume. Capacity factor is a measure of how well the sample molecule is retained 
by a column during an isocratic separation. It is determined by using following 
formula: 
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k’ = 
0
01
t
t-t
 
 
Where by t0 is the void volume of the column and t1 is the retention time 
of the corresponding peak. The ideal value of k’ ranges from 2-10.  
 
5. Selectivity (α) 
 
The selectivity is a measure of relative retention of two components in a 
mixture. Selectivity is the ratio of the capacity factors of both corresponding 
peaks. It can be calculated by following formula: 
 
α =  
01
12
t-t
t-t
 
 
Where by t0 is the void volume of the column and t1 and t2 are the 
retention times of the corresponding peak. The ideal value of α should not be less 
than 1.  
     
2.2 Analytical method validation   
 
The developed analytical procedure used to measure the quality of 
pharmaceutical products. It is necessary to assure that the performance 
characteristics of the developed analytical procedure meet the requirements for 
the intended analytical application. The procedure which provides assurance for 
the same by the means of laboratory studies is defined as method validation. 
Method validation is the process of demonstrating that analytical procedures are 
suitable for their intended use and that they support the identity, strength and 
quality, for the quantification of the drug substances and drug products. 
 
Method validation has received considerable attention in the literature and 
from industrial committees and regulatory agencies. The U.S. FDA CGMP24 
Section-2: Chromatography 
 
                                                                    
25 
states for validation for the test methods employed by the firm. The U.S. FDA has 
also proposed industry guidance for Analytical Procedures and Methods 
Validation25. ISO/IEC 17025 includes a chapter on the validation of methods26 
with list validation parameters. The ICH27 has developed a consensus text on the 
validation of analytical procedures. ICH also developed guidance with detailed 
methodology28. The U.S. EPA prepared guidance for method’s development and 
validation for the Resource Conservation and Recovery Act (RCRA)29. The 
AOAC, the EPA and other scientific organizations provide methods that are 
validated through multi-laboratory studies. The USP has published specific 
guidelines for method validation for compound evaluation30. The WHO published 
validation guidelines under the title, ‘Validation of analytical procedures used in 
the examination of pharmaceutical materials’ in the 32nd report of the WHO 
expert committee on ‘specifications for pharmaceutical preparations’. 
 
Representatives of the pharmaceutical and chemical industry have 
published papers on the validation of analytical methods. Hokanson31,32 applied 
the life cycle approach, developed for computerized systems, to the validation and 
revalidation of methods. Green33 gave a practical guide for analytical method 
validation, with a description of a set of minimum requirements for a method. 
Wegscheider34 has published procedures for method validation with a special 
focus on calibration, recovery experiments, method comparison and investigation 
of ruggedness. Seno et al.35 have described how analytical methods are validated 
in a Japanese QC laboratory. The AOAC36 has developed a Peer-Verified 
Methods validation program with detailed guidelines on exactly which parameters 
should be validated. Winslow and Meyer37 recommend the definition and 
application of a master plan for validating analytical methods. J. Breaux and 
colleagues have published a study on analytical methods development and 
validation38.  
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2.2.1  Strategy for the Validation of Methods 
 
Method development and validation are an iterative process. The influence 
of operating parameters on the performance of the method can be assessed at the 
validation stage which was not done during development/optimization stage of the 
method. The most significant point raised for validation is that the validity of a 
method can be demonstrated only through laboratory studies. It is not sufficient to 
simply review historical results; instead, laboratory studies must be conducted 
which are intended to validate the specific method, and those studies should be 
pre-planned and described in a suitable documentation. This documentation 
should clearly indicate the method's intended use and principles of operation, as 
well as the validation parameters to be studied, and a rationale for why this 
method and these parameters were chosen. It also must include pre-defined 
acceptance criteria and a description of the analytical procedure. 
 
2.2.2  Parameters for Method Validation 
  
The parameters for method validation have been defined in different 
working groups of national and international committees and are described in the 
literature. An attempt at harmonization was made for pharmaceutical applications 
through the ICH27-28. The defined validation parameters by the ICH and other 
regulatory bodies are summarized as under:  
 
a)  Specificity study 
b)  Linearity and  range study 
c)  Limit of detection and  Limit of quantitation study  
d)  Precision study  
e)  Accuracy study  
f)  Robustness study 
g)  Solution stability study  
h)  System suitability  
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A brief introduction of above parameters is as below: 
 
a) Specificity study  
   
Specificity of an analytical method is its ability to measure accurately an 
analyte in the presence of interference, such as synthetic precursors, excipients, 
enantiomers and known (or likely) degradation products that may be expected to 
be present in the sample matrix. The term specificity is also referring to selectivity 
when a number of chemical entities that may or may not be distinguished from 
each other.  
  
Specificity study should also assess interferences that may be caused by 
the matrix, e.g., urine, blood, soil, water or food. Optimized sample preparation 
can eliminate most of the matrix components, e.g. placebo. The absence of matrix 
interferences for a quantitative method should be demonstrated by the analysis of 
control matrix in specificity. An investigation of specificity should be conducted 
during the validation of identification tests, the determination of impurities and 
the assay. In order to check the interference of degradation products, analyte is 
forcely subject to chemical (acid, alkali and oxidative) and physical (thermal and 
photolytic) degradation, known as stress application. In each stress application, 
peak purity of the analyte peak is also evaluated39.  
 
b) Linearity and range study 
  
Linearity 
 
The linearity of an analytical method is its ability to elicit test results that 
are directly proportional to the concentration (amount) of analyte in samples 
within a given range. Linearity may be demonstrated directly on the test substance 
(by dilution of a standard stock solution) and/or by using separate weighings of 
synthetic mixtures of the test product components, using the proposed procedure. 
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Linearity is determined by replicate injections of 5 or more concentrations 
level within the range of 40–160 %. The response should be directly proportional 
to the concentrations of the analytes or proportional by means of a well-defined 
mathematical calculation. Linearity is evaluated graphically by plotting a graph of 
the relative responses on the y-axis and the corresponding concentrations on the 
x-axis. A linear regression equation is applied to the results to evaluate correlation 
coefficient. In addition, y-intercept, slope of the regression line and residual sum 
of squares should also calculate.  
 
Range 
  
The range of an analytical method is the interval between the upper and 
lower concentrations (amounts) of analyte in the sample (including these 
concentrations) for which it has been demonstrated that the analytical procedure 
has a suitable level of precision, accuracy and linearity. The range is normally 
expressed in the same units as the test results (e.g., percentage, parts per million) 
obtained by the analytical method. 
 
c) Limit of detection (LOD) and Limit of quantitation (LOQ) study 
 
Figure-5: Explanation for the LOD and LOQ   
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Limit of detection: 
 
The detection limit of an analytical method is the lowest amount of analyte 
in a sample which can be detected but not necessarily quantitated as an exact 
value. 
  
In chromatography, the detection limit is the injected amount that results 
in a peak with a height at least two or three times as high as the baseline noise 
level. Besides this signal/noise method, LOD can be measured by another three 
different methods; (i) visual inspection (ii) standard deviation of the blank 
response (iii) standard deviation of the response based on the slope of the 
calibration curve.  
 
Limit of quantitation: 
 
The quantitation limit of an analytical method is the lowest amount of 
analyte in a sample which can be quantitated with suitable precision and accuracy.  
 
In chromatography, the quantitation limit is the minimum injected amount 
that produces quantitative measurements in the target matrix with acceptable 
precision, typically requiring peak heights 10 to 20 times higher than the baseline 
noise. Beside this signal/noise method, LOQ can be measured by another three 
different methods; (i) visual inspection (ii) standard deviation of the response (iii) 
standard deviation of the response based on the slope of the calibration curve.  
 
d) Precision study 
  
The precision of an analytical method expresses the closeness of 
agreement (degree of scatter) between a series of measurements obtained from 
multiple sampling of the homogeneous sample under the prescribed conditions.  
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The measurement of precision of an analytical method is performed on 
replicate standard preparations and replicate sample preparations. The results for 
the same are usually expressed as the variance, standard deviation or confidence 
level of a series of measurements. Precision is performed by means of 
repeatability, reproducibility and intermediate precision (ruggedness). 
 
Repeatability: Repeatability expresses the precision under the same operating 
conditions over a short interval of time. Repeatability is also termed intra-assay 
precision.  
 
Reproducibility: Reproducibility expresses the precision between laboratories. 
The reproducibility of an analytical method is determined by analyzing aliquots 
from same homogeneous lots. 
 
Intermediate Precision: Intermediate precision expresses within-laboratories 
variations; different days, different analysts, different equipment, etc. The 
objective of intermediate precision validation is to verify that in the same 
laboratory the method will provide the same results once the development phase 
is over. The objective is also extent to verify that the method will provide the 
same results in different laboratories (ruggedness). 
 
e) Accuracy study 
  
The accuracy of the analytical method is the closeness of agreement 
between the value which is accepted either as a conventional true value or an 
accepted reference value, and the value found. The accuracy of an analytical 
method is the extent to which test results generated by the method and the true 
value agree. 
  
The true value for accuracy assessment can be assessed by analyzing a 
sample with known concentrations (e.g., a control sample or certified reference 
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material) and comparing the measured value with the true value as supplied with 
the material. If certified reference materials or control samples are not available, a 
blank sample matrix of interest can be spiked with a known concentration by 
weight or volume. After extraction of the analyte from the matrix and injection 
into the analytical instrument, its recovery can be determined by comparing the 
response of the extract with the response of the reference material dissolved in a 
pure solvent (without matrix). 
    
The ICH document on validation methodology recommends accuracy to 
be assessed using a minimum of nine determinations over a minimum of three 
concentration levels covering the specified range (e.g., three concentrations/three 
replicates each). Accuracy should be reported as percent recovery by the assay of 
known added amount of analyte in the sample or as the difference between the 
mean and the accepted true value.  
 
f) Robustness study 
 
The robustness of an analytical method is a measure of its capacity to 
remain unaffected by small, but deliberate, variations in method parameters and 
provides an indication of its reliability during normal usage.  
 
Robustness tests examine the effect that operational parameters have on 
the analysis results. For the determination of a method’s robustness, method 
parameters like pH, flow rate, column temperature, column lot or mobile phase 
composition, are varied within a realistic range, and the quantitative influence of 
the variables is determined. If the influence of the parameter is within a 
previously specified tolerance, the parameter is said to be within the method’s 
robustness range.  
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            g) Solution stability study 
 
Many solutes readily decompose prior to chromatographic investigations, 
for example, during the preparation of the sample solutions, extraction, cleanup, 
phase transfer or storage of prepared vials (in refrigerators or in an automatic 
sampler). Under these circumstances, method validation should investigate the 
stability of the analytes and standards in solution form (in analytical preparations). 
The standard and test preparations are stored up to specified period at specified 
temperature and its stability is evaluated by comparing solution preparations at 
different time intervals to that of initial. 
 
h) System suitability study 
  
In addition, prior to the start of laboratory studies to demonstrate method 
validity, some type of system suitability must be done to demonstrate that the 
analytical system is performing properly. System suitability should be determined 
by replicate analysis of the standard or reference solution. System suitability is 
considered appropriate when the RSD, theoretical plates, tailing factor and 
resolution parameters calculated on the results obtained at different time intervals, 
does not exceed more than of specified limit of the corresponding value of the 
system precision.  
 
 
2.2.3  Prior steps of Validation 
 
Prior to start method validation, validation aim should be a well-planned 
according to scientific soundness and completeness with pre-defined acceptance 
criteria. Because the type of analysis and the other information of a sample have 
so much influence on the validation, the objective and scope of the method should 
always be defined as the first step of any method validation. For an efficient 
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validation process, it is of utmost importance to specify the right validation 
parameters.  
 
Subsequent to the execution of the validation, results, conclusions and 
deviations should present in report. Provided the pre-defined acceptance criteria 
are met, and the deviations (if any) do not affect the scientific interpretation of the 
data, then the developed analytical method can be considered as valid. 
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3.0 Objective of the work  
  
The prime and specific objective of the work to develop and validate 
analytical methods for the quantification of drug from its pharmaceutical dosage 
form. This objective is further extending to combined pharmaceutical dosage 
form of the drug. The details are as under: 
  
 To develop analytical method for assay and content uniformity 
determination of Ezetimibe from pharmaceutical dosage form  
 
 To develop analytical method for assay determination of Ezetimibe and 
Rosuvastatin from their combined pharmaceutical dosage form 
 
 To develop analytical method for assay determination of Ezetimibe and 
Atorvastatin from their combined pharmaceutical dosage form 
 
 To develop analytical method for assay determination of Ezetimibe and 
Simvastatin from their combined pharmaceutical dosage form 
 
 To develop analytical method for assay determination of Ezetimibe, 
Atorvastatin and Fenofibrate from their combined pharmaceutical dosage 
form 
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4.0 Method development and validation for assay and content uniformity 
determination of Ezetimibe from its pharmaceutical dosage form 
 
4.1 Introduction to Ezetimibe  
 
4.1.1  Description 
 
Ezetimibe is chemically 1-(4-flurophenyl)-3(R)-[3-(4-flourophenyl)-3(S)- 
hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. Its molecular formula is  
C24H21F2NO3 and it has a molecular weight of 409.43 g mol-1. Its structural 
formula is as under: 
                               
F
N
O
F
OH
OH
S SR
 
 
Ezetimibe is a white crystalline powder that is practically insoluble in 
water and freely to very soluble in ethanol, methanol, and acetone40.  
 
4.1.2  Clinical pharmacology and mechanism of action 
 
Ezetimibe is the first in a new class of lipid-lowering drug, known as 
selective cholesterol absorption inhibitors (CAI), that inhibit intestinal absorption 
of cholesterol and related phytosterols41 by inhibiting absorption of dietary and 
biliary cholesterol from the intestinal lumen. The drug has been found useful for 
treatment of hyperlipoproteinemia. Ezetimibe, either as monotherapy or in 
combination with Statins (3-hydroxyl-3-methylglutaryl-coenzyme A (HMGCoA) 
reductase inhibitors)42, is used for reduction of low-density lipoproteincholesterol 
(LDL-C), total cholesterol (TC), and apolipoprotein B (Apo B) when combined 
with dietary measures for treatment of primary hypercholesterolemia. As 
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monotherapy, Ezetimibe seems to reduce overall LDL-C by 17%; in combination 
therapy with Statins it reduces LDL-C by an additional 12–20%43-48 and is useful 
for the treatment of homozygous familial hypercholesterolemia (HoFH). It also 
reduces elevated levels of sitosterol and campesterol in the treatment of 
homozygous familial sitosterolemia49. Ezetimibe, administered in combination 
with Fenofibrate, is used as adjunctive therapy to diet for the reduction of elevated 
TC, LDL-C, Apo B, and non-HDL-C (high-density lipoprotein–cholesterol) in 
patients with mixed hyperlipidemia41. 
 
Ezetimibe has a mechanism of action that differs from those of other 
classes of cholesterol-reducing compounds. A new mechanism of cholesterol-
lowering is the inhibition of intestinal cholesterol absorption by inhibiting 
absorption of dietary and biliary cholesterol from intestinal lumen. After oral 
administration, Ezetimibe is rapidly metabolized to Ezetimibe-Glucuronide. 
Ezetimibe and Ezetimibe-Glucuronide are the major drug delivered compounds in 
plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in 
plasma, respectively. Both Ezetimibe and Ezetimibe-Glucuronide are slowly 
eliminated from plasma with a half-life of approximately 22 hours. Plasma 
concentration-time profiles exhibit multiple peaks, suggesting enterohepatic 
recycling. 
 
4.1.3  Literature review 
 
The literature reviews regarding Ezetimibe suggest that analytical methods 
were reported for its determination as API and pharmaceutical formulation. Brief 
details for the same are as under:  
 
(1) Oliveira PR, Brum L Jr, Fronza M, Bernardi LS, Masiero SMK, and Dalmora 
SL have developed an analytical method based on liquid chromatography-
tandem mass spectrometry (LC-MS-MS) for the determination of Ezetimibe 
in human plasma. Ezetimibe and Etoricoxib (internal standard) were extracted 
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from the plasma by liquid-liquid extraction and separated on a C18 analytical 
column (50 × 3.0 mm I.D.) with Acetonitrile:Water (85:15, v/v) as mobile 
phase. Detection was carried out by positive electrospray ionization (ESI+) in 
multiple reaction monitoring (MRM) mode50. 
 
(2) Sistla R, Tata VSSK, Kashyap YV, Chandrasekar D, Diwan PV have 
developed reversed-phase HPLC method for assaying Ezetimibe in 
pharmaceutical dosage forms. The assay involved an isocratic elution of 
Ezetimibe in a Kromasil 100 C18 column using a mobile phase composition of 
water (pH 6.8, 0.05%, w/v 1-heptane sulfonic acid) and Acetonitrile (30:70, 
v/v). The flow rate was 0.5 ml/min and the analyte monitored at 232 nm51. 
 
(3) Singh S, Singh B, Bahuguna R, Wadhwa L, Saxena R have developed an 
analytical method with C8 column and a mobile phase composed of 
ammonium acetate buffer (0.02 M, pH adjusted to 7.0 with ammonium 
hydroxide) and Acetonitrile, which was pushed through the column in a 
gradient mode. The detection was carried out at 250 nm52. 
 
4.1.4  Aim of work 
 
Methods reported in the literature for analysis of Ezetimibe include 
determination of the drug in human plasma by LC-tandem MS50 and a reversed-
phase HPLC method for determination of the pharmaceutical form of the drug51. 
The latter report includes a limited investigation of the effect of stress; another 
briefly described study of the effect of stress used active pharmaceutical 
ingredient only52. There are no reports of methods for study of the effect of stress 
on pharmaceutical dosage forms and there is no validated LC method, which 
enables both assay and determination of content uniformity of Ezetimibe in 
pharmaceutical dosage forms. 
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The objective of this work was to develop a stability-indicating liquid 
chromatographic analytical method for assay of Ezetimibe and for determination 
of the content uniformity of a tablet formulation, to validate the method in 
accordance with ICH guidelines53, and to investigate the effect of applying 
degradative stress to the product. Reported work in the literature51 includes 
application of limited stress in which a single product seemed to be formed under 
the action of alkali. In the current work a more intensive stress study was 
performed on the pharmaceutical dosage form and showed that the drug 
decomposed into numerous products under different stress conditions. 
Accordingly, a stability- indicating method was established in which the analyte 
peak was well resolved from those of all the degradation products formed under 
all stress conditions. The stress study also furnished information about the 
percentage degradation of the drug under different stress conditions, information 
which is not reported in the literature52. 
 
The validation procedure followed the guidelines of USP 3054. The 
method was successfully used for assay of Ezetimibe and determination of the 
content uniformity of the tablet formulation. Determination of content uniformity 
is, nowadays, an important test included in USP 3054. Because there is no 
literature report of a validated analytical method for determination of the content 
uniformity of Ezetimibe in pharmaceutical dosage forms this was performed in 
the current work to enhance the imperative for the same. 
 
4.2 Analytical method development for the method of assay and content 
uniformity determination of Ezetimibe  
 
In the present work, an analytical method based on LC was developed and 
validated for assay and content uniformity determination of Ezetimibe in tablet 
formulation. The basic chromatographic conditions used for this method were 
designed to be simple and easy to use and reproduce. The analytical conditions 
were selected after testing the different parameters that influence LC analysis, 
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such as column, aqueous and organic phase for mobile phase, mobile phase 
proportion, wavelength, diluent, concentration of analyte and other 
chromatographic parameters. A C18 Phenomenex column (250 x 4.6mm) having 
5 µm particle size was used because of its advantages of high degree of retention, 
high resolution capacity,  better reproducibility, ability to produce lower back 
pressure, and low degree of tailing. For mobile phase selection, the preliminary 
trials using different compositions of mobile phases consisting of phosphate 
buffer and acetonitile gave poor peak shape. The representative chromatogram for 
the same is shown as under: 
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Above chromatogram clearly indicate that the peak is not symmetrical and 
value of theoretical plates is lower side. In focus to develop good symmetrical 
peak, phosphate buffer was replaced by water which is adjusted to acidic pH by 
orthophosphoric acid and thus, better peak shape was obtained. The representative 
chromatogram for the same is shown as under: 
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Further, the mobile phase proportion was optimized to retain analyte 
properly that provide good resolution between Ezetimibe and its degradation 
impurities obtained in alkali degradation. Proportion of acetonitrile is finalized to 
50 % of the mobile phase. A detection wavelength of 232 nm was selected by 
scanning the standard solution over the range of 190 nm to 370 nm by PDA. 
Detection at 232 nm wavelength offered high response, good linearity, and the 
best option for detection conditions. The representative spectrum for the same is 
shown as under: 
Spectrum at time 11.73 min.
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As a diluent, the mixture of water-acetonitrile-methanol (40:50:10, v/v) 
was made. Injection volume was fixed to 20 µl and the flow rate of the mobile 
phase is set to 1.0 ml/minute. On this finalized chromatographic condition, 
obtained chromatogram was having of good peak symmetry and higher theoretical 
plates. The representative chromatogram for the same is shown as under: 
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The drug substance was easily extracted from pharmaceutical dosage 
using diluent as water-acetonitrile-methanol (40:50:10, v/v). Tablet was easily 
dispersed using water and the drug substance is freely to very soluble in methanol. 
Extraction trials are finalized to keep sonication time for 30 minutes. Solutions of 
standard preparation and test preparation were found stable in diluent. By keeping 
same concentration of analyte for assay and content uniformity determination, 
validation study was clubbed in all validation parameters except precision study. 
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4.3 Analytical method validation for the method of assay determination of 
Ezetimibe  
 
4.3.1 Objective 
To perform analytical method validation of the developed chromatographic 
method for assay determination of Ezetimibe from Ezetimibe tablets. 
 
4.3.2 Scope 
This protocol is applicable to the standard testing procedure for assay 
quantification of Ezetimibe from Ezetimibe tablets developed by Department of 
Chemistry, Saurashtra University. 
 
4.3.3 Standard testing procedure 
 
Aim:  
To determine assay of Ezetimibe from Ezetimibe tablets through High 
performance liquid chromatography 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
 
Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
            Orthophosphoric acid (GR grade) 
            Water (HPLC grade) 
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Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (50:50, v/v)                              
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Water:Acetonitrile:Methanol (40:50:10, v/v) 
                       
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Stock solution: Weigh accurately about 50 mg Ezetimibe reference standard and 
transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 500 µg/ml of Ezetimibe. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is   
50 µg/ml of Ezetimibe.  
 
Test Preparation: 
Weigh accurately 20 tablets and find out the average weight. Weigh accurately 10 
tablets and transfer into 200 ml volumetric flask. Add 140 ml of diluent into the 
flask and sonicate of 30 minutes with normal hand-shaking. Cool the flask to 
room temperature and dilute to volume with diluent. Filter 10 ml of this solution 
through 0.45 µm nylon syringe filter. The concentration obtained is 500 µg/ml of 
Ezetimibe. 
 
Pipette out 5 ml of above test stock solution and transfer into 50 ml volumetric 
flask and dilute to volume with diluent. The concentration obtained is 50 µg/ml of  
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Ezetimibe. 
 
System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
analyte peak. 
• Asymmetry of the analyte peak should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the analyte peak should be more than 5000 in 
standard preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram.  
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparation in duplicate and record the chromatograms. 
• Calculate the % assay of the sample. 
 
Calculation: 
Calculate the % assay of the sample using following formula: 
 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
 
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
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4.3.4 Product Information 
(1) Name:- Ezetimibe tablets   (2) Label claim:- 10 mg 
 
4.3.5 Reason for validation 
To establish intended applicability of the developed analytical method 
 
4.3.6 Validation Approach 
Validation of analytical method will be done by using Ezetimibe tablets 10 
mg formulation to establish by laboratory studies, that the performance 
characteristic of the method meets the requirement for the intended analytical 
application. The whole experiment of validation is applicable to above mentioned 
Standard Testing Procedure for determination of assay.    
 
4.3.7 Chemicals and Reagents used in validation process 
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
            Orthophosphoric acid (GR grade) 
            Water (HPLC grade) 
 Hydrochloric acid (GR grade) 
Sodium hydroxide (GR grade) 
Hydrogen peroxide (AR grade) 
 
4.3.8 Validation Parameters 
a) Specificity study 
b) Linearity and range study 
c) Limit of detection and  Limit of quantitation study 
d) Precision study  
e) Accuracy study  
f) Robustness study 
g) Solution stability study 
h) System suitability study 
Section-4: Method development… 
 
                                                                    
46 
4.4 Validation procedure for assay determination of Ezetimibe  
 
4.4.1 Specificity study  
 
The evaluation of the specificity of the method was determined against 
placebo and stress (forced degradation) application. The interference of the 
excipients of the claimed placebo present in the pharmaceutical dosage form was 
derived from placebo solution. Further the specificity of the method toward the 
drug was established by means of the interference of the degradation products 
against drug during the forced degradation study.  
 
Blank, standard and sample preparation was prepared as per analytical method.  
 
Blank preparation:  
Diluent was used as blank. 
 
Standard preparation: 
Stock solution: 50.9 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 509 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.9 µg/ml of Ezetimibe.  
 
Test Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1010.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
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with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is about 500 µg/ml of 
Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Average weight of the tablets: 
Randomly selected 20 tablets were weighed accurately (2030.0 mg) and the mean 
weight was calculated for the same. This mean weight (101.5 mg) was used as 
average weight through out all experiments. 
 
Placebo preparation: 
Stock solution: Placebo equivalent to 10 times of average placebo weight was 
weighed (915.4 mg) and transferred into 200 ml volumetric flask.140 ml of 
diluent was added into the volumetric flask and sonicated of 30 minutes with 
normal hand-shaking. The volumetric flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter.  
 
5 ml of above placebo stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by dilute to volume with diluent.  
 
  Application of the Stress (forced degradation) Study: 
 
Stress study was carried out by application of chemical and physical 
forced degradation. To perform forced degradation study, the drug content 
equivalent to 50 mg was employed for acidic, alkaline and oxidant media and also 
for thermal and photolytic conditions. After the degradation treatments were 
Section-4: Method development… 
 
                                                                    
48 
completed, the stress content were allowed to equilibrate to room temperature and 
diluted with diluent to attain 50 µg/ml concentration. Pattern of stress 
(degradation) conditions and preparation for same was described as under:  
 
4.4.1.1 Chemical forced degradation  
 
(i) Acidic Condition 
 
Application: Acidic degradation study was performed by refluxing the drug 
content in 1 N HCl at 80˚ C for 1 hour and then the mixture was neutralized. 
 
Sample preparation for acidic degradation: 
Stock solution: 10 Tablets were accurately weighed (1016.2 mg) and transferred 
into 250 ml round bottom flask. About 20 ml of diluent was added into the round 
bottom flask and sonicated of 10 minutes with normal hand-shaking for 
dispersion the tablets. About 30 ml of 1 N HCl was added to the round bottom 
flask and the mixture was refluxed at 80˚ C for 1 hour. After, the mixture was 
cooled to room temperature and neutralized with NaOH solution. The mixture 
was transferred into 200 ml volumetric flask and diluted to volume with diluent. 
10 ml of this solution was filtered through 0.45 µm nylon syringe filter. The 
concentration obtained is about 500 µg/ml of Ezetimibe. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent. The concentration obtained is 
about 50 µg/ml of Ezetimibe. 
 
Placebo preparation and blank preparation was also performed for acidic 
degradation to identify the peaks which arise due to placebo and blank. Placebo 
and blank was subjected under same acid-stress condition as that of sample. 
Preparations are as under: 
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Placebo preparation for acidic degradation: 
 
Stock solution: Placebo equivalent to 10 times of average placebo weight was 
weighed (914.6 mg) and transferred into 250 ml round bottom flask. About 20 ml 
of diluent was added into the round bottom flask and sonicated of 10 minutes with 
normal hand-shaking. About 30 ml of 1 N HCl was added to the round bottom 
flask and the mixture was refluxed at 80˚ C for 1 hour. After, the mixture was 
cooled to room temperature and neutralized with NaOH solution. The mixture 
was transferred into 200 ml volumetric flask and diluted to volume with diluent. 
10 ml of this solution was filtered through 0.45 µm nylon syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
Blank preparation for acidic degradation: 
 
 
Stock solution: About 20 ml of diluent and about 30 ml of 1 N HCl was added 
into the round bottom flask and the mixture was refluxed at 80˚ C for 1 hour. 
After, the mixture was cooled to room temperature and neutralized with NaOH 
solution. The mixture was transferred into 200 ml volumetric flask and diluted to 
volume with diluent. 10 ml of this solution was filtered through 0.45 µm nylon 
syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
(ii) Alkaline Condition 
 
Application: Alkaline degradation study was performed by keeping the drug 
content in 0.1 N NaOH at room temperature for 90 minutes and then the mixture 
was neutralized.  
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Sample preparation for alkaline degradation: 
Stock solution: 10 Tablets were accurately weighed (1017.7 mg) and transferred 
into 200 ml volumetric flask. About 20 ml of diluent was added into the 
volumetric flask and sonicated of 10 minutes with normal hand-shaking for 
dispersion the tablets. About 80 ml of 0.1 N NaOH was added to the volumetric 
flask and the mixture was kept at room temperature up to 90 minutes. After, the 
mixture was neutralized with HCl solution and diluted to volume with diluent. 10 
ml of this solution was filtered through 0.45 µm nylon syringe filter. The 
concentration obtained is about 500 µg/ml of Ezetimibe. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent. The concentration obtained is 
about 50 µg/ml of Ezetimibe. 
 
Placebo preparation and blank preparation was also performed for alkaline 
degradation to identify the peaks which arise due to placebo and blank. Placebo 
and blank was subjected under same alkali-stress condition as that of sample. 
Preparations are as under: 
 
Placebo preparation for alkaline degradation: 
 
Stock solution: Placebo equivalent to 10 times of average placebo weight was 
weighed (917.6 mg) and transferred into 200 ml volumetric flask. About 20 ml of 
diluent was added into the volumetric flask and sonicated of 10 minutes with 
normal hand-shaking. About 80 ml of 0.1 N NaOH was added to the volumetric 
flask and the mixture was kept at room temperature up to 90 minutes. After, the 
mixture was neutralized with HCl solution and diluted to volume with diluent. 10 
ml of this solution was filtered through 0.45 µm nylon syringe filter. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
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Blank preparation for alkali degradation: 
 
Stock solution: About 20 ml of diluent and about 80 ml of 0.1 N NaOH was 
added into the 200 ml volumetric flask and the mixture was kept at room 
temperature up to 90 minutes. After, the mixture was neutralized with HCl 
solution and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
 
(iii) Oxidative Condition 
 
Application: Oxidative degradation study was performed by refluxing the drug 
content in 3% v/v H2O2 at 80˚ C for 1 hour. 
 
Sample preparation for oxidative degradation: 
Stock solution: 10 Tablets were accurately weighed (1016.2 mg) and transferred 
into 250 ml round bottom flask. About 20 ml of diluent was added into the round 
bottom flask and sonicated of 10 minutes with normal hand-shaking for 
dispersion the tablets. About 30 ml of 3% v/v H2O2 was added to the round 
bottom flask and the mixture was refluxed at 80˚C for 1 hour. After, the mixture 
was cooled to room temperature. The mixture was transferred into 200 ml 
volumetric flask and diluted to volume with diluent. 10 ml of this solution was 
filtered through 0.45 µm nylon syringe filter. The concentration obtained is about 
500 µg/ml of Ezetimibe. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent. The concentration obtained is 
about 50 µg/ml of Ezetimibe. 
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Placebo preparation and blank preparation was also performed for oxidative 
degradation to identify the peaks which arise due to placebo and blank. Placebo 
and blank was subjected under same oxidative-stress condition as that of sample. 
Preparations are as under: 
 
Placebo preparation for oxidative degradation: 
 
Stock solution: Placebo equivalent to 10 times of average placebo weight was 
weighed (914.9 mg) and transferred into 250 ml round bottom flask. About 20 ml 
of diluent was added into the round bottom flask and sonicated of 10 minutes with 
normal hand-shaking. About 30 ml of 3% v/v H2O2 was added to the round 
bottom flask and the mixture was refluxed at 80˚ C for 1 hour. After, the mixture 
was cooled to room temperature. The mixture was transferred into 200 ml 
volumetric flask and diluted to volume with diluent. 10 ml of this solution was 
filtered through 0.45 µm nylon syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
Blank preparation for oxidative degradation: 
 
Stock solution: About 20 ml of diluent and about 30 ml of 3% v/v H2O2 was 
added into the round bottom flask and the mixture was refluxed at 80˚ C for 1 
hour. After, the mixture was cooled to room temperature. The mixture was 
transferred into 200 ml volumetric flask and diluted to volume with diluent. 10 ml 
of this solution was filtered through 0.45 µm nylon syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
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4.4.1.2 Physical forced degradation 
 
(i) Thermal Condition  
 
Application: Thermal degradation study was performed by keeping the powdered 
drug content at 70˚ C for 72 hours. 
 
Sample preparation for thermal degradation: 
Stock solution: 20 Tablets were taken and then powdered. The powdered drug 
content was kept at 70˚ C for 72 hours. Thermally degraded drug content 
equivalent to 10 times of average weight was weighed (1015.7 mg) and 
transferred into 200 ml volumetric flask. About 140 ml of diluent was added into 
the volumetric flask and sonicated of 30 minutes with normal hand-shaking. 
After, the mixture was cooled to room temperature and diluted to volume. 10 ml 
of this solution was filtered through 0.45 µm nylon syringe filter. The 
concentration obtained is about 500 µg/ml of Ezetimibe. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent. The concentration obtained is 
about 50 µg/ml of Ezetimibe. 
 
Placebo preparation was also performed for thermal degradation to identify the 
peaks which arise due to placebo. Placebo was subjected under same thermal-
stress condition as that of sample. Preparation is as under: 
 
Placebo preparation for thermal degradation: 
Stock solution: Placebo equivalent to 10 times of average weight (916.4 mg) 
which was previously kept at 70˚ C for 72 hours was weighed and transferred into 
200 ml volumetric flask. About 140 ml of diluent was added into the volumetric 
flask and sonicated of 30 minutes with normal hand-shaking. After, the mixture 
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was cooled to room temperature and diluted to volume. 10 ml of this solution was 
filtered through 0.45 µm nylon syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
Blank preparation for thermal degradation: 
Diluent was used as blank. 
 
(v) Photolytic Condition  
 
Application: Photolytic degradation study was performed by exposing the 
powdered drug content in sun-light for 72 hour. 
 
Sample preparation for photolytic degradation: 
Stock solution: 20 Tablets were taken and then powdered. The powdered drug 
content was exposed to sun-light for 72 hours. Photolytically degraded drug 
content equivalent to 10 times of average weight was weighed (1016.1 mg) and 
transferred into 200 ml volumetric flask. About 140 ml of diluent was added into 
the volumetric flask and sonicated of 30 minutes with normal hand-shaking. 
After, the mixture was cooled to room temperature and diluted to volume. 10 ml 
of this solution was filtered through 0.45 µm nylon syringe filter. The 
concentration obtained is about 500 µg/ml of Ezetimibe. 
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent. The concentration obtained is 
about 50 µg/ml of Ezetimibe. 
 
Placebo preparation was also performed for photolytic degradation to identify the 
peaks which arise due to placebo. Placebo was subjected under same photolytic-
stress condition as that of sample. Preparation is as under: 
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Placebo preparation for photolytic degradation: 
Stock solution: Placebo equivalent to 10 times of average placebo weight (915.8 
mg) which was previously exposed at sun-light for 72 hours was weighed and 
transferred into 200 ml volumetric flask. About 140 ml of diluent was added into 
the volumetric flask and sonicated of 30 minutes with normal hand-shaking. 
After, the mixture was cooled to room temperature and diluted to volume. 10 ml 
of this solution was filtered through 0.45 µm nylon syringe filter.  
 
5 ml of above stock solution was pipette out and transferred into 50 ml volumetric 
flask followed by dilute to volume with diluent.  
 
Blank preparation for photolytic degradation: 
Diluent was used as blank. 
 
The peak purity index of drug in all above stress samples of test 
preparations (i.e., acidic, alkali, oxidative, thermal and photolytic) was measured 
using PDA detector. 
 
Chromatographic sequence for Specificity study is represented through Table 1: 
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Table 1: Sequence of Specificity study 
No. Description Injection 
replicate 
Remark 
1 Blank 1 
2 Standard preparation 5 
3 Test preparation 2 
4 Bracketing standard 1 
As Such 
5 Blank preparation of Acidic stress 1 
6 Placebo preparation of Acidic stress 1 
7 Test preparation of Acidic stress 2 
8 Bracketing standard 1 
Acidic 
forced 
degradation  
9 Blank preparation of Alkali stress 1 
10 Placebo preparation of Alkali stress 1 
11 Test preparation of Alkali stress 2 
12 Bracketing standard 1 
Alkali 
forced 
degradation 
13 Blank preparation of Oxidative stress 1 
14 Placebo preparation of Oxidative stress 1 
15 Test preparation of Oxidative stress 2 
16 Bracketing standard 1 
Oxidative 
forced 
degradation 
17 Blank preparation of thermal stress 1 
18 Placebo preparation of thermal stress 1 
19 Test preparation of thermal stress 2 
20 Bracketing standard 1 
Thermal 
forced 
degradation 
21 Blank preparation of photolytic stress 1 
22 Placebo preparation of photolytic stress 1 
23 Test preparation of photolytic stress 2 
24 Bracketing standard 1 
Photolytic 
forced 
degradation 
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Observation, calculation and chromatograms: 
       
Table 2: Summary of standard and test preparation 
Observation  
 
Data for Standard preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 2677187  1 2630628 
2 2673551  2 2628587 
3 2674330  Average 2629608 
4 2673621    
5 2672927    
Average 2674323    
Stdev 1676.32    
% RSD 0.06    
     
Standard weight 50.9 mg  Test weight 1010.2 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
% Assay calculation for test sample is as under: 
 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
2.1010
200
50
5
100
9.50
2674323
2629608 xxxxxx  
               = 100.4  
  
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
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          Table 3. Summary of forced degradation profile in specificity study  
 
 
 
 
 
 
 
 
Chromatogram of blank preparation of specificity study: 
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Degradation 
condition 
Peak 
purity 
Total 
Degradation, % 
Major 
impurity, % 
RRT of major 
impurity 
     
Acidic 1.0000 73.89 36.58 1.6 
Alkali 1.0000 23.87 20.74 1.6 
Oxidative 1.0000 8.75 2.05 1.6 
Thermal 1.0000 0.94 0.32 0.3 
Photolytic 1.0000 3.90 2.31 0.3 
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Chromatogram of standard preparation of specificity study: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
 
Chromatogram of test preparation of specificity study: 
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Chromatogram of acidic stress test preparation of specificity study (Zoom view): 
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Chromatogram of alkali stress test preparation of specificity study (Zoom view): 
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Chromatogram of oxidative stress test preparation of specificity study (Zoom view): 
Minutes
4 6 8 10 12 14 16 18 20 22
m
A
U
0
10
20
30
40
 
   
     
 
  
E
ze
tim
ib
e
  
  
 
 
 
Chromatogram of thermal stress test preparation of specificity study (Zoom view): 
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Chromatogram of photolytic stress test preparation of specificity study (Zoom view): 
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Acceptance criteria: 
1) There should not be any interference from blank peaks, placebo peaks and 
impurity peaks with the analyte peak in test preparation and stress test 
preparations. 
2) The peak purity of the analyte peak in standard preparation, test preparation 
and stress test preparations should be more than 0.995 
 
Results: 
1) There is no any interference of blank peaks, placebo peaks and impurity peaks 
with the analyte peak in test preparation and stress test preparations. 
2) The peak purity of the analyte peak in standard preparation, test preparation 
and stress test preparations is well with-in the acceptance criteria. 
 
Conclusion:  
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found specific. 
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4.4.2 Linearity and range study 
 
 The linearity plot was prepared with 7 concentration levels (20, 30, 40, 50, 
60, 70, and 80 µg/ml of Ezetimibe). These concentration levels were respectively 
corresponding to 40, 60, 80, 100, 120, 140, and 160% of test solution 
concentration.  
 
 Stock solution for Linearity study was prepared and further diluted to 
attain concentration of about 40, 60, 80, 100, 120, 140, and 160% of test solution 
concentration.  
 
Blank and standard preparation is prepared as per method as under: 
 
Blank preparation:  
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 50.1 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was making up with diluent. The concentration 
obtained is 501 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.1 µg/ml of Ezetimibe.  
 
Sample preparations for linearity levels are as under: 
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Stock Solution for Linearity:  
50.3 mg of Ezetimibe standard was weighed and transferred into 100 ml 
volumetric flask. About 70 ml of diluent was added into the volumetric flask and 
substance was dissolved by sonication of one minute. After, the mixture was 
diluted to volume with diluent. The concentration obtained is 503 µg/ml of 
Ezetimibe. 
 
Linearity Level 1 (40%):- 
2 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
20.12 µg/ml of Ezetimibe. 
 
Linearity Level 2 (60%):- 
3 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
30.18 µg/ml of Ezetimibe. 
 
Linearity Level 3 (80%):- 
4 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
40.24 µg/ml of Ezetimibe. 
 
Linearity Level 4 (100%):- 
5 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
50.30 µg/ml of Ezetimibe. 
 
Linearity Level 5 (120%):- 
6 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
60.36 µg/ml of Ezetimibe. 
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Linearity Level 6 (140%):- 
7 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
70.42 µg/ml of Ezetimibe. 
 
Linearity Level 7 (160%):- 
8 ml of stock solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent. The concentration obtained is 
80.48 µg/ml of Ezetimibe. 
 
For each linearity level, the solution was injected in duplicate. Linearity 
was evaluated by linear regression analysis. 
 
Chromatographic sequence for Linearity study is represented through Table 4 as 
under: 
 
Table 4: Sequence of Linearity and range study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Linearity level 1 (40 %) 2 
4 Linearity level 2 (60 %) 2 
5 Linearity level 3 (80 %) 2 
6 Linearity level 4 (100 %) 2 
7 Linearity level 5 (120 %) 2 
8 Linearity level 6 (140 %) 2 
9 Linearity level 7 (160 %) 2 
10 Bracketing standard 1 
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 Observation, calculation and chromatograms: 
 
Table 5: Summary of Linearity and range study 
 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 50.1 mg 
1 2784996  Standard potency 99.8 % 
2 2783794   
3 2778503   
4 2783355   
5 2782413   
Average 2782612   
Stdev 2477.71   
% RSD 0.09   
 
Data for Linearity Level preparations 
 
Linearity Level Replicate Area Mean area 
1 1114515 Level 1 (40 %) 2 1112406 1113461 
    
1 1689608 Level 2 (60 %) 2 1691866 1690737 
    
1 2234876 Level 3 (80 %) 2 2237897 2236387 
    
1 2804842 Level 4 (100 %) 2 2802699 2803771 
    
1 3336594 Level 5 (120 %) 2 3332086 3334340 
    
1 3894257 Level 6 (140 %) 2 3890482 3892370 
    
1 4412854 Level 7 (160 %) 2 4423602 4418228 
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 Table 6: Summary of concentration and linearity evaluation 
 
 
 
 
 
 
 
 
 
 
  
Chart 1: Evaluation of linearity  
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Linearity Level  % of Level Concentration (µg/ml) Mean area 
1 40 20.12 1113461 
2 60 30.18 1690737 
3 80 40.24 2236387 
4 100 50.30 2803771 
5 120 60.36 3334340 
6 140 70.42 3892370 
7 160 80.48 4418228 
  
Correlation co-efficient 0.9999 
Slope 54727.06 
Intercept 31412.96 
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Chromatogram of 40% Linearity level: 
Minutes
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Chromatogram of 60% Linearity level: 
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Chromatogram of 80% Linearity level: 
Minutes
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Chromatogram of 100% Linearity level: 
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Chromatogram of 120% Linearity level: 
Minutes
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Chromatogram of 140% Linearity level: 
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Chromatogram of 160% Linearity level: 
Minutes
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Acceptance criteria: 
The correlation coefficient value should not be less than 0.995 over the working 
range. 
 
Results: 
The correlation coefficient value of the analytical method is 0.9999 over the 
working range of 20 µg/ml to 80 µg/ml. 
 
Conclusion:  
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found linear. 
 
4.4.3 Limit of detection and Limit of quantitation study 
 
The limit of detection (LOD) and limit of quantitation (LOQ) were 
determined by calculating the signal to noise (S/N) ratio of the LOD preparation 
and LOQ preparation.  
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LOQ value is precised by six replicate injections and checked for linear 
response with respect to other linearity levels by extended linearity curve. 
 
For LOD and  LOQ study, blank, standard preparation, LOD preparation and 
LOQ preparation was prepared as under: 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 49.8 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 498 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 49.8 µg/ml of Ezetimibe.  
 
LOD and  LOQ preparation: 
Solution-A: 50.0 mg of Ezetimibe reference standard was accurately weighed and 
transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 500 µg/ml of Ezetimibe. 5 ml of this solution was pipette out and 
transferred into 50 ml volumetric flask followed by diluted to volume with 
diluent. The concentration obtained is 50.0 µg/ml of Ezetimibe. 5 ml of this 
solution was pipette out and transferred into 50 ml volumetric flask followed by 
diluted to volume with diluent. The concentration obtained is 5.0 µg/ml of 
Ezetimibe. This solution is designated as Solution-A. 
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LOD preparation:  
1 ml of above Solution-A was pipette out and transferred into 50 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained is 
0.1 µg/ml of Ezetimibe.  
 
LOQ preparation:  
2 ml of above Solution-A was pipette out and transferred into 50 ml volumetric 
flask followed by diluted to volume with diluent. The concentration obtained is 
0.2 µg/ml of Ezetimibe.  
 
Chromatographic sequence for LOD and  LOQ study is represented through Table 
7 as under: 
Table 7: Sequence of LOD and  LOQ study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Blank 1 
4 LOD preparation 2 
5 LOQ preparation 6 
6 Bracketing standard 1 
 
Observation, calculation and chromatograms: 
 Table 8: Summary of LOQ study 
Observation  
 
Data for Standard preparation  Data for LOQ preparation 
   
Replicate Area  Replicate Area 
1 2724800  1 10312 
2 2733707  2 10257 
3 2731324  3 10275 
4 2720542  4 10123 
5 2723842  5 11050 
Average 2726843  6 10277 
Stdev 5478.97  Average 10382 
% RSD 0.20  Stdev 333.56 
  % RSD 3.21 
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Chromatogram of LOD preparation: 
Minutes
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Chromatogram of LOQ preparation: 
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Signal-to-noise ratio calculation: 
 
For LOD preparation: 
S/N ratio = 
HeightNoise
HeightSignal  
               = 
cm0.1
cm8.3
 
               =  3.8  
 
For LOQ preparation: 
S/N ratio = 
HeightNoise
HeightSignal  
               = 
cm4.0
cm8.4
 
               = 12.0  
 
LOQ value of the analytical method is evaluated by establish linearity 
upto LOQ value. Hence linearity study is extended to LOQ value as under: 
 
Table 9: Summary of LOQ study by evaluating linearity upto LOQ concentration 
  
 
 
 
 
 
 
 
 
 
Linearity Level  % of Level Concentration (µg/ml) Mean area 
1 LOQ 0.20 10382 
2 40 20.12 1113461 
3 60 30.18 1690737 
4 80 40.24 2236387 
5 100 50.30 2803771 
6 120 60.36 3334340 
7 140 70.42 3892370 
8 160 80.48 4418228 
  
Correlation co-efficient 0.9999 
Slope 55005.75 
Intercept 15143.64 
 
Section-4: Method development… 
 
                                                                    
76 
Chart 2: Confirmation of LOQ value by extended linearity study upto LOQ level 
            
Extended Linearity study for Ezetimibe upto LOQ value
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Acceptance criteria: 
1) Signal-to-noise ratio for LOD level should not be less than 3. 
2) Signal-to-noise ratio for LOQ level should not be less than 10. 
3) % RSD of six replicate injections of LOQ level should be less than 15. 
 
Results: 
1) Signal-to-noise ratio for LOD level is 3.8 
2) Signal-to-noise ratio for LOQ level is 12.0 
3) % RSD of six replicate injections of LOQ level is 3.21 
 
Conclusion:  
All the results are well with-in the acceptance criteria. Hence, the LOD and  LOQ 
values of the analytical method are 0.1 µg/ml and 0.2 µg/ml respectively which 
correspond to 0.2 % and 0.4 % of working concentration.  
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4.4.4 Precision study 
 
Precision study was established by evaluating method precision and 
intermediate precision study. 
 
Method precision of the analytical method was determined by analyzing 
six sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard 
deviation and 95% confidence interval for the same was calculated.   
 
Intermediate precision of the analytical method was determined by 
performing method precision on another day by another analyst using different 
make of raw materials under same experimental condition. Assay of all six 
replicate sample preparations was determined and mean % assay value, standard 
deviation, % relative standard deviation and 95% confidence interval for the same 
was calculated. Overall assay value of method precision and intermediate 
precision was compared and % difference and  overall % relative standard 
deviation was calculated. 
 
For method precision, blank, standard preparation and six sets of test preparations 
was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 49.0 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 490 µg/ml of Ezetimibe. 
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5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 49.0 µg/ml of Ezetimibe.  
 
Test Preparation (Set 1): 
Test stock solution: 10 Tablets were accurately weighed (1020.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is about 500 µg/ml of 
Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 2): 
Test stock solution: 10 Tablets were accurately weighed (1024.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
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Test Preparation (Set 3): 
Test stock solution: 10 Tablets were accurately weighed (1014.0 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 4): 
Test stock solution: 10 Tablets were accurately weighed (1012.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 5): 
Test stock solution: 10 Tablets were accurately weighed (1020.0 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
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temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 6): 
Test stock solution: 10 Tablets were accurately weighed (1019.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for Method precision study is represented through 
Table 10 as under: 
Table 10: Sequence of Method precision study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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For intermediate precision, blank, standard preparation and six sets of test 
preparations was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 49.1 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 491 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 49.1 µg/ml of Ezetimibe.  
 
Test Preparation (Set 1): 
Test stock solution: 10 Tablets were accurately weighed (1017.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
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Test Preparation (Set 2): 
Test stock solution: 10 Tablets were accurately weighed (1008.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 3): 
Test stock solution: 10 Tablets were accurately weighed (1025.0 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 4): 
Test stock solution: 10 Tablets were accurately weighed (1015.4 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
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temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 5): 
Test stock solution: 10 Tablets were accurately weighed (1012.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Test Preparation (Set 6): 
Test stock solution: 10 Tablets were accurately weighed (1017.4 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
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5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for Intermediate precision study is represented 
through Table 11 as under: 
 
Table 11: Sequence of Intermediate precision study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 12: Summary of method precision study 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 49.0 mg 
1 2801242  Standard potency 99.8 % 
2 2802113   
3 2799597   
4 2805735   
5 2805914   
Average 2802920   
Stdev 2801.67   
% RSD 0.10   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2900000 1 2 2901370 2900685 1020.2 mg 
     
1 2947850 2 2 2948305 2948078 1024.8 mg 
     
1 2904173 3 2 2908177 2906175 1014.0 mg 
     
1 2911627 4 2 2926363 2918995 1012.8 mg 
     
1 2902090 5 2 2897027 2899559 1020.0 mg 
     
1 2917721 6 2 2921456 2919589 1019.8 mg 
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% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
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100 2
1  
               = 8.99 
10
5.101
5
50
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200
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2900685 xxxxxx  
               = 100.7 
 
For Set 2:- 
% Assay = xP
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               = 8.99 
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               = 101.9 
 
For Set 3:- 
% Assay = xP
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               = 8.99 
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For Set 4:- 
% Assay = xP
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               = 102.1 
 
For Set 5:- 
% Assay = xP
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W
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5
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               = 8.99 
10
5.101
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               = 100.7 
 
For Set 6:- 
% Assay = xP
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W
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5
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               = 8.99 
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               = 101.4 
 
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
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Chromatogram of standard preparation of method precision study: 
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Prototype chromatogram of test preparation (set 1) of method precision study: 
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Table 13: Summary of Intermediate precision study    
Observation  
 
Data for Standard preparation 
Replicate Area  Standard weight 49.1 mg 
1 2787178  Standard potency 99.8 % 
2 2790033   
3 2783101   
4 2785738   
5 2785229   
Average 2786256   
Stdev 2568.70   
% RSD 0.09   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2886135 1 2 2875218 2880677 1017.8 mg 
     
1 2889707 2 2 2891922 2890815 1008.2 mg 
     
1 2874049 3 2 2871206 2872628 1025.0 mg 
     
1 2887173 4 2 2886867 2887020 1015.4 mg 
     
1 2872424 5 2 2895279 2883852 1012.2 mg 
     
1 2907535 6 2 2903730 2905633 1017.4 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1   
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               = 8.99 
10
5.101
5
50
8.1017
200
50
5
100
1.49
2786256
2880677 xxxxxx  
               = 101.0 
 
For Set 2:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1008.2
200
50
5
100
1.49
2786256
2890815 xxxxxx  
               = 102.4 
 
For Set 3:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1025.0
200
50
5
100
1.49
2786256
2872628 xxxxxx  
               = 100.1 
 
For Set 4:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1015.4
200
50
5
100
1.49
2786256
2887020 xxxxxx  
               = 101.5 
 
For Set 5:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1012.2
200
50
5
100
1.49
2786256
2883852 xxxxxx  
               = 101.7 
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For Set 6:- 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1017.4
200
50
5
100
1.49
2786256
2905633 xxxxxx  
               = 102.0 
 
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
Chromatogram of standard preparation of intermediate precision study: 
Minutes
0 2 4 6 8 10 12 14
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Prototype chromatogram of test preparation (set 1) of intermediate precision 
study: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
et
im
ib
e
 
 
Table 14: Summary of Precision study 
Study Set No. Assay 
(%) 
Mean 
Assay 
(%) 
Stdev RSD 
(%) 
95% 
Confidence 
Interval 
1 100.7 
2 101.9 
3 101.5 
4 102.1 
5 100.7 
Method 
Precision 
6 101.4 
101.4 0.59 0.58 0.62 
1 101.0 
2 102.4 
3 100.1 
4 101.5 
5 101.7 
Intermediate 
Precision 
6 102.0 
101.0 0.81 0.80 0.85 
Mean 101.0 
Stdev 0.68 Overall 
RSD (%) 0.67 
 
Absolute difference between mean 
% assay values of method precision 
and  Intermediate precision = 0.4 
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Acceptance criteria: 
1) %RSD of six replicate sets of method precision study should be less than 2.0 
2) %RSD of six replicate sets of intermediate precision study should be less than 
2.0 
3) Overall %RSD of replicate sets of method and intermediate precision study 
should not be more than 2.0 
4) Absolute difference between mean % assay values of method precision and  
Intermediate precision should not be more than 2.0 
 
Results: 
1) %RSD of six replicate sets of method precision study is 0.58 
2) %RSD of six replicate sets of intermediate precision study is 0.80 
3) Overall %RSD of replicate sets of method and intermediate precision study is 
0.67 
4) Absolute difference between mean % assay values of method precision and  
Intermediate precision is 0.4 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
4.4.5 Accuracy study 
 
This parameter was determined by the recovery test. Recovery of the 
method is evaluated at 3 different concentration levels (corresponding to 50, 100, 
and 150% of test solution concentration) by addition of known amounts of 
standard to placebo preparation. For each concentration level, 3 sets were 
prepared and injected in duplicate. 
 
Blank and standard preparation is prepared as per method as under: 
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Blank preparation:  
Diluent was used as blank. 
  
Standard preparation: 
Stock solution: 49.5 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was making up with diluent. The concentration 
obtained is 495 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 49.5 µg/ml of Ezetimibe.  
 
Sample preparations for accuracy levels are as under: 
 
Accuracy level 1 (50%) – Set 1: 
Test stock solution: 50.8 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.9 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 254 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 25.4 µg/ml of Ezetimibe. 
 
  
Section-4: Method development… 
 
                                                                    
95 
Accuracy level 1 (50%) – Set 2: 
Test stock solution: 50.4 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 914.5 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 252 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 25.2 µg/ml of Ezetimibe. 
 
 Accuracy level 1 (50%) – Set 3: 
Test stock solution: 50.7 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 914.6 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 253.5 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 25.35 µg/ml of Ezetimibe. 
 
  Accuracy level 2 (100%) – Set 1: 
Test stock solution: 100.6 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.1 mg placebo 
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(equivalent of 10 average weight) was weighed and transferred into this 200 ml 
volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 503 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.3 µg/ml of Ezetimibe. 
 
 Accuracy level 2 (100%) – Set 2: 
Test stock solution: 100.8 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 914.6 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 504 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.4 µg/ml of Ezetimibe. 
 
 Accuracy level 2 (100%) – Set 3: 
Test stock solution: 100.9 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.7 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
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shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 504.5 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.45 µg/ml of Ezetimibe. 
 
 Accuracy level 3 (150%) – Set 1: 
Test stock solution: 150.4 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.2 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 752 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 75.2 µg/ml of Ezetimibe. 
  
 Accuracy level 3 (150%) – Set 2: 
Test stock solution: 150.2 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.0 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 751 µg/ml of Ezetimibe. 
Section-4: Method development… 
 
                                                                    
98 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 75.1 µg/ml of Ezetimibe. 
 
 Accuracy level 3 (150%) – Set 3: 
Test stock solution: 150.9 mg of Ezetimibe reference standard was accurately 
weighed and transferred into 200 ml volumetric flask. 915.4 mg placebo 
(equivalent of 10 average placebo weight) was weighed and transferred into this 
200 ml volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceeding for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 754.5 µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 75.45 µg/ml of Ezetimibe. 
 
Chromatographic sequence for Accuracy study is represented through Table 15 as 
under: 
 
Table 15: Sequence of Accuracy study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Accuracy Level 1 Preparation ; (Set 1) 2 
4 Accuracy Level 1 Preparation ; (Set 2) 2 
5 Accuracy Level 1 Preparation ; (Set 3) 2 
6 Accuracy Level 2 Preparation ; (Set 1) 2 
7 Accuracy Level 2 Preparation ; (Set 2) 2 
8 Accuracy Level 2 Preparation ; (Set 3) 2 
9 Accuracy Level 3 Preparation ; (Set 1) 2 
10 Accuracy Level 3 Preparation ; (Set 2) 2 
11 Accuracy Level 3 Preparation ; (Set 3) 2 
12 Bracketing standard 1 
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Observation, calculation and chromatograms: 
Table 16: Summary of accuracy study 
Observation  
 
Data for Standard preparation 
Replicate Area  Standard weight 49.5 mg 
1 2870232  Standard potency 99.8 % 
2 2871017  Standard conc. 49.5 µg/ml  
3 2872907   
4 2870484   
5 2872130   
Average 2871354   
Stdev 1133.95   
% RSD 0.04   
 
Data for Test preparations 
Accuracy Level Set No. Replicate Area Mean area 
1 1481614 1 2 1479073 1480344 
    
1 1479204 2 2 1478923 1479064 
    
1 1479737 
I (50 %) 
 
3 2 1483265 1481501 
1 2999951 1 2 3001464 3000708 
    
1 3000890 2 2 3004552 3002721 
    
1 2999563 
II (100 %) 
3 2 3000162 2999863 
1 4409716 1 2 4400094 4404905 
    
1 4404162 2 2 4403388 4403775 
    
1 4409067 
III (150 %) 
 
3 2 4417441 4413254 
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Table 17: Summary for added amount 
Accuracy 
Level 
Set 
No. 
Wt. 
taken 
(mg) 
Volume 1 
(ml) 
Volume 2 
(ml) 
Volume 
3 (ml) 
Amount 
added 
(µg/ml) 
1 50.8 200 5 50 25.40 
2 50.4 200 5 50 25.20 I (50 %) 
3 50.7 200 5 50 25.35 
 
1 100.6 200 5 50 50.30 
2 100.8 200 5 50 50.40 II (100 %) 
3 100.9 200 5 50 50.45 
 
1 150.4 200 5 50 75.20 
2 150.2 200 5 50 75.10 III (150 %) 
3 150.9 200 5 50 75.45 
 
 
Where by, Amount added (µg/ml) = 1000
3
2
1
. x
Volume
Volumex
Volume
takenWt  
 
Prototype calculation for Set-1 of Accuracy Level – I is as under: 
 
Amount added (µg/ml) = 1000
3
2
1
. x
Volume
Volumex
Volume
takenWt  
      = 1000
50
5
200
8.50 xx      
                                      = 25.4  
 
Amount added for remaining all sets is calculated as per above formula and 
recorded in Table 17.  
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Table 18: Summary for % recovery 
Accuracy 
Level 
Set 
No. 
Amount 
added 
(µg/ml) 
Amount 
found 
(µg/ml) 
Recovery
(%) 
Mean 
Recovery 
(%) 
Stdev RSD (%) 
1 25.40 25.52 100.47 
2 25.20 25.50 101.19 I (50 %) 
3 25.35 25.54 100.75 
100.80 0.36 0.36 
 
1 50.30 51.73 102.84 
2 50.40 51.76 102.70 II (100 %) 
3 50.45 51.72 102.52 
102.69 0.16 0.16 
 
1 75.20 75.94 100.98 
2 75.10 75.92 101.09 III (150 %) 
3 75.45 76.08 100.83 
100.97 0.13 0.13 
 
 
Prototype calculation for Set-1 of Accuracy Level – I is as under: 
 
Amount found (µg/ml) = .cconstandardx
npreparatiostandardofareaAverage
npreparatiotestofareaMean
 
     = 5.49
2871354
1480344
x  
     = 25.52  
 
% Recovery = 100x
addedAmount
foundAmount  
          = 100
40.25
52.25 x                    
          = 100.47  
 
Amount added for remaining all sets is calculated as per above formula and 
recorded in Table 18.  
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Prototype chromatogram of accuracy level-I (50 %): 
Minutes
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Prototype chromatogram of accuracy level-II (100 %): 
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Prototype chromatogram of accuracy level-III (150 %): 
Minutes
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Acceptance criteria: 
1) % Recovery and mean % Recovery should between 97.0 to 103.0 
2) % RSD of % Recovery of replicate sets of each level should not be more than 
2.0 
 
Results: 
1) % Recovery and mean % Recovery values found between 97.0 to 103.0 
2) % RSD of % Recovery of replicate sets of each level found less than 2.0 
 
Conclusion: 
All results are well with-in the limit. Hence,  analytical method is found accurate. 
 
4.4.6 Robustness study 
 
Robustness of the method was evaluated by assaying test solutions under 
slight but deliberate changes in analytical conditions, such as change in flow rate 
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(± 0.1 ml min-1), change in proportions of Buffer-Acetonitrile (52:48 and 48:52, 
v/v), and change in column-lot. 
 
4.4.6.1 Robust parameter: Change in Flow rate – ‘At 0.9 ml min-1 flow’ and ‘At 1.1 
ml min-1 flow’  
 
 In this parameter, analytical method was deliberately changed to flow rate. 
Sample was assayed by changing flow rate to 0.9 ml min-1 and 1.1 ml min-1 flow 
respectively. 
 
Blank preparation:  
Diluent was used as blank. 
  
Standard preparation: 
Stock solution: 50 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was making up with diluent. The concentration 
obtained is 500 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe.  
 
Test Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1020.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
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through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for Flow change parameter of Robustness study is 
represented through Table 19 as under: 
 
Table 19: Sequence of Flow change parameter of Robustness study 
Sr. No. Description Replicate Chromatographic parameter 
1 Blank  1 
2 Standard preparation 5 
3 Test Preparation 2 
4 Bracketing standard 1 
At 0.9 ml/min 
flow rate 
5 Blank  1 
6 Standard preparation 5 
7 Test Preparation 2 
8 Bracketing standard 1 
At 1.1 ml/min 
flow rate 
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Observation, calculation and chromatograms: 
 
Table 20: Summary for Flow change parameter of Robustness study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Assay calculation for flow rate change is as under: 
 
At 0.9 ml/min flow rate: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
8.1020
200
50
5
100
0.50
3100002
3183007 xxxxxx  
               = 101.9 
At 0.9 ml/min flow rate  At 1.1ml/min flow rate 
   
Data for Standard preparation  Data for Standard preparation 
   
Replicate Area  Replicate Area 
1 3093202  1 2503168 
2 3090125  2 2496820 
3 3091170  3 2502338 
4 3125283  4 2497781 
5 3100228  5 2501978 
Mean 3100002  Mean 2500417 
Stdev 14671.23  Stdev 2897.49 
% RSD 0.47  % RSD 0.12 
     
Data for Test preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 3182421  1 2563620 
2 3183593  2 2564373 
Mean 3183007  Mean 2563997 
     
Standard wt.(mg) 50.0  Standard wt.(mg) 50.0 
Test wt.(mg) 1020.8  Test wt.(mg) 1020.8 
Label claim 10  Label claim 10 
Average wt.(mg) 101.5  Average wt.(mg) 101.5 
% Assay 101.9  % Assay  101.8 
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At 1.1 ml/min flow rate: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
8.1020
200
50
5
100
0.50
2500417
2563997 xxxxxx  
               = 101.8 
 
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
  
 Chromatogram of standard preparation at 0.9 ml/min flow rate: 
Minutes
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Chromatogram of test preparation at 0.9 ml/min flow rate: 
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 Chromatogram of standard preparation at 1.1 ml/min flow rate: 
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Chromatogram of test preparation at 1.1 ml/min flow rate: 
Minutes
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4.4.6.2 Robust parameter: Change in mobile phase composition – ‘Buffer-
Acetonitrile (52:48, v/v)’ and ‘Buffer-Acetonitrile (48:52, v/v)’ 
 
 In this parameter, analytical method was deliberately changed for 
composition of mobile phase. Sample was assayed by changing mobile phase 
composition to Buffer-Acetonitrile (52:48, v/v) as aqueous component of mobile 
phase was increased and organic component was decreased in same proportion. 
Then after sample was assayed by changing mobile phase composition to Buffer-
Acetonitrile (48:52, v/v) as aqueous component of mobile phase was decreased 
and organic component was increased in same proportion.  
 
Blank preparation:  
Diluent was used as blank.  
 
Standard preparation:  
Stock solution: 50.4 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
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volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was making up with diluent. The concentration 
obtained is 504 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.4 µg/ml of Ezetimibe.  
 
Test Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1015.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is 500 µg/ml of 
Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for mobile phase composition change parameter of 
Robustness study is represented through Table 21. 
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Table 21: Sequence of mobile phase composition change parameter of Robustness 
study  
Sr. No. Description Replicate Chromatographic parameter 
1 Blank  1 
2 Standard preparation 5 
3 Test Preparation 2 
4 Bracketing standard 1 
Buffer-Acetonitrile 
 (48:52, v/v) 
5 Blank  1 
6 Standard preparation 5 
7 Test Preparation 2 
8 Bracketing standard 1 
Buffer-Acetonitrile 
 (52:48, v/v) 
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Observation, calculation and chromatograms: 
 
Table 22: Summary for mobile phase composition change parameter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Assay calculation for mobile phase composition change is as under: 
 
For mobile phase composition of Buffer-Acetonitrile (48:52, v/v): 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
2.1015
200
50
5
100
4.50
2816753
2849512 xxxxxx  
               = 101.7 
Buffer-Acetonitrile (48:52, v/v)  Buffer-Acetonitrile (52:48, v/v) 
   
Data for Standard preparation  Data for Standard preparation 
   
Replicate Area  Replicate Area 
1 2817022  1 2825466 
2 2816139  2 2805835 
3 2818778  3 2806197 
4 2814871  4 2807975 
5 2816953  5 2839509 
Mean 2816753  Mean 2816996 
Stdev 1425.82  Stdev 15009.50 
% RSD 0.05  % RSD 0.53 
     
Data for Test preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 2850600  1 2841871 
2 2848424  2 2867886 
Mean 2849512  Mean 2854879 
     
Standard wt.(mg) 50.4  Standard wt.(mg) 50.4 
Test wt.(mg) 1015.2  Test wt.(mg) 1015.2 
Label claim 10  Label claim 10 
Average wt.(mg) 101.5  Average wt.(mg) 101.5 
% Assay 101.7  % Assay  101.9 
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For mobile phase composition of Buffer-Acetonitrile (52:48, v/v): 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
2.1015
200
50
5
100
4.50
2816996
2854879 xxxxxx  
               = 101.9 
 
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
 
Chromatogram of standard preparation of Buffer-Acetonitrile (48:52, v/v): 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
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200
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 Chromatogram of test preparation of Buffer-Acetonitrile (48:52, v/v) 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
 
Chromatogram of standard preparation of Buffer-Acetonitrile (52:48, v/v): 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
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Chromatogram of test preparation of Buffer-Acetonitrile (52:48, v/v): 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
4.4.6.3 Robust parameter: Change in column lot  
 
 In this parameter, column used in analytical method was changed to 
different lot. Sample was assayed by changing the lot of column. 
 
Blank preparation:  
Diluent was used as blank. 
 
Standard preparation: 
Stock solution: 50.1 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was making up with diluent. The concentration 
obtained is 501 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.1 µg/ml of Ezetimibe.  
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Test Preparation: 
Test stock solution: 10 Tablets were accurately weighed (1011.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceeding for sonication of 30 
minutes with normal hand-shaking. Then, the flask was cooled to room 
temperature and diluted to volume with diluent. 10 ml of this solution was filtered 
through 0.45 µm nylon syringe filter. The concentration obtained is about 500 
µg/ml of Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for column change parameter of Robustness study is 
represented through Table 23 as under:  
 
Table 23: Sequence of column change parameter of Robustness study 
  
 
 
 
 
  
 
Sr. No. Description Replicate Chromatographic parameter 
1 Blank  1 
2 Standard preparation 5 
3 Test Preparation 2 
4 Bracketing standard 1 
Column change 
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Observation, calculation and chromatograms: 
 
Table 24: Summary for column change parameter of Robustness study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Assay calculation for column change is as under: 
 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
8.1011
200
50
5
100
1.50
2803577
2855343 xxxxxx  
               = 102.2 
Column Lot change 
 
Data for Standard preparation 
 
Replicate Area 
1 2800700 
2 2804678 
3 2803786 
4 2802343 
5 2806376 
Mean 2803577 
Stdev 2173.14 
% RSD 0.08 
  
Data for Test preparation 
 
Replicate Area 
1 2853872 
2 2856813 
Mean 2855343 
  
Standard wt.(mg) 50.1 
Test wt.(mg) 1011.8 
Label claim 10 
Average wt.(mg) 101.5 
% Assay  102.2 
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Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
Chromatogram of standard preparation of column change parameter 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
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ib
e
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Chromatogram of test preparation of column change parameter 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
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ib
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Table 25: Summary of robustness study 
System suitability 
parameters Robust conditions Assay (%) 
% Assay 
difference 
RT,  
minute Theoretical 
plates 
Asymmetry
      
0.9 ml/min flow  101.9 0.5  12.98 15750 1.19 
1.1 ml/min flow  101.8 0.4 10.51 14274 1.15 
Buffer-acetonitrile (48:52,v/v) 101.7 0.3 10.53 14359 1.22 
Buffer-acetonitrile (52:48,v/v) 101.9 0.5 14.19 16284 1.15 
Column (lot change)  102.2 0.8 11.80 15011 1.16 
 
% Assay difference is calculated with respect to mean value of method precision 
 
 
 Acceptance criteria: 
1) % Assay value of the sample should not differ than ± 2.0 % from the actual 
value during each robust parameter.  
2) System suitability should comply during each robust parameter. 
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Result:   
1) % Assay value of the sample is well with-in the acceptance criteria.  
2) System suitability is complies during each robust parameter. 
 
4.4.7 Solution stability study 
 
Solution stability period for the solutions of standard preparation and test 
preparation was evaluated. The solutions were stored at 5˚ C and ambient 
temperature without protection against light and tested at interval of 6, 12, 24, 36, 
and 48 h. The responses for the aged solution were evaluated using a freshly 
prepared standard solution55.  
 
 Stage of solution stability study: Initial 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 51.3 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 513 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 51.3 µg/ml of Ezetimibe.  
 
Test Preparation:  
Test stock solution: 10 Tablets were accurately weighed (1008.1 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
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volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is about 500 µg/ml of 
Ezetimibe. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is about 50 µg/ml of Ezetimibe. 
 
Chromatographic sequence for Initial stage of solution stability study is 
represented through Table 26 as under: 
 
Table 26: Sequence for Initial stage of solution stability study 
 
Sr. No. Description Replicate
1 Blank  1 
2 Standard preparation 5 
3 Test Preparation 2 
4 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
 Table 27: Summary of Initial stage of solution stability study 
 
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation 
   
Replicate Area  Replicate Area 
1 2902135  1 2814998 
2 2901226  2 2813349 
3 2900660  Average 2814174 
4 2900068    
5 2897362    
Average 2900290    
Stdev 1805.51    
% RSD 0.06    
     
Standard weight 51.3 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
%Assay of test solution at ‘Initial’ stage: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
3.51
2900290
2814174 xxxxxx  
               = 100.03  
  
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
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Chromatogram of standard preparation of Initial stage: 
Minutes
0 2 4 6 8 10 12 14
m
A
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Chromatogram of test preparation of Initial stage: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
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Stage of solution stability study: After 6 hours 
 
Blank preparation: 
Diluent was used as blank. 
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Standard preparation (freshly prepared): 
Stock solution: 50.7 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 507 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.7 µg/ml of Ezetimibe.  
 
Standard preparation (of  5˚ C) for stability: 
Standard preparation solution which is stored at 5˚ C for 6 hours was injected (and 
% RSD for the same solution was measured against initially injected standard). 
 
Standard preparation (of room temperature) for stability: 
Standard preparation solution which is stored at room temperature for 6 hours was 
injected (and % RSD for the same solution was measured against initially injected 
standard). 
 
Test Preparation (of 5˚ C) for stability: 
Test preparation solution which is stored at 5˚ C for 6 hours was injected (and 
assay for the same solution was measured against freshly prepared standard 
followed by comparison of that of initial). 
 
Test Preparation (of room temperature) for stability: 
Test preparation solution which is stored at room temperature for 6 hours was 
injected (and assay for the same solution was measured against freshly prepared 
standard followed by comparison of that of initial). 
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Chromatographic sequence for ‘After 6 hours’ stage of solution stability study is 
represented through Table 28 as under: 
 
Table 28: Sequence for ‘After 6 hours’ stage of solution stability study 
 
Sr. No. Description Replicate 
1 Blank  1 
2 Standard preparation 5 
3 Standard preparation (At 5˚ C) 2 
4 Standard preparation (At room temperature) 2 
5 Test preparation (At 5˚ C) 2 
6 Test preparation (At room temperature) 2 
7 Bracketing standard 1 
 
Observation, calculation and chromatograms: 
 
Table 29: Summary of ‘After 6 hours’ stage of solution stability study 
 
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation (at 5˚ C temperature) 
Replicate Area  Replicate Area 
1 2857361  1 2810384 
2 2859906  2 2811034 
3 2861165  Average 2810709 
4 2867835   
5 2864644  
Average 2862182  
Data for Test preparation 
(at room temperature) 
Stdev 4107.14  Replicate Area 
% RSD 0.14  1 2808649 
   2 2809183 
   Average 2808916 
    
Standard weight 50.7 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
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% Assay of Test preparation solution stored at 5˚ C temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
7.50
2862182
2810709 xxxxxx  
               = 100.06  
 
% Assay of Test preparation solution stored at room temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99x
10
5.101
x
5
50
x
1.1008
200
x
50
5
x
100
7.50
x
2862182
2808916
  
               = 99.99  
Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
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Table 30: Summary for standard solution stability at ‘After 6 hours’ stage: 
Observation  
 
Data for Standard preparation 
(at 5˚ C temperature) 
 Data for Standard preparation 
(at room temperature) 
   
Stage Replicate Area  Stage Replicate Area 
1 2902135  1 2902135 
2 2901226  2 2901226 
3 2900660  3 2900660 
4 2900068  4 2900068 
Initial 
5 2897362  
Initial 
5 2897362 
1 2899098  1 2894301 After 6 
hours 2 2906204  
After 6 
hours 2 2898904 
 Average 2900965   Average 2899237 
 Stdev 2776.36   Stdev 2678.95 
 % RSD 0.10   % RSD 0.09 
   
Stage Mean area  Stage Mean area 
Initial 2900290  Initial 2900290 
After 6 hours 2902651  After 6 hours 2896603 
Absolute 
Difference (%) 0.08 
 Absolute 
Difference (%) 0.13 
 
       
For standard preparation (at 5˚ C temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
       = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2902651100 x  
       = 0.08 
 
For standard preparation (at room temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
                  = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2896603100 x  
       = 0.13 
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Where by, 
AR = Standard mean area of respective time interval stage 
AI = Standard mean area of initial stage 
 
Chromatogram of standard preparation of ‘After 6 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
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e
 
Chromatogram of standard preparation of ‘After 6 hours stage’ at room temp.: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
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300
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e
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Chromatogram of test preparation of ‘After 6 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
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Chromatogram of test preparation of ‘After 6 hours stage’ at room temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
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300
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Stage of solution stability study: After 12 hours 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation (freshly prepared): 
Stock solution: 51 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 510 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 51 µg/ml of Ezetimibe.  
 
Standard preparation (of 5˚ C) for stability: 
Standard preparation solution which is stored at 5˚ C for 12 hours was injected 
(and % RSD for the same solution was measured against initially injected 
standard). 
 
Standard preparation (of room temperature) for stability: 
Standard preparation solution which is stored at room temperature for 12 hours 
was injected (and % RSD for the same solution was measured against initially 
injected standard). 
 
Test Preparation (of 5˚ C) for stability: 
Test preparation solution which is stored at 5˚ C for 12 hours was injected (and 
assay for the same solution was measured against freshly prepared standard 
followed by comparison of that of initial). 
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Test Preparation (of room temperature) for stability: 
Test preparation solution which is stored at room temperature for 12 hours was 
injected (and assay for the same solution was measured against freshly prepared 
standard followed by comparison of that of initial). 
 
Chromatographic sequence for ‘After 12 hours’ stage of solution stability study is 
represented through Table 31 as under: 
 
Table 31: Sequence for ‘After 12 hours’ stage of solution stability study 
 
Sr. No. Description Replicate 
1 Blank  1 
2 Standard preparation 5 
3 Standard preparation (At 5˚ C) 2 
4 Standard preparation (At room temperature) 2 
5 Test preparation (At 5˚ C) 2 
6 Test preparation (At room temperature) 2 
7 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 32: Summary of ‘After 12 hours’ stage of solution stability study  
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation (at 5˚ C temperature) 
Replicate Area  Replicate Area 
1 2880077  1 2810711 
2 2886772  2 2814680 
3 2892030  Average 2812696 
4 2885316   
5 2887232  
Average 2886285  
Data for Test preparation 
(at room temperature) 
Stdev 4290.02  Replicate Area 
% RSD 0.15  1 2805281 
   2 2810676 
   Average 2807979 
     
Standard weight 51.0 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
% Assay of Test preparation solution stored at 5˚ C temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
0.51
2886285
2812696 xxxxxx  
               = 99.88  
 
% Assay of Test preparation solution stored at room temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
0.51
2886285
2807979 xxxxxx  
               = 99.71  
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Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
Table 33: Summary for standard solution stability at ‘After 12 hours’ stage 
Observation  
 
Data for Standard preparation 
(at 5˚ C temperature) 
 Data for Standard preparation 
(at room temperature) 
   
Stage Replicate Area  Stage Replicate Area 
1 2902135  1 2902135 
2 2901226  2 2901226 
3 2900660  3 2900660 
4 2900068  4 2900068 
Initial 
5 2897362  
Initial 
5 2897362 
1 2912657  1 2884149 After 12 
hours 2 2904476  
After 12 
hours 2 2887159 
 Average 2902655   Average 2896108 
 Stdev 4905.05   Stdev 7343.88 
 % RSD 0.17   % RSD 0.25 
   
Stage Mean area  Stage Mean area 
Initial 2900290  Initial 2900290 
After 12 hours 2908567  After 12 hours 2885654 
Absolute 
Difference (%) 0.29 
 Absolute 
Difference (%) 0.50 
 
For standard preparation (at 5˚ C temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
           = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2908567100 x  
       = 0.29 
Section-4: Method development… 
 
                                                                    
134 
For standard preparation (at room temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
                  = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2885654100 x  
       = 0.50 
 
Where by, 
AR = Standard mean area of respective time interval stage 
AI = Standard mean area of initial stage 
 
Chromatogram of standard preparation of ‘After 12 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
et
im
ib
e
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Chromatogram of standard preparation of ‘After 12 hours stage’ at room 
temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
 
Chromatogram of test preparation of ‘After 12 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
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200
300
E
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e
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 Chromatogram of test preparation of ‘After 12 hours stage’ at room temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
et
im
ib
e
 
  
 
 Stage of solution stability study: After 24 hours 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation (freshly prepared): 
Stock solution: 49.3 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 493 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 49.3 µg/ml of Ezetimibe.  
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Standard preparation (of 5˚ C) for stability: 
Standard preparation solution which is stored at 5˚ C for 24 hours was injected 
(and % RSD for the same solution was measured against initially injected 
standard). 
 
Standard preparation (of room temperature) for stability: 
Standard preparation solution which is stored at room temperature for 24 hours 
was injected (and % RSD for the same solution was measured against initially 
injected standard). 
 
Test Preparation (of 5˚ C) for stability: 
Test preparation solution which is stored at 5˚ C for 24 hours was injected (and 
assay for the same solution was measured against freshly prepared standard 
followed by comparison of that of initial). 
 
Test Preparation (of room temperature) for stability: 
Test preparation solution which is stored at room temperature for 24 hours was 
injected (and assay for the same solution was measured against freshly prepared 
standard followed by comparison of that of initial). 
 
Chromatographic sequence for ‘After 24 hours’ stage of solution stability study is 
represented through Table 34 as under: 
 
Table 34: Sequence for ‘After 24 hours’ stage of solution stability study 
 
Sr. No. Description Replicate 
1 Blank  1 
2 Standard preparation 5 
3 Standard preparation (At 5˚ C) 2 
4 Standard preparation (At room temperature) 2 
5 Test preparation (At 5˚ C) 2 
6 Test preparation (At room temperature) 2 
7 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 35: Summary for ‘After 24 hours’ stage of solution stability study 
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation (at 5˚ C temperature) 
Replicate Area  Replicate Area 
1 2790226  1 2816760 
2 2795948  2 2816535 
3 2791627  Average 2816648 
4 2791489   
5 2791716  
Average 2792201  
Data for Test preparation 
(at room temperature) 
Stdev 2180.15  Replicate Area 
% RSD 0.08  1 2791101 
   2 2797839 
   Average 2794470 
    
Standard weight 49.3 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
% Assay of Test preparation solution stored at 5˚ C temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
3.49
2792201
2816648 xxxxxx  
               = 99.94  
 
% Assay of Test preparation solution stored at room temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
3.49
2792201
2794470 xxxxxx  
               = 99.16  
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Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
     Table 36: Summary for standard solution stability at ‘After 24 hours’ stage 
Observation  
 
Data for Standard preparation 
(at 5˚ C temperature) 
 Data for Standard preparation 
(at room temperature) 
   
Stage Replicate Area  Stage Replicate Area 
1 2902135  1 2902135 
2 2901226  2 2901226 
3 2900660  3 2900660 
4 2900068  4 2900068 
Initial 
5 2897362  
Initial 
5 2897362 
1 2896367  1 2873645 After 24 
hours 2 2901055  
After 24 
hours 2 2884018 
 Average 2899839   Average 2894159 
 Stdev 2144.40   Stdev 10989.86 
 % RSD 0.07   % RSD 0.38 
   
Stage Mean area  Stage Mean area 
Initial 2900290  Initial 2900290 
After 24 hours 2898711  After 24 hours 2878832 
Absolute 
Difference (%) 0.05 
 Absolute 
Difference (%) 0.74 
 
 
For standard preparation (at 5˚ C temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
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                   = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2898711100 x  
       = 0.05 
 
            For standard preparation (at room temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
       = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2878832100 x  
       = 0.74 
Where by, 
AR = Standard mean area of respective time interval stage 
AI = Standard mean area of initial stage 
 
Chromatogram of standard preparation of ‘After 24 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
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Section-4: Method development… 
 
                                                                    
141 
Chromatogram of standard preparation of ‘After 24 hours stage’ at room 
temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
 
 Chromatogram of test preparation of ‘After 24 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
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 Chromatogram of test preparation of ‘After 24 hours stage’ at room temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
  
 
Stage of solution stability study: After 36 hours 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation (freshly prepared): 
Stock solution: 50.5 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 505 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.5 µg/ml of Ezetimibe.  
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Standard preparation (of 5˚ C) for stability: 
Standard preparation solution which is stored at 5˚ C for 36 hours was injected 
(and % RSD for the same solution was measured against initially injected 
standard). 
 
Standard preparation (of room temperature) for stability: 
Standard preparation solution which is stored at room temperature for 36 hours 
was injected (and % RSD for the same solution was measured against initially 
injected standard). 
 
Test Preparation (of 5˚ C) for stability: 
Test preparation solution which is stored at 5˚ C for 36 hours was injected (and 
assay for the same solution was measured against freshly prepared standard 
followed by comparison of that of initial). 
 
Test Preparation (of room temperature) for stability: 
Test preparation solution which is stored at room temperature for 36 hours was 
injected (and assay for the same solution was measured against freshly prepared 
standard followed by comparison of that of initial). 
 
Chromatographic sequence for ‘After 36 hours’ stage of solution stability study is 
represented through Table 37 as under: 
 
Table 37: Sequence for ‘After 36 hours’ stage of solution stability study 
 
Sr. No. Description Replicate 
1 Blank  1 
2 Standard preparation 5 
3 Standard preparation (At 5˚ C) 2 
4 Standard preparation (At room temperature) 2 
5 Test preparation (At 5˚ C) 2 
6 Test preparation (At room temperature) 2 
7 Bracketing standard 1 
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Observations, calculation and chromatograms: 
 
Table 38: Summary for ‘After 36 hours’ stage of solution stability study 
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation (at 5˚ C temperature) 
Replicate Area  Replicate Area 
1 2857063  1 2818290 
2 2854169  2 2814714 
3 2854215  Average 2816502 
4 2861988   
5 2854899  
Average 2856467  
Data for Test preparation 
(at room temperature) 
Stdev 3303.32  Replicate Area 
% RSD 0.12  1 2788190 
   2 2786973 
   Average 2787582 
    
Standard weight 50.5 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
% Assay of Test preparation solution stored at 5˚ C temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
5.50
2856467
2816502 xxxxxx  
               = 100.07 
 
% Assay of Test preparation solution stored at room temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
5.50
2856467
2787582 xxxxxx  
               = 99.04  
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Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
Table 39: Summary for standard solution stability at ‘After 36 hours’ stage 
Observation  
 
Data for Standard preparation 
(at 5˚ C temperature) 
 Data for Standard preparation 
(at room temperature) 
   
Stage Replicate Area  Stage Replicate Area 
1 2902135  1 2902135 
2 2901226  2 2901226 
3 2900660  3 2900660 
4 2900068  4 2900068 
Initial 
5 2897362  
Initial 
5 2897362 
1 2898857  1 2869288 After 36 
hours 2 2903724  
After 36 
hours 2 2877686 
 Average 2900576   Average 2892632 
 Stdev 2094.15   Stdev 13382.86 
 % RSD 0.07   % RSD 0.46 
   
Stage Mean area  Stage Mean area 
Initial 2900290  Initial 2900290 
After 36 hours 2901291  After 36 hours 2873487 
Absolute 
Difference (%) 0.03 
 Absolute 
Difference (%) 0.92 
 
 
For standard preparation (at 5˚ C temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
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       = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2901291100 x  
       = 0.03 
 
            For standard preparation (at room temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
       = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2873487100 x  
       = 0.92 
 
Where by, 
AR = Standard mean area of respective time interval stage 
AI = Standard mean area of initial stage 
 
Chromatogram of standard preparation of ‘After 36 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
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A
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Chromatogram of standard preparation of ‘After 36 hours stage’ at room 
temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
E
ze
tim
ib
e
 
 
  
Chromatogram of test preparation of ‘After 36 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
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 Chromatogram of test preparation of ‘After 36 hours stage’ at room temperature: 
 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
et
im
ib
e
 
 
  
Stage of solution stability study: After 48 hours 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation (freshly prepared): 
Stock solution: 50.9 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 509 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50.9 µg/ml of Ezetimibe.  
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Standard preparation (of 5˚ C) for stability: 
Standard preparation solution which is stored at 5˚ C for 48 hours was injected 
(and % RSD for the same solution was measured against initially injected 
standard). 
 
Standard preparation (of room temperature) for stability: 
Standard preparation solution which is stored at room temperature for 48 hours 
was injected (and % RSD for the same solution was measured against initially 
injected standard). 
 
Test Preparation (of 5˚ C) for stability: 
Test preparation solution which is stored at 5˚ C for 48 hours was injected (and 
assay for the same solution was measured against freshly prepared standard 
followed by comparison of that of initial). 
 
Test Preparation (of room temperature) for stability: 
Test preparation solution which is stored at room temperature for 48 hours was 
injected (and assay for the same solution was measured against freshly prepared 
standard followed by comparison of that of initial). 
 
Chromatographic sequence for ‘After 48 hours’ stage of solution stability study is 
represented through Table 40 as under: 
 
Table 40: Sequence for ‘After 48 hours’ stage of solution stability study 
 
Sr. No. Description Replicate 
1 Blank  1 
2 Standard preparation 5 
3 Standard preparation (At 5˚ C) 2 
4 Standard preparation (At room temperature) 2 
5 Test preparation (At 5˚ C) 2 
6 Test preparation (At room temperature) 2 
7 Bracketing standard 1 
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Observations, calculation and chromatograms: 
 
Table 41: Summary for ‘After 48 hours’ stage of solution stability study 
Observation  
 
Standard Details  Test Details 
   
Data for Standard preparation  Data for Test preparation (at 5˚ C temperature) 
Replicate Area  Replicate Area 
1 2846944  1 2757505 
2 2845652  2 2758820 
3 2848059  Average 2758163 
4 2848430   
5 2858337  
Average 2849484  
Data for Test preparation 
(at room temperature) 
Stdev 5065.89  Replicate Area 
% RSD 0.18  1 2720017 
   2 2723838 
   Average 2721928 
    
Standard weight 50.9 mg  Test weight 1008.1 mg 
Standard potency 99.8 %  Label claim 10 mg 
 
 
% Assay of Test preparation solution stored at 5˚ C temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
9.50
2849484
2758163 xxxxxx  
               = 99.01  
 
% Assay of Test preparation solution stored at room temperature: 
% Assay = xP
LC
AWxx
W
xxWx
A
A
S
T
5
50200
50
5
100 2
1  
               = 8.99 
10
5.101
5
50
1.1008
200
50
5
100
9.50
2849484
2721928 xxxxxx  
               = 97.71  
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Where by, 
AT = Average area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
Table 42: Summary for standard solution stability at ‘After 48 hours’ stage 
Observation  
 
Data for Standard preparation 
(at 5˚ C temperature) 
 Data for Standard preparation 
(at room temperature) 
   
Stage Replicate Area  Stage Replicate Area 
1 2902135  1 2902135 
2 2901226  2 2901226 
3 2900660  3 2900660 
4 2900068  4 2900068 
Initial 
5 2897362  
Initial 
5 2897362 
1 2841627  1 2786973 After 48 
hours 2 2841658  
After 48 
hours 2 2856708 
 Average 2883534   Average 2877876 
 Stdev 28655.09   Stdev 43275.21 
 % RSD 0.99   % RSD 1.50 
   
Stage Mean area  Stage Mean area 
Initial 2900290  Initial 2900290 
After 48 hours 2841643  After 48 hours 2821841 
Absolute 
Difference (%) 2.02 
 Absolute 
Difference (%) 2.70 
 
 
For standard preparation (at 5˚ C temperature): 
Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
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       = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2841643100 x  
       = 2.02 
 
             For standard preparation (at room temperature): 
 Absolute Difference (%) = ⎥⎦
⎤⎢⎣
⎡− 100100 x
A
A
I
R  
        = ⎥⎦
⎤⎢⎣
⎡− 100
2900290
2821841100 x  
        = 2.70 
 
Where by, 
AR = Standard mean area of respective time interval stage 
AI = Standard mean area of initial stage 
 
Chromatogram of standard preparation of ‘After 48 hours stage’ at 5˚ C: 
Minutes
0 2 4 6 8 10 12 14
m
A
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Chromatogram of standard preparation of ‘After 48 hours stage’ at room 
temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
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 Chromatogram of test preparation of ‘After 48 hours stage’ at 5˚ C: 
Minutes
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m
A
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 Chromatogram of test preparation of ‘After 48 hours stage’ at room temperature: 
Minutes
0 2 4 6 8 10 12 14
m
A
U
0
100
200
300
Ez
et
im
ib
e
 
Table 43: Summary for solution stability study 
 
 
 
 
 
 
 
 
 
 
 
Acceptance criteria: 
1) For standard solution, absolute difference between Initial stage and value 
obtained at different time interval should be not more than ± 2.0 %. Overall % 
RSD for area between Initial stage and different time interval should be not 
more than ± 2.0.  
2) For test solution, absolute difference between Initial assay value and assay 
value obtained at different time interval should be not more than ± 2.0 %. 
Absolute difference in assay 
for standard solution, % 
Absolute difference in assay 
for test solution, % Time intervals 
At 5°C At room temperature At 5°C 
At room 
temperature 
     
After 6 hours 0.08 0.13 0.03 0.04 
After 12 hours 0.29 0.50 0.15 0.32 
After 24 hours 0.05 0.74 0.09 0.87 
After 36 hours 0.03 0.92 0.04 0.99 
After 48 hours 2.02 2.70 1.02 2.32 
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Result: Up to certain time period, 
1) For standard solution, results are well with-in the acceptance criteria. 
2) For test solution, results are well with-in the acceptance criteria. 
 
Conclusion: 
Solution stability time period for Standard solution is 36 hours at 5 °C and room 
temperature. Solution stability time period for test solution is 48 hours at 5 °C and 
36 hours at room temperature.  
  
4.4.8 System suitability study 
 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
 
 Table 44: Summary for system suitability study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
System suitability parameters 
 (In-house limit) 
% RSDa  
(NMTb 2.0) 
Theoretical plates 
(NLTc 5000) 
Asymmetry    
(NMTb 2.0) 
    
Validation parameters    
    
  Specificity 0.06 15488 1.19 
  Linearity and range  0.09 14411 1.13 
  LOD and  LOQ 0.20 14109 1.15 
  Precision  0.10 14667 1.17 
  Intermediate precision  0.09 14843 1.18 
  Accuracy 0.04 14787 1.16 
  Solution stability 0.06 14902 1.15 
  Robustness  0.12 14556 1.16 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
 
Section-4: Method development… 
 
                                                                    
156 
Acceptance criteria: 
1) Theoretical plates of the analyte peak should be more than 5000 for standard 
preparation during each validation parameter. 
2) Asymmetry of the analyte peak should be less than 2.0 for standard 
preparation during each validation parameter. 
3) RSD of peak area of five replicate standard preparations should be less than 
2.0 % during each validation parameter. 
 
Result: 
1) Theoretical plates of the analyte peak are found more than 5000 for standard 
preparation during each validation parameter. 
2) Asymmetry of the analyte peak is found less than 2.0 for standard preparation 
during each validation parameter. 
3) RSD of peak area of five replicate standard preparations should be less than 
2.0 % during each validation parameter. 
 
Conclusion: 
System suitability was found satisfactory during each validation parameter. 
Hence, system is suitable for the same. 
 
4.5     Reporting of deviation 
 
 The entire validation activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
4.6     Discussion and conclusion 
 
 The observation and result obtained for each validation parameter 
including specificity, linearity, LOD and  LOQ, precision, accuracy, robustness, 
solution stability and system suitability lies well with-in the acceptance criteria. 
Since, all the results are with-in the limit, the developed analytical method is 
considered as validated and suitable for intended use. 
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4.7 Analytical method validation for the method of content uniformity 
determination of Ezetimibe  
 
4.7.1 Objective: 
To perform analytical method validation of the developed chromatographic 
method for content uniformity determination of Ezetimibe from Ezetimibe tablets. 
 
4.7.2 Scope: 
This protocol is applicable to the standard testing procedure for content 
uniformity quantification of Ezetimibe from Ezetimibe tablets developed by 
Department of Chemistry, Saurashtra University. 
 
4.7.3 Standard testing procedure: 
 
Aim:  
To determine content uniformity of Ezetimibe from Ezetimibe tablets through 
High performance liquid chromatography. 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
 
Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
Orthophosphoric acid (GR grade) 
Water (HPLC grade) 
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Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (50:50, v/v)                              
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Water:Acetonitrile:Methanol (40:50:10, v/v) 
                       
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Stock solution: Weigh accurately about 50 mg Ezetimibe reference standard and 
transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 500 µg/ml of Ezetimibe. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
50 µg/ml of Ezetimibe.  
 
Test Preparation: 
Weigh accurately 1 tablet and transfer into 200 ml volumetric flask. Add 140 ml 
of diluent into the flask and sonicate of 30 minutes with normal hand-shaking. 
Cool the flask to room temperature and dilute to volume with diluent. Filter 10 ml 
of this solution through 0.45 µm nylon syringe filter. The concentration obtained 
is 50 µg/ml of Ezetimibe. 
Repeat the same above procedure for other nine tablets. 
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System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
analyte peak. 
• Asymmetry of the analyte peak should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the analyte peak should be more than 5000 in 
standard preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram. 
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparations in single and record the chromatograms. 
• Calculate the % content uniformity of the sample and also calculate % 
RSD for the same. 
 
Calculation: 
Calculate the % content of the tablet using following formula. 
 
% Content = xP
LC
xx
W
x
A
A
S
T 200
50
5
100
 
Where by, 
AT = Area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W = Weight taken of Ezetimibe reference standard (mg) 
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
4.7.4 Product Information: 
(1) Name:- Ezetimibe tablets   (2) Label claim:- 10 mg 
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4.7.5 Reason for validation: 
To establish intended applicability of the developed analytical method 
 
4.7.6 Validation Approach:  
Validation of analytical method will be done by using Ezetimibe tablets 10 
mg formulation to establish by laboratory studies, that the performance 
characteristic of the method meets the requirement for the intended analytical 
application.  
 
This whole experiment of validation is applicable to above mentioned 
Standard Testing Procedure for determination of content uniformity. As 
chromatographic parameters and concentration of content uniformity test are 
same as that of assay method, only precision study is performed for analytical 
method validation of content uniformity determination.   
 
4.7.7 Chemicals and Reagents used in validation process 
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
            Orthophosphoric acid (GR grade)s 
            Water (HPLC grade) 
 
4.7.8 Validation Parameters 
a) Precision study 
b) System suitability study 
 
4.8 Validation procedure for content uniformity determination of Ezetimibe  
 
4.8.1 Precision study 
 
Precision study was established by evaluating method precision and 
intermediate precision study. Method precision of the analytical method was 
determined by analyzing test preparations. Content of all test preparations was 
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determined and mean % content uniformity value, standard deviation, % relative 
standard deviation and 95% confidence interval for the same was calculated.  
  
Intermediate precision of the analytical method was determined by 
performing method precision on another day by another analyst using different 
make of raw materials under same experimental condition. Content of all test 
preparations was determined and mean % content uniformity value, standard 
deviation, % relative standard deviation and 95% confidence interval for the same 
was calculated. Overall content value of method precision and intermediate 
precision was compared and % difference and  overall % relative standard 
deviation was calculated. 
 
For method precision, blank, standard preparation and test preparations was 
prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 51.6 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 516 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 51.6 µg/ml of Ezetimibe.  
 
Test Preparation (Unit 1): 
1 Tablet was accurately weighed (99.9 mg) and transferred into 200 ml 
volumetric flask. 140 ml of diluent added into the volumetric flask. The 
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volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is about 50 µg/ml of Ezetimibe. 
Above preparation was repeated for other nine tablets. 
 
Chromatographic sequence for Method precision study is represented through 
Table 1 as under: 
 
Table 1: Sequence of Method precision study: 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Unit 1) 1 
4 Test Preparation (Unit 2) 1 
5 Test Preparation (Unit 3) 1 
6 Test Preparation (Unit 4) 1 
7 Test Preparation (Unit 5) 1 
8 Test Preparation (Unit 6) 1 
9 Test Preparation (Unit 7) 1 
10 Test Preparation (Unit 8) 1 
11 Test Preparation (Unit 9) 1 
12 Test Preparation (Unit 10) 1 
13 Bracketing standard 1 
  
For intermediate precision, blank, standard preparation and test preparations was 
prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank.  
 
Standard preparation: 
Stock solution: 51.5 mg of Ezetimibe reference standard was accurately weighed 
and transferred into 100 ml volumetric flask. 70 ml of diluent was added into the 
volumetric flask and the standard substance was dissolved by sonication for one 
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minute.  Then, volume of the flask was make up with diluent. The concentration 
obtained is 515 µg/ml of Ezetimibe. 
 
5 ml of above standard stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 51.5 µg/ml of Ezetimibe.  
 
Test Preparation (Unit 1): 
1 Tablet was accurately weighed (100.4 mg) and transferred into 200 ml 
volumetric flask. 140 ml of diluent added into the volumetric flask. The 
volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is about 50 µg/ml of Ezetimibe. 
Above preparation was repeated for other nine tablets. 
 
Chromatographic sequence for Intermediate precision study is represented 
through Table 2. 
 
Table 2: Sequence of Intermediate precision study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Unit 1) 1 
4 Test Preparation (Unit 2) 1 
5 Test Preparation (Unit 3) 1 
6 Test Preparation (Unit 4) 1 
7 Test Preparation (Unit 5) 1 
8 Test Preparation (Unit 6) 1 
9 Test Preparation (Unit 7) 1 
10 Test Preparation (Unit 8) 1 
11 Test Preparation (Unit 9) 1 
12 Test Preparation (Unit 10) 1 
13 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 3: Summary of method precision study 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 51.6 mg 
1 2768197  Standard potency 99.8 % 
2 2779313   
3 2767094   
4 2775563   
5 2768436   
Average 2771721   
Stdev 5408.75   
% RSD 0.20   
 
Data for Test preparations  
 
Unit No. Area % Assay Weight of the tablet (mg) 
1 2736272 101.7 99.9 
2 2724166 101.2 99.3 
3 2730031 101.4 101.6 
4 2747213 102.1 102.4 
5 2757922 102.5 103.3 
6 2728942 101.4 101.4 
7 2747151 102.1 101.8 
8 2734399 101.6 100.2 
9 2733805 101.6 100.3 
10 2744383 102.0 101.3 
 Mean 101.8  
 Stdev 0.40  
 % RSD 0.39  
 
 
Calculation for % Content for each unit is as under: 
 
For Unit 1:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
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              = 8.99 
10
200
50
5
100
6.51
2771721
2736272 xxxx  
                      = 101.7 
 
For Unit 2:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2724166 xxxx  
                      = 101.2 
 
For Unit 3:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2730031 xxxx  
                      = 101.4 
 
For Unit 4:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2747213 xxxx  
                      = 102.1 
 
For Unit 5:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2757922 xxxx  
                      = 102.5 
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For Unit 6:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2728942 xxxx  
                      = 101.4 
 
For Unit 7:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                        = 8.99 
10
200
50
5
100
6.51
2771721
2747151 xxxx  
                      = 102.1 
 
For Unit 8:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                       = 8.99 
10
200
50
5
100
6.51
2771721
2734399 xxxx  
                      = 101.6 
 
For Unit 9:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
6.51
2771721
2733805 xxxx  
                      = 101.6 
 
For Unit 10:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                        = 8.99 
10
200
50
5
100
6.51
2771721
2744383 xxxx  
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                      = 102.0 
Where by, 
AT = Area of Ezetimibe obtained in test preparation 
AS = Average area of Ezetimibe obtained in standard preparation 
W = Weight taken of Ezetimibe reference standard (mg) 
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
 
 Prototype chromatogram of test preparation for method precision study: 
Minutes
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Table 4: Summary of Intermediate precision study 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 51.5 mg 
1 2759154  Standard potency 99.8 % 
2 2760810   
3 2758683   
4 2762901   
5 2765190   
Average 2761348   
Stdev 2710.08   
% RSD 0.10   
 
Data for Test preparations 
 
Unit No. Area % Assay Weight of the tablet (mg) 
1 2722333 101.3 100.4 
2 2750077 102.4 102.3 
3 2720555 101.3 100.8 
4 2735428 101.8 100.7 
5 2735867 101.8 101.7 
6 2715231 101.1 101.8 
7 2724759 101.4 101.1 
8 2741880 102.1 102.4 
9 2726593 101.5 100.9 
10 2746359 102.2 101.9 
 Mean 101.7  
 Stdev 0.44  
 % RSD 0.43  
 
 
Calculation for % Content for each unit is as under: 
 
For Unit 1:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2722333 xxxx  
                     = 101.3 
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For Unit 2:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2750077 xxxx  
                     = 102.4 
 
For Unit 3:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                        = 8.99 
10
200
50
5
100
5.51
2761348
2720555 xxxx  
                      = 101.3 
 
For Unit 4:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2735428 xxxx  
                      = 101.8 
 
For Unit 5:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2735867 xxxx  
                      = 101.8 
 
For Unit 6:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2715231 xxxx  
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                      = 101.1 
 
For Unit 7:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2724759 xxxx  
                      = 101.4 
 
For Unit 8:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                  = 8.99 
10
200
50
5
100
5.51
2761348
2741880 xxxx  
                  = 102.1 
 
For Unit 9:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                        = 8.99 
10
200
50
5
100
5.51
2761348
2726593 xxxx  
                      = 101.5 
 
For Unit 10:- 
% Content = xP
LC
xxWx
A
A
S
T 200
50
5
100
 
                         = 8.99 
10
200
50
5
100
5.51
2761348
2746359 xxxx  
                      = 102.2 
 
Where by, 
AT = Area of Ezetimibe obtained in test preparation 
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AS = Average area of Ezetimibe obtained in standard preparation 
W = Weight taken of Ezetimibe reference standard (mg) 
LC = Label claim (mg) 
P = Potency of Ezetimibe reference standard (%) 
 
 
 Prototype chromatogram of test preparation of intermediate precision study: 
Minutes
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Table 5: Summary of Precision study 
Study Set No. Assay (%) 
Mean 
Assay 
(%) 
Stdev RSD (%) 
95% 
Confidence 
Interval 
1 101.7 
2 101.2 
3 101.4 
4 102.1 
5 102.5 
6 101.4 
7 102.1 
8 101.6 
9 101.6 
Method  
Precision 
10 102.0 
101.8 0.40 0.39 0.28 
1 101.3 
2 102.4 
3 101.3 
4 101.8 
5 101.8 
6 101.1 
7 101.4 
8 102.1 
9 101.5 
Intermediate 
Precision 
10 102.2 
101.7 0.44 0.43 0.31 
Mean 101.7 
Stdev 0.40 Overall 
RSD(%) 0.39 
 
Absolute Difference between mean % 
content values of method precision and 
Intermediate precision = 0.1  
 
 
Acceptance criteria: 
1) %RSD of six replicate sets of method precision study should be less than 6.0 
2) %RSD of six replicate sets of intermediate precision study should be less than 
6.0 
3) Overall %RSD of replicate sets of method and intermediate precision study 
should not be more than 6.0 
4) Absolute difference between mean % content values of method precision and  
Intermediate precision should not be more than 5.0 
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Results: 
1) %RSD of six replicate sets of method precision study is 0.39 
2) %RSD of six replicate sets of intermediate precision study is 0.43 
3) Overall %RSD of replicate sets of method and intermediate precision study is 
0.39 
4) Absolute difference between mean % content values of method precision and  
Intermediate precision is 0.1 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
4.8.2 System suitability study: 
 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
 
 Table 6: Summary for system suitability study 
  
 
 
 
 
 
 
 
 
 
 
System suitability parameters 
 (In-house limit) 
% RSDa  
(NMTb 2.0) 
Theoretical plates 
(NLTc 5000) 
Asymmetry    
(NMTb 2.0) 
    
Validation parameters 
    
  Method precision  0.20 15846 1.17 
  Intermediate precision  0.10 15548 1.12 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
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Acceptance criteria: 
1) Theoretical plates of the analyte peak should be more than 5000 for standard 
preparation during each validation parameter. 
2) Asymmetry of the analyte peak should be less than 2.0 for standard 
preparation during each validation parameter. 
3) RSD of peak area of five replicate standard preparations should be less than 
2.0 % during each validation parameter. 
 
Result: 
1) Theoretical plates of the analyte peak are found more than 5000 for standard 
preparation during each validation parameter. 
2) Asymmetry of the analyte peak is found less than 2.0 for standard preparation 
during each validation parameter. 
3) RSD of peak area of five replicate standard preparations should be less than 
2.0 % during each validation parameter. 
 
Conclusion: 
System suitability was found satisfactory during each validation parameter. 
Hence, system is suitable for the same. 
 
4.9 Reporting of deviation 
 
The entire validation activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
4.10 Discussion and conclusion 
 
The observation and result obtained for each validation parameter 
including specificity, linearity, LOD and  LOQ, precision, accuracy, robustness, 
solution stability and system suitability lies well with-in the acceptance criteria. 
Since, all the results are with-in the limit, the developed analytical method is 
considered as validated and suitable for intended use. 
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5.0 Method development and precision study for assay determination of 
Ezetimibe, Statins and  Fibrate from their combined pharmaceutical dosage 
forms 
 
5.1 Introduction to combination dosage forms of Ezetimibe with Statins and  
Fibrate  
 
5.1.1 Description of Stains and Fibrate: 
 
Hypolipidemic drugs belonging to the class of pharmaceuticals is called as 
‘Statins’. Statins are used to control hypercholesterolemia (elevated cholesterol 
levels) and to prevent cardiovascular disease. Rosuvastatin, Atorvastatin and 
Simvastatin are the compounds which fall in the category of Statins. 
 
Rosuvastatin is chemically 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
(methyl-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid. 
It is avail in its calcium salt and termed as Rosuvastatin calcium. Molecular 
formula of Rosuvastatin calcium is C44H54CaF2N6O12S2 and it has a molecular 
weight of 1001.14 g mol-1. Its structural formula is: 
 
                   
 
Rosuvastatin calcium is off-white to creamish white crystalline powder 
that is soluble in acetonitrile and slightly soluble in acetone56.  
 
Atorvastatin is chemically [R-(R*, R*)]-2-(4-fluorophenyl)-β, δ-
dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H- pyrrole-1-
heptanoic acid. It is avail in its calcium salt and termed as Atorvastatin calcium. 
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Molecular formula of Atorvastatin calcium is C66H68CaF2N4O10 and it has a 
molecular weight of 1155.36 g mol-1. Its structural formula is: 
 
                   
 
Atorvastatin calcium is a white to off-white crystalline powder that is very 
slightly soluble in water and acetonitrile, slightly soluble in ethanol (95%) and 
freely soluble in methanol57.  
 
Simvastatin is chemically (1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-
oxotetrahydro-2H-pyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-
hexahydronaphthalen-1-yl 2,2-dimethylbutanoate. Its molecular formula is 
C25H38O5 and it has a molecular weight of 418.57 g mol-1. Its structural formula 
is: 
                                               
 
Simvastatin is a white or almost white crystalline powder that is 
practically insoluble in water, very soluble in methylene chloride and freely 
soluble in alcohol58.  
 
Fenofibrate is chemically 1-methylethyl 2-[4-(4-chlorobenzoyl) phenoxy]-
2-methylpropanoate. Its molecular formula is C20H21ClO4 and it has a molecular 
weight of 360.84 g mol-1. Its structural formula is:                     
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Fenofibrate is a white or almost white crystalline powder that is practically 
insoluble in water, very soluble in methylene chloride and slightly soluble in 
alcohol59.  
 
5.1.2 Clinical pharmacology and mechanism of action of Statins and Fibrates 
 
Clinical studies have demonstrated that elevated levels of total cholesterol 
(total-C), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (Apo 
B), the major protein constituent of LDL, promote human atherosclerosis. In 
addition, decreased levels of high-density lipoprotein cholesterol (HDL-C) are 
associated with the development of atherosclerosis. Epidemiologic studies have 
established that cardiovascular morbidity and mortality vary directly with the 
level of total-C and LDL-C and inversely with the level of HDL-C. Like LDL, 
cholesterol-enriched triglyceride-rich lipoproteins, including very-low- density 
lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can 
also promote atherosclerosis. The independent effect of raising HDL-C or 
lowering triglycerides (TG) on the risk of coronary and cardiovascular morbidity 
and mortality has not been determined60. 
 
Statins are the inhibitors of 3-Hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA). HMG-CoA reductase is the rate-limiting step in cholesterol 
biosynthesis that catalyzes the conversion of HMG-CoA to mevalonate, a 
precursor of cholesterol. By inhibiting cholesterol biosynthesis, Statins lead to 
increased hepatic LDL receptor activity and accelerated clearance of circulating 
LDL. Statins inhibits hepatic synthesis of VLDL, which reduces the total number 
of VLDL and LDL particles. Statins reduces total cholesterol (total-C), LDL-C, 
Apo B, intermediate density lipoprotein cholesterol (IDL-C), non-HDL-C in 
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patients with homozygous and heterozygous familial hypercholesterolemia (FH), 
non familial forms of hypercholesterolemia, mixed dyslipidemia and 
dysbetalipoproteinemia. Statins also reduces plasma triglycerides in a dose-
dependent fashion, which is proportional to their LDL-C lowering effects [if the 
triglycerides are less than 3.9 mmol/L (<350 mg/dL). Statins have a modest HDL-
raising effect (5 to 10%)61-62.  
 
Statins currently available differ in their LDL-C reducing effect. Numbers 
of  patients have been treated with Statins for over last 8 years as a part of large 
randomized controlled clinical trials and no increase in any major noncardiac 
diseases have been seen in these individuals. Statins are the drug class of choice 
for LDL-C reduction and are by far the most widely used class of lipid-lowering 
drugs62.  
 
Fibric acid derivatieves, or fibrates, are agonists of PPARα (Peroxisome 
proliferator activated receptor α), a nuclear receptor involved in the regulation of 
carbohydrate and lipid metabolism. Fibrates stimulates LPL activity (enhancing 
triglyceride hydrolysis), reduce apoC-III synthesis (enhancing lipoprotein remnant 
clearance), and may reduce VLDL production. Fibrates are the most effective 
drugs available for reducing triglyceride levels and they also raise HDL-C levels. 
Fibrates are the drug class of choice in patients with severe hypertriglyceridemia 
[11.3 mmol/L (>1000 mg/dL)] and are a reasonable considerations in patients 
with moderate hypertriglyceridemia [4.5 to 11.3 mmol/L (400 to 1000 mg/dL)] 62.    
 
Fenofibric acid, the active metabolite of Fenofibrate, produces reductions 
in total cholesterol, LDL cholesterol, apoprotein B, total glycerides and 
triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment 
with Fenofibrate results in increases in high density lipoprotein (HDL), and 
apolipoproteins - apo AI and apo AII. The effect of fenofibric acid as seen in 
clinical practice has been explained in vitro in human hepaStocyte cultures by the 
activation of PPARα. Through this mechanism, Fenofibrate increases lipolysis 
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and elimination of triglyceriderich particles from plasma by activating lipoprotein 
lipase and reducing production of apoprotein C-III. The resulting produces larger 
particles which have a greater affinity for cholesterol receptors and are 
catabolized rapidly. Activation of PPARα also induces an increase in the 
synthesis of apoproteins A-I, A-II, and HDL-Cholesterol. Fenofibrate also reduces 
serum uric acid levels in hyperuricemic and normal individuals by increasing the 
urinary excretions of uric acid63.   
 
The relative successful indications of Ezetimibe with Statins and Fibrate in 
the role of combined therapy are being determined by clinical trials also64-84.  
 
5.1.3 Literature review 
 
The literature reviews regarding combined dosage forms of Ezetimibe 
suggest that analytical methods were reported for its simultaneous determination 
as combined pharmaceutical formulation with Statins. Brief details for the same 
are as under:  
 
(1) Rajkondawar V. V. developed an analytical method based on reversed-phase 
liquid chromatography for the simultaneous determination of Ezetimibe and 
Rosuvastatin. Separation was achieved on a C18 analytical column (150 × 4.6 
mm i.d.) with mobile phase consisting of 50 mM KH2PO4 buffer-acetonitrile 
(55:45, v/v). The flow rate was 1.0 ml/min and the analyte monitored at 235 
nm85.   
 
(2) Syed S. Q., Syed N. R., Islam U. K., Muhammad A. and Zeba A. S. have 
developed reversed-phase HPLC method for the simultaneous quantitation of 
Ezetimibe and Atorvastatin in pharmaceutical formulations. The 
chromatographic separation involved an elution on a Hypersil phenyl-2 
column (250 × 4.6 mm i.d.) using a mobile phase composition of 0.1 M 
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ammonium acetate (pH 6.5) and acetonitrile (28:72, v/v). Eluent was 
monitored by absorbance at 242 nm86. 
 
(3) Chaudhari B. G., Patel N. M., Shah P. B., Patel L. J. and Patel V. P. have 
developed an analytical method on LiChrospher 100 C18 column and a mobile 
phase composed of acetonitrile-water-methanol (45:40:15, v/v/v) with 
apparent pH to 4.0; flow rate was 1.0 ml/min and UV detection was carried 
out at 250 nm. The proposed method was useful for simultaneous 
determination for Ezetimibe and Atorvastatin in combine pharmaceutical 
dosage forms 87. 
 
(4) Unnam S. and Chandrasekhar B. K. have developed an analytical method by 
revered-phase HPLC for simultaneous determination of Ezetimibe and 
Atorvastatin using 0.01 M ammonium acetate buffer (pH 3.0)-acetonitrile 
(50:50, v/v) as mobile phase. The detection was monitored at 254 nm88.   
 
(5) N. Ozaltin and E. Ucakturk have developed an analytical method through 
liquid chromatography for simultaneous determination of Ezetimibe and 
Simvastatin. The chromatographic separation was achieved on C8 column 
(200 × 4.6 mm i.d.) by   application of dual-mode solvent through gradient 
pattern. The developed method was successfully applied to pharmaceutical 
formulations89. 
 
(6) Chaudhari B. G., Patel N. M., Shah P. B. have developed an analytical method 
through the reversed-phase liquid chromatography for simultaneous 
determination of Ezetimibe and Simvastatin in pharmaceutical dosage forms. 
The proposed method utilizes a LiChrospher 100 C18 column (250 × 4.6 mm 
i.d.) and mobile phase consisting of acetonitrile-water-methanol (60:25:15, 
v/v/v) of apparent pH of 4.0 ; flow rate was 1.5 ml/min and detection was 
monitored at 238 nm90.  
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(7) Oliveira P. R., Barth T., Todeschini V., and Dalmora S. L. have developed an 
analytical method for simultaneous determination of Ezetimibe and 
Simvastatin in pharmaceutical dosage forms. A reversed-phase liquid 
chromatographic separation was achieved on a Synergi fusion C18 column 
using mobile phase consisting of 0.03 M phosphate buffer (pH 4.5)-
acetonitrile (35:65, v/v). The flow rate was 0.6 ml/min and detection was 234 
nm by PDA91.                                       
 
5.1.4 Aim of work 
 
Methods reported in the literature for analysis of Ezetimibe with Statins 
have reversed-phase HPLC technique for the determination of the drug in 
combined pharmaceutical form. All analytical methods are differing in stationary 
phases, components of mobile phase, flow rate and detection pattern. There is no 
similarity in these methods as those are differ according to its combined dosage 
form with different type of Statin (i.e. Rosuvastatin, Atorvastatin and 
Simvastatin). The aim of present work is to develop such type of analytical 
methods that are similar in stationary phase, components of mobile phase, flow 
rate and detection pattern and able to determine the combined pharmaceutical 
dosage forms of Ezetimibe with mentioned type of Statins. The advantage of 
these newly developed analytical methods is that different combination dosage 
forms of Statins with Ezetimibe will be analyzed simultaneously on a single 
HPLC instrument by keeping just different composition of mobile phase’s 
components according to each combination dosage forms.  Selection of different 
composition of mobile phase’s components can be performed through the dual 
mode of pump-ports of modern HPLC system.  The proposed arrangement 
reduces labor work of preparing different mobile phase for each combined dosage 
forms and also infers the requirement of saturation of different type of stationary 
phase accordingly. Hence, it saves considerable time duration of the analysis and 
results can be achieved in short period of time.  
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Further, study of literature reveals that there are no reports of analytical 
methods for determination of Ezetimibe, Statins and Fibrates simultaneously. In 
the present work, an analytical method is developed that estimate Ezetimibe, 
Atorvastatin and Fenofibrate simultaneously from their combined triple dosage 
form of pharmaceutical formulation. 
 
 
5.2 Analytical method development for assay determination of combination 
dosage forms of Ezetimibe with Statins and  Fibrate  
 
Analytical methods based on LC were developed for assay determination 
of combination dosage forms of Ezetimibe named by as under: 
 
(1) Ezetimibe + Rosuvastatin 
(2) Ezetimibe + Atorvastatin 
(3) Ezetimibe + Simvastatin 
(4) Ezetimibe + Atorvastatin + Fenofibrate 
 
The basic chromatographic conditions used for analytical separations of 
above combination dosage forms were designed to be simple and easy to use and 
reproduce. The analytical conditions were selected after testing the different 
parameters that influence LC analysis, such as column, aqueous and organic 
phase for mobile phase, mobile phase proportion, wavelength, diluent, 
concentration of analyte and other chromatographic parameters.  
 
In focus to develop analytical separation for ‘Ezetimibe and Rosuvastatin’, 
solution of Rosuvastatin is injected under the same chromatographic condition 
which is developed for determination of Ezetimibe as earlier mentioned. Under 
this chromatographic condition, the retention of Rosuvastatin peak is achieved. 
The representative chromatogram for the same is shown as under:    
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All other parameters of chromatographic condition are being kept same as 
that of method of Ezetimibe. A schematic chromatogram which states for 
obtained analytical separation of Ezetimibe and Rosuvastatin is shown as under: 
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Above chromatogram is clearly indicated that both peaks are symmetrical 
and resolution between the both peaks is very good. Rosuvastatin elutes first and 
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Ezetimibe elutes later in developed analytical method. The preciseness of the 
analytical method is evaluated and determined through Section 5.3  
 
In focus to develop analytical separation for ‘Ezetimibe and Atorvastatin’, 
solution of Atorvastatin is injected under the same chromatographic condition 
which is developed for determination of Ezetimibe as earlier mentioned. Under 
this chromatographic condition, the retention of Atorvastatin peak is achieved. 
The representative chromatogram for the same is shown as under:    
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All other parameters of chromatographic condition are being kept same as 
that of method of Ezetimibe. A schematic chromatogram which states for 
obtained analytical separation of Ezetimibe and Atorvastatin is shown as under: 
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Above chromatogram is clearly indicated that both peaks are symmetrical 
and resolution between the both peaks is very good. Ezetimibe elutes first and 
Atorvastatin elutes later in developed analytical method. The preciseness of the 
analytical method is evaluated and determined through Section 5.4  
 
In focus to develop analytical separation for ‘Ezetimibe and Simvastatin’, 
solution of Simvastatin is injected under the same chromatographic condition 
which is developed for determination of Ezetimibe as earlier mentioned. Under 
this chromatographic condition, the retention of Simvastatin peak is achieved but 
being very late eluted. The representative chromatogram for the same is shown as 
under:    
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Above chromatogram states that retention time of Simvastatin is very 
longer. An attempt was made to reduce late elution of Simvastatin by increasing 
proportion of organic phase (Acetonitrile) of the mobile phase. After different 
trials, it was achieved at proportion of 70% of organic phase. The representative 
chromatogram for the same is shown as under: 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
400
500
Si
m
va
st
at
in
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Except mobile phase proportion, all other parameters of chromatographic 
condition are being kept same as that of method of Ezetimibe. At present mobile 
phase proportion, elution of Ezetimibe is changed to early. A schematic 
chromatogram which states for obtained analytical separation of Ezetimibe and 
Simvastatin is shown as under: 
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Above chromatogram is clearly indicated that both peaks are symmetrical 
and resolution between the both peaks is very good. Ezetimibe elutes first and 
Simvastatin elutes later in developed analytical method. The preciseness of the 
analytical method is evaluated and determined through Section 5.5  
 
In focus to develop analytical separation for ‘Ezetimibe, Atorvastatin and 
Fenofibrate’, solution of Fenofibrate is injected under the same chromatographic 
condition which is developed for determination of Ezetimibe as earlier mentioned. 
Under this chromatographic condition, the retention of Fenofibrate peak is 
achieved but being very late eluted. The representative chromatogram for the 
same is shown as under:    
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Above chromatogram states that elution of Fenofibrate is too much late. 
This chromatographic condition is not suitable even though peak of Fenofibrate is 
found symmetrical. An attempt was made to reduce late elution of Fenofibrate by 
increasing proportion of organic phase (Acetonitrile) of the mobile phase. After 
different trials, it was achieved at proportion of 70% of organic phase but at this 
condition, peak of Ezetimibe and Atorvastatin are merged. Further, an attempt 
was made to separate the peaks of Ezetimibe and Atorvastatin by decreasing 
proportion of organic phase vice versa increasing proportion of aqueous phase 
(Buffer). At 35% proportion of aqueous phase (Buffer), peaks of Ezetimibe and 
Atorvastatin are found to be completely resolved. In this similar chromatographic 
condition, solution of Fenofibrate is injected. All analyte peaks are found 
symmetrical and completely resolved to each other.  
 
During the extraction trials, the preliminary diluent 
(Water:Acetonitrile:Methanol :: 40:50:10) which is used for extraction of all 
earlier dosage form is found unsuitable for this triple dosage form. The present 
dosage form does not produce complete dispersion of tablet in selected diluent. 
Afterwards on the basis of other experiments, it is concluded that presence of 
water in diluent is being interfere in the extraction process. Hence, the diluent is 
modified to (Acetonitrile:Methanol :: 50:50) by removing water and complete 
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extraction is achieved. At the optimized chromatographic condition, the 
representative chromatograms of all analytes are shown as under:  
 
For Ezetimibe:- 
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For Fenofibrate:- 
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Hence, the chromatographic method to evaluate all three analyte 
simultaneously is developed. The chromatogram that represent simultaneous 
evaluation for the same is shown as under: 
Minutes
0 5 10 15 20 25 30 35
m
A
U
0
250
500
750
1000
1250
Ez
et
im
ib
e
A
to
rv
as
ta
tin
Fe
no
fib
ra
te
 
Above chromatogram is clearly indicated that all peaks are symmetrical 
and completely resolved. Except mobile phase proportion and components of 
diluent, all other parameters of chromatographic condition are being kept same as 
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that of the method of Ezetimibe. At present mobile phase proportion, the elution 
order is in the sequence of Ezetimibe, Atorvastatin and Fenofibrate. The 
preciseness of the analytical method is evaluated and determined through Section 
5.6  
 
5.3 Determination method of Ezetimibe and Rosuvastatin 
  
5.3.1 Objective: 
To develop analytical method for the assay determination of Ezetimibe and 
Rosuvastatin from combination dosage form  
 
5.3.2 Standard testing procedure: 
 
Aim:  
To determine assay of Ezetimibe and Rosuvastatin from its combination dosage 
form (tablet) through High performance liquid chromatography 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
 
Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
Orthophosphoric acid (GR grade) 
Water (HPLC grade) 
 
Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (50:50, v/v)   
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
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Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Water:Acetonitrile:Methanol (40:50:10, v/v) 
 
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Stock solution: Weigh accurately about 50 mg Ezetimibe reference standard and 
52.09 Rosuvastatin calcium reference standard (equivalent to 50 mg Rosuvastatin) 
and transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 500 µg/ml of Ezetimibe and 500 µg/ml of 
Rosuvastatin. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin.  
 
Test Preparation: 
Weigh accurately 20 tablets and find out the average weight. Weigh accurately 10 
tablets and transfer into 200 ml volumetric flask. Add 140 ml of diluent into the 
flask and sonicate of 30 minutes with normal hand-shaking. Cool the flask to 
room temperature and dilute to volume with diluent. Filter 10 ml of this solution 
through 0.45 µm nylon syringe filter. The concentration obtained is 500 µg/ml of 
Ezetimibe and 500 µg/ml of Rosuvastatin. 
 
Pipette out 5 ml of above test stock solution and transfer into 50 ml volumetric 
flask and dilute to volume with diluent. The concentration obtained is 50 µg/ml of 
Ezetimibe and 50 µg/ml of Rosuvastatin. 
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System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
both analyte peaks. 
• Asymmetry of the both analyte peaks should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the both analyte peaks should be more than 5000 in 
standard preparation. 
• Resolution of the both analyte peak should be more than 10.0 in standard 
preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram.  
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparation in duplicate and record the chromatograms. 
• Calculate the % assay of the sample. 
 
Elution order: 
1. Rosuvastatin 
2. Ezetimibe 
 
Calculation: 
Calculate the % assay of Ezetimibe and Rosuvastatin in the sample using 
following formula. 
 
For Ezetimibe: 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
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W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
 
For Rosuvastatin: 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
 
(Equivalency: 1001.14 mg of Rosuvastatin calcium ≈ 961.06 mg of Rosuvastatin) 
Where by, 
AT2 = Average area of Rosuvastatin obtained in test preparation 
AS2 = Average area of Rosuvastatin obtained in standard preparation 
W3 = Weight taken of Rosuvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Rosuvastatin (mg) 
P2 = Potency of Rosuvastatin calcium reference standard (%) 
 
 
5.3.3 Product Information: 
Name  :- Ezetimibe and Rosuvastatin tablet 
Label claim :- 10 mg for Ezetimibe ; 10 mg for Rosuvastatin 
 
5.3.4 Method precision study: 
Method precision of the analytical method was determined by analyzing 
six sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard 
deviation and 95% confidence interval for the same was calculated.   
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For method precision, blank, standard preparation and six sets of test preparations 
was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank. 
  
Standard preparation: 
Stock solution: Accurately weighed 49.0 mg Ezetimibe reference standard and 
54.4 Rosuvastatin calcium reference standard (equivalent to 52.2 mg 
Rosuvastatin) were transferred into 100 ml volumetric flask. 70 ml of diluent was 
added into the volumetric flask to dissolve the substance by sonication for one 
minute and then diluted to volume with diluent. The concentration obtained is 490 
µg/ml of Ezetimibe and 522 µg/ml of Rosuvastatin. 
 
5 ml of above standard stock solution was pipetted out and transferred into 50 ml 
volumetric flask and diluted to volume with diluent. The concentration obtained is 
49.0 µg/ml of Ezetimibe and 52.2 µg/ml of Rosuvastatin.  
 
Test Preparation (Set 1): 
Test stock solution: 10 Tablets were accurately weighed (2335.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
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Test Preparation (Set 2): 
Test stock solution: 10 Tablets were accurately weighed (2328.9 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
 
Test Preparation (Set 3): 
Test stock solution: 10 Tablets were accurately weighed (2339.1 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
 
Test Preparation (Set 4): 
Test stock solution: 10 Tablets were accurately weighed (2331.6 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
Section-5: Method development… 
 
                                                                    
197 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
 
Test Preparation (Set 5): 
Test stock solution: 10 Tablets were accurately weighed (2325.5 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
 
Test Preparation (Set 6): 
Test stock solution: 10 Tablets were accurately weighed (2340.7 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Rosuvastatin. 
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5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Rosuvastatin. 
 
 Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly 
selected and weighed (4670.0 mg) for the same. The average weight (233.5 mg) is 
calculated. 
 
Chromatographic sequence for Method precision study is represented through 
Table 1 as under: 
 
Table 1: Sequence of Method precision study: 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 2: Summary of method precision study for Ezetimibe 
 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 49.0 mg 
1 2685398  Standard potency 99.8 % 
2 2700761   
3 2675829   
4 2688642   
5 2696707   
Average 2689467   
Stdev 9787.80   
% RSD 0.36   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2790429 1 2 2797286 2793858 2335.8 mg 
     
1 2783867 2 2 2773390 2778629 2328.9 mg 
     
1 2778223 3 2 2777827 2778025 2339.1 mg 
     
1 2783867 4 2 2773574 2778721 2331.6 mg 
     
1 2778059 5 2 2770246 2774153 2325.5 mg 
     
1 2769313 6 2 2778881 2774097 2340.7 mg 
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% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.233
5
50
8.2335
200
50
5
100
0.49
2689467
2793858 xxxxxx  
               = 101.6 
 
For Set 2:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.233
5
50
9.2328
200
50
5
100
0.49
2689467
2778629 xxxxxx  
               = 101.3 
 
For Set 3:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.233
5
50
1.2339
200
50
5
100
0.49
2689467
2778025 xxxxxx  
               = 100.8 
 
For Set 4:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.233
5
50
6.2331
200
50
5
100
0.49
2689467
2778721 xxxxxx  
               = 101.2 
 
For Set 5:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
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               = 8.99 
10
5.233
5
50
5.2325
200
50
5
100
0.49
2689467
2774153 xxxxxx  
               = 101.3 
 
For Set 6:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.233
5
50
7.2340
200
50
5
100
0.49
2689467
2774097 xxxxxx  
               = 100.6 
 
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
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Table 3: Summary of method precision study for Rosuvastatin 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 54.4 mg 
1 2460597  Standard potency 98.4 % 
2 2462498   
3 2444174   
4 2453446   
5 2453667   
Average 2454876   
Stdev 7226.07   
% RSD 0.29   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2392226 1 2 2385083 2388655 2335.8 mg 
     
1 2397758 2 2 2398180 2397969 2328.9 mg 
     
1 2392156 3 2 2382049 2387103 2339.1 mg 
     
1 2395432 4 2 2391019 2393226 2331.6 mg 
     
1 2384145 5 2 2382153 2383149 2325.5 mg 
     
1 2391627 6 2 2393832 2392730 2340.7 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
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               = 4.98
10
5.233
5
50
2335.8
200
14.1001
06.961
50
5
100
4.54
2454876
2388655 xxxxxxx  
               = 100.0 
 
For Set 2:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 4.98
10
5.233
5
50
2328.9
200
14.1001
06.961
50
5
100
4.54
2454876
2397969 xxxxxxx  
               = 100.7 
 
For Set 3:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 4.98
10
5.233
5
50
2339.1
200
14.1001
06.961
50
5
100
4.54
2454876
2387103 xxxxxxx  
               = 99.8 
 
For Set 4:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 4.98
10
5.233
5
50
2331.6
200
14.1001
06.961
50
5
100
4.54
2454876
2393226 xxxxxxx  
               = 100.3 
 
For Set 5:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 4.98
10
5.233
5
50
2325.5
200
14.1001
06.961
50
5
100
4.54
2454876
2383149 xxxxxxx  
               = 100.2 
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For Set 6:- 
% Assay = 2
22
3
2
2
5
50200
14.1001
06.961
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 4.98
10
5.233
5
50
2340.7
200
14.1001
06.961
50
5
100
4.54
2454876
2392730 xxxxxxx  
               = 99.9 
 
Where by, 
AT2 = Average area of Rosuvastatin obtained in test preparation 
AS2 = Average area of Rosuvastatin obtained in standard preparation 
W3 = Weight taken of Rosuvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Rosuvastatin (mg) 
P2 = Potency of Rosuvastatin calcium reference standard (%) 
 
Table 4: Summary of Method Precision study 
Analyte Set No. Assay (%) 
Mean 
Assay 
(%) 
Stdev RSD (%) 
95% 
Confidence 
Interval 
1 101.6 
2 101.3 
3 100.8 
4 101.2 
5 101.3 
Ezetimibe 
6 100.6 
101.1 0.37 0.37 0.39 
1 100.0 
2 100.7 
3 99.8 
4 100.3 
5 100.2 
Rosuvastatin 
6 99.9 
100.2 0.33 0.33 0.34 
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Chromatogram of blank preparation of method precision study: 
Minutes
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Chromatogram of standard preparation of method precision study: 
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Prototype chromatogram of test preparation of method precision study: 
Minutes
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Acceptance criteria: 
%RSD of six replicate sets of method precision study for both analyte should be 
less than 2.0 
 
Results: 
%RSD of six replicate sets of method precision study is 0.37 for Ezetimibe and 
0.33 for Rosuvastatin. 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
5.3.5 System suitability study: 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
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Table 5: Summary for System suitability of method precision 
 
Acceptance criteria: 
1) RSD of peak area of five replicate standard preparations should be less than 
2.0 %  
2) Theoretical plates of the analyte peak should be more than 5000 for standard 
preparation. 
3) Asymmetry of the analyte peak should be less than 2.0 for standard 
preparation.  
4) Resolution of the both analyte peak should be more than 10.0 in standard 
preparation. 
 
Result: 
1) RSD of peak area of five replicate standard preparations is found less than 2.0 
% for both analyte peak. 
2) Theoretical plates of the both analyte peak is found more than 5000 in 
standard preparation. 
3) Asymmetry of the both analyte peak is found less than 2.0 for standard 
preparation. 
4) Resolution of the both analyte peak is found more than 10.0 for standard 
preparation. 
 
System suitability  
parameters (In-house limit) 
% RSDa  
(NMTb 2.0) 
Theoretical plates 
(NLTc 5000) 
Asymmetry   
(NMTb 2.0) 
Resolution
(NLTc 10) 
     
Method Precision      
     Rosuvastatin 0.29 10147 1.30 -- 
     Ezetimibe 0.36 15865 1.12 17.4 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
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Conclusion: 
System suitability was found satisfactory during method precision. Hence, system 
is suitable for the same. 
 
5.3.6 Reporting of deviation 
The entire precision activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
5.3.7 Discussion and conclusion 
The observation and result obtained for precision and system suitability 
lies well with-in the acceptance criteria. Since, all the results are with-in the limit, 
the developed analytical method is considered as precise for assay quantification. 
 
 
 
5.4 Determination method of Ezetimibe and Atorvastatin 
 
 
5.4.1 Objective: 
To develop analytical method for the assay determination of Ezetimibe and 
Atorvastatin from combination dosage form  
 
5.4.2 Standard testing procedure: 
 
Aim:  
To determine assay of Ezetimibe and Atorvastatin from its combination dosage 
form (tablet) through High performance liquid chromatography 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
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Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
Orthophosphoric acid (GR grade) 
Water (HPLC grade) 
 
Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (50:50, v/v)   
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Water:Acetonitrile:Methanol (40:50:10, v/v) 
 
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Stock solution: Weigh accurately about 50 mg Ezetimibe reference standard and 
51.8 Atorvastatin calcium reference standard (equivalent to 50 mg Atorvastatin) 
and transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 500 µg/ml of Ezetimibe and 500 µg/ml of 
Atorvastatin. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin.  
 
Test Preparation:  
Weigh accurately 20 tablets and find out the average weight. Weigh accurately 10  
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tablets and transfer into 200 ml volumetric flask. Add 140 ml of diluent into the 
flask and sonicate of 30 minutes with normal hand-shaking. Cool the flask to 
room temperature and dilute to volume with diluent. Filter 10 ml of this solution 
through 0.45 µm nylon syringe filter. The concentration obtained is 500 µg/ml of 
Ezetimibe and 500 µg/ml of Atorvastatin. 
 
Pipette out 5 ml of above test stock solution and transfer into 50 ml volumetric 
flask and dilute to volume with diluent. The concentration obtained is 50 µg/ml of 
Ezetimibe and 50 µg/ml of Atorvastatin. 
 
System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
both analyte peaks. 
• Asymmetry of the both analyte peaks should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the both analyte peaks should be more than 5000 in 
standard preparation. 
• Resolution of the both analyte peak should be more than 5.0 in standard 
preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram.  
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparation in duplicate and record the chromatograms. 
• Calculate the % assay of the sample. 
 
Elution order: 
1. Ezetimibe 
2. Atorvastatin 
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Calculation: 
Calculate the % assay of Ezetimibe and Atorvastatin in the sample using 
following formula. 
 
For Ezetimibe: 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
 
For Atorvastatin: 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
(Equivalency: 1155.36 mg of Atorvastatin calcium ≈ 1115.28 mg of Atorvastatin) 
Where by, 
AT2 = Average area of Atorvastatin obtained in test preparation 
AS2 = Average area of Atorvastatin obtained in standard preparation 
W3 = Weight taken of Atorvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Atorvastatin (mg) 
P2 = Potency of Atorvastatin calcium reference standard (%) 
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5.4.3 Product Information: 
Name  :- Ezetimibe and Atorvastatin tablet 
Label claim :- 10 mg for Ezetimibe ; 10 mg for Atorvastatin 
 
5.4.4 Method precision study: 
Method precision of the analytical method was determined by analyzing 
six sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard 
deviation and 95% confidence interval for the same was calculated.   
 
For method precision, blank, standard preparation and six sets of test preparations 
was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank. 
  
Standard preparation: 
Stock solution: Weigh accurately about 49.6 mg Ezetimibe reference standard and 
51.5 Atorvastatin calcium reference standard (equivalent to 49.7 mg Atorvastatin) 
and transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 496 µg/ml of Ezetimibe and 497 µg/ml of 
Atorvastatin. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
49.6 µg/ml of Ezetimibe and 49.7 µg/ml of Atorvastatin.  
 
Test Preparation (Set 1): 
Test stock solution: 10 Tablets were accurately weighed (1535.9 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
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volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
 
Test Preparation (Set 2): 
Test stock solution: 10 Tablets were accurately weighed (1526.8 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
 
Test Preparation (Set 3): 
Test stock solution: 10 Tablets were accurately weighed (1517.7 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
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5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
 
Test Preparation (Set 4): 
Test stock solution: 10 Tablets were accurately weighed (1529.7 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
 
Test Preparation (Set 5): 
Test stock solution: 10 Tablets were accurately weighed (1525.5 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
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Test Preparation (Set 6): 
Test stock solution: 10 Tablets were accurately weighed (1514.6 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Atorvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Atorvastatin. 
 
 Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly 
selected and weighed (3050.0 mg) for the same. The average weight (152.5 mg) is 
calculated.  
  
Chromatographic sequence for Method precision study is represented through 
Table 1 as under: 
 
Table 1: Sequence of Method precision study: 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 2: Summary of method precision study for Ezetimibe 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 49.6 mg 
1 2717854  Standard potency 99.8 % 
2 2718728   
3 2720391   
4 2722413   
5 2721015   
Average 2720080   
Stdev 1816.37   
% RSD 0.07   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2808145 1 2 2813505 2810825 1535.9 mg 
     
1 2772342 2 2 2773121 2772732 1526.8 mg 
     
1 2781229 3 2 2762402 2771816 1517.7 mg 
     
1 2806070 4 2 2802560 2804315 1529.7 mg 
     
1 2778989 5 2 2768833 2773911 1525.5 mg 
     
1 2761638 6 2 2783073 2772356 1514.6 mg 
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% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.152
5
50
9.1535
200
50
5
100
6.49
2720080
2810825 xxxxxx  
               = 101.6 
 
For Set 2:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.152
5
50
8.1526
200
50
5
100
6.49
2720080
2772732 xxxxxx  
               = 100.8 
 
For Set 3:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.152
5
50
7.1517
200
50
5
100
6.49
2720080
2771816 xxxxxx  
               = 101.4 
 
For Set 4:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.152
5
50
7.1529
200
50
5
100
6.49
2720080
2804315 xxxxxx  
               = 101.8 
 
For Set 5:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
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               = 8.99 
10
5.152
5
50
5.1525
200
50
5
100
6.49
2720080
2773911 xxxxxx  
               = 100.9 
 
For Set 6:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.152
5
50
6.1514
200
50
5
100
6.49
2720080
2772356 xxxxxx  
               = 101.6 
 
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
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Table 3: Summary of method precision study for Atorvastatin 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 51.5 mg 
1 2488821  Standard potency 99.2 % 
2 2496533   
3 2503887   
4 2491552   
5 2494948   
Average 2495148   
Stdev 5729.1   
% RSD 0.23   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2556521 1 2 2559823 2558172 1535.9 mg 
     
1 2524320 2 2 2513293 2518807 1526.8 mg 
     
1 2506264 3 2 2503277 2504771 1517.7 mg 
     
1 2538147 4 2 2544136 2541142 1529.7 mg 
     
1 2500372 5 2 2510875 2505624 1525.5 mg 
     
1 2490697 6 2 2494090 2492394 1514.6 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
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               = 2.99
10
5.152
5
50
1535.9
200
36.1155
28.1115
50
5
100
5.51
2495148
2558172 xxxxxxx  
               = 100.4 
 
For Set 2:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 2.99
10
5.152
5
50
1526.8
200
36.1155
28.1115
50
5
100
5.51
2495148
2518807 xxxxxxx  
               = 99.4 
 
For Set 3:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 2.99
10
5.152
5
50
1517.7
200
36.1155
28.1115
50
5
100
5.51
2495148
2504771 xxxxxxx  
               = 99.5 
 
For Set 4:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 2.99
10
5.152
5
50
1529.7
200
36.1155
28.1115
50
5
100
5.51
2495148
2541142 xxxxxxx  
               = 100.1 
 
For Set 5:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 2.99
10
5.152
5
50
1525.5
200
36.1155
28.1115
50
5
100
5.51
2495148
2505624 xxxxxxx  
               = 99.0 
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For Set 6:- 
% Assay = 2
22
3
2
2
5
50200
36.1155
28.1115
50
5
100
xP
LC
AWxx
W
xxxWx
A
A
S
T  
               = 2.99
10
5.152
5
50
1514.6
200
36.1155
28.1115
50
5
100
5.51
2495148
2492394 xxxxxxx  
               = 99.2 
 
Where by, 
AT2 = Average area of Atorvastatin obtained in test preparation 
AS2 = Average area of Atorvastatin obtained in standard preparation 
W3 = Weight taken of Atorvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Atorvastatin (mg) 
P2 = Potency of Atorvastatin calcium reference standard (%) 
 
 
Table 4: Summary of Method Precision study 
Analyte Set No. Assay (%) 
Mean 
Assay 
(%) 
Stdev RSD (%) 
95% 
Confidence 
Interval 
1 101.6 
2 100.8 
3 101.4 
4 101.8 
5 100.9 
Ezetimibe 
6 101.6 
101.4 0.41 0.40 0.43 
1 100.4 
2 99.4 
3 99.5 
4 100.1 
5 99.0 
Atorvastatin 
6 99.2 
99.6 0.54 0.54 0.57 
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Chromatogram of blank preparation of method precision study: 
Minutes
0 2 4 6 8 10 12 14 16 18 20
m
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0
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300
(E
ze
tim
ib
e)
(A
to
rv
as
ta
tin
)
 
 
 
Chromatogram of standard preparation of method precision study: 
Minutes
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Prototype chromatogram of test preparation of method precision study: 
Minutes
0 2 4 6 8 10 12 14 16 18 20
m
A
U
0
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200
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or
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Acceptance criteria: 
%RSD of six replicate sets of method precision study for both analyte should be 
less than 2.0 
 
Results: 
%RSD of six replicate sets of method precision study is 0.40 for Ezetimibe and 
0.54 for Atorvastatin. 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
5.4.5 System suitability study: 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
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Table 5: Summary for System suitability of method precision 
 
Acceptance criteria: 
1) RSD of peak area of five replicate standard preparations should be less 
than 2.0 %  
2) Theoretical plates of the analyte peak should be more than 5000 for 
standard preparation. 
3) Asymmetry of the analyte peak should be less than 2.0 for standard 
preparation.  
4) Resolution of the both analyte peak should be more than 5.0 in standard 
preparation. 
 
Result: 
1) RSD of peak area of five replicate standard preparations is found less than 
2.0 % for both analyte peak. 
2) Theoretical plates of the both analyte peak is found more than 5000 in 
standard preparation. 
3) Asymmetry of the both analyte peak is found less than 2.0 for standard 
preparation. 
4) Resolution of the both analyte peak is found more than 5.0 for standard 
preparation. 
 
System suitability  
parameters (In-house limit) 
% RSDa  
(NMTb 2.0) 
Theoretical plates 
(NLTc 5000) 
Asymmetry   
(NMTb 2.0) 
Resolution
(NLTc 5) 
     
Method Precision      
     Atorvastatin 0.23 15267 1.14 -- 
     Ezetimibe 0.07 16580 1.08 8.8 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
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Conclusion: 
System suitability was found satisfactory during method precision. Hence, system 
is suitable for the same. 
 
 
5.4.6 Reporting of deviation 
The entire precision activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
5.4.7 Discussion and conclusion 
The observation and result obtained for precision and system suitability 
lies well with-in the acceptance criteria. Since, all the results are with-in the limit, 
the developed analytical method is considered as precise for assay quantification. 
 
 
 
5.5  Determination method of Ezetimibe and Simvastatin 
 
 
5.5.1 Objective: 
To develop analytical method for the assay determination of Ezetimibe and 
Simvastatin from combination dosage form  
 
5.5.2 Standard testing procedure: 
 
Aim:  
To determine assay of Ezetimibe and Simvastatin from its combination dosage 
form (tablet) through High performance liquid chromatography 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
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Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
Orthophosphoric acid (GR grade) 
Water (HPLC grade) 
 
Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (30:70, v/v)   
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Water:Acetonitrile:Methanol (40:50:10, v/v) 
 
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Stock solution: Weigh accurately about 50 mg Ezetimibe reference standard and 
50 Simvastatin reference standard and transfer into 100 ml volumetric flask. Add 
70 ml of diluent to dissolve the substance by sonication for one minute and then 
dilute to volume with diluent. The concentration obtained is 500 µg/ml of 
Ezetimibe and 500 µg/ml of Simvastatin. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin.  
 
Test Preparation: 
Weigh accurately 20 tablets and find out the average weight. Weigh accurately 10 
tablets and transfer into 200 ml volumetric flask. Add 140 ml of diluent into the 
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flask and sonicate of 30 minutes with normal hand-shaking. Cool the flask to 
room temperature and dilute to volume with diluent. Filter 10 ml of this solution 
through 0.45 µm nylon syringe filter. The concentration obtained is 500 µg/ml of 
Ezetimibe and 500 µg/ml of Simvastatin. 
 
Pipette out 5 ml of above test stock solution and transfer into 50 ml volumetric 
flask and dilute to volume with diluent. The concentration obtained is 50 µg/ml of 
Ezetimibe and 50 µg/ml of Simvastatin. 
 
System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
both analyte peaks. 
• Asymmetry of the both analyte peaks should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the both analyte peaks should be more than 5000 in 
standard preparation. 
• Resolution of the both analyte peak should be more than 20.0 in standard 
preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram.  
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparation in duplicate and record the chromatograms. 
• Calculate the % assay of the sample. 
 
Elution order: 
     1.  Ezetimibe 
     2.  Simvastatin 
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Calculation: 
Calculate the % assay of Ezetimibe and Simvastatin in the sample using following 
formula. 
 
For Ezetimibe: 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
 
For Simvastatin: 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
Where by, 
AT2 = Average area of Simvastatin obtained in test preparation 
AS2 = Average area of Simvastatin obtained in standard preparation 
W3 = Weight taken of Simvastatin reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Simvastatin (mg) 
P2 = Potency of Simvastatin reference standard (%) 
 
5.5.3 Product Information: 
Name  :- Ezetimibe and Simvastatin tablet 
Label claim :- 10 mg for Ezetimibe ; 10 mg for Simvastatin 
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5.5.4 Method precision study: 
Method precision of the analytical method was determined by analyzing 
six sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard 
deviation and 95% confidence interval for the same was calculated.   
 
For method precision, blank, standard preparation and six sets of test preparations 
was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank. 
  
Standard preparation: 
Stock solution: Weigh accurately about 49.1 mg Ezetimibe reference standard and 
50.8 Simvastatin reference standard and transfer into 100 ml volumetric flask. 
Add 70 ml of diluent to dissolve the substance by sonication for one minute and 
then dilute to volume with diluent. The concentration obtained is 491 µg/ml of 
Ezetimibe and 508 µg/ml of Simvastatin. 
 
Pipette out 5 ml of above standard stock solution and transfer into 50 ml 
volumetric flask and dilute to volume with diluent. The concentration obtained is 
49.1 µg/ml of Ezetimibe and 50.8 µg/ml of Simvastatin.  
 
Test Preparation (Set 1): 
Test stock solution: 10 Tablets were accurately weighed (1941.4 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
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5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
 
Test Preparation (Set 2): 
Test stock solution: 10 Tablets were accurately weighed (1934.7 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
 
Test Preparation (Set 3): 
Test stock solution: 10 Tablets were accurately weighed (1957.3 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
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Test Preparation (Set 4): 
Test stock solution: 10 Tablets were accurately weighed (1944.2 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
 
Test Preparation (Set 5): 
Test stock solution: 10 Tablets were accurately weighed (1945.9 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
 
Test Preparation (Set 6): 
Test stock solution: 10 Tablets were accurately weighed (1952.1 mg) and 
transferred into 200 ml volumetric flask. 140 ml of diluent added into the 
volumetric flask. The volumetric flask was proceed for sonication of 30 minutes 
with normal hand-shaking. Then, the flask was cooled to room temperature and 
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diluted to volume with diluent. 10 ml of this solution was filtered through 0.45 
µm nylon syringe filter. The concentration obtained is 500 µg/ml of Ezetimibe 
and 500 µg/ml of Simvastatin. 
 
5 ml of above test stock solution was pipette out and transferred into 50 ml 
volumetric flask followed by diluted to volume with diluent. The concentration 
obtained is 50 µg/ml of Ezetimibe and 50 µg/ml of Simvastatin. 
 
 Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly 
selected and weighed (3890.0 mg) for the same. The average weight (194.5 mg) is 
calculated.  
 
Chromatographic sequence for Method precision study is represented through 
Table 1. 
 
Table 1: Sequence of Method precision study 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 2: Summary of method precision study for Ezetimibe 
 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 49.1 mg 
1 2741870  Standard potency 99.8 % 
2 2731024   
3 2754641   
4 2736033   
5 2756210   
Average 2743956   
Stdev 11165.7   
% RSD 0.41   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2817699 1 2 2826961 2822330 1941.4 mg 
     
1 2825263 2 2 2823660 2824462 1934.7 mg 
     
1 2822345 3 2 2826329 2824337 1957.3 mg 
     
1 2823972 4 2 2826641 2825307 1944.2 mg 
     
1 2825346 5 2 2820643 2822995 1945.9 mg 
     
1 2823000 6 2 2826594 2824797 1952.1 mg 
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% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.194
5
50
4.1941
200
50
5
100
1.49
2743956
2822330 xxxxxx  
               = 101.0 
 
For Set 2:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.194
5
50
7.1934
200
50
5
100
1.49
2743956
2824462 xxxxxx  
               = 101.4 
 
For Set 3:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.194
5
50
3.1957
200
50
5
100
1.49
2743956
2824337 xxxxxx  
               = 100.2 
 
For Set 4:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.194
5
50
2.1944
200
50
5
100
1.49
2743956
2825307 xxxxxx  
               = 101.0 
 
For Set 5:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
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               = 8.99 
10
5.194
5
50
9.1945
200
50
5
100
1.49
2743956
2822995 xxxxxx  
               = 100.8 
 
For Set 6:- 
% Assay = 1
12
1
1
1
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 8.99 
10
5.194
5
50
1.1952
200
50
5
100
1.49
2743956
2824797 xxxxxx  
               = 100.5 
 
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
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Table 3: Summary of method precision study for Simvastatin 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 50.8 mg 
1 3241987  Standard potency 99.4 % 
2 3276418   
3 3245604   
4 3246158   
5 3251826   
Average 3252399   
Stdev 13881.4   
% RSD 0.43   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 3198957 1 2 3228633 3213795 1941.4 mg 
     
1 3202822 2 2 3220842 3211832 1934.7 mg 
     
1 3201042 3 2 3219084 3210063 1957.3 mg 
     
1 3205122 4 2 3217245 3211184 1944.2 mg 
     
1 3196393 5 2 3211904 3204149 1945.9 mg 
     
1 3190909 6 2 3212914 3201912 1952.1 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
Section-5: Method development… 
 
                                                                    
237 
               = 4.99
10
5.194
5
50
1941.4
200
50
5
100
8.50
3252399
3213795 xxxxxx  
               = 100.0 
 
For Set 2:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 4.99
10
5.194
5
50
1934.7
200
50
5
100
8.50
3252399
3211832 xxxxxx  
               = 100.3 
 
For Set 3:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 4.99
10
5.194
5
50
1957.3
200
50
5
100
8.50
3252399
3210063 xxxxxx  
               = 99.0 
 
For Set 4:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 4.99
10
5.194
5
50
1944.2
200
50
5
100
8.50
3252399
3211184 xxxxxx  
               = 99.8 
 
For Set 5:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 4.99
10
5.194
5
50
1945.9
200
50
5
100
8.50
3252399
3204149 xxxxxx  
               = 99.4 
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For Set 6:- 
% Assay = 2
22
3
2
2
5
50200
50
5
100
xP
LC
AWxx
W
xxWx
A
A
S
T  
               = 4.99
10
5.194
5
50
1952.1
200
50
5
100
8.50
3252399
3201912 xxxxxx  
               = 99.1 
 
Where by, 
AT2 = Average area of Simvastatin obtained in test preparation 
AS2 = Average area of Simvastatin obtained in standard preparation 
W3 = Weight taken of Simvastatin reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Simvastatin (mg) 
P2 = Potency of Simvastatin reference standard (%) 
 
 
Table 4: Summary of Method Precision study 
Analyte Set No. Assay (%) 
Mean 
Assay 
(%) 
Stdev RSD (%) 
95% 
Confidence 
Interval 
1 101.0 
2 101.4 
3 100.2 
4 101.0 
5 100.8 
Ezetimibe 
6 100.5 
100.8 0.42 0.42 0.44 
1 100.0 
2 100.3 
3 99.0 
4 99.8 
5 99.4 
Simvastatin 
6 99.1 
99.6 0.52 0.52 0.54 
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Chromatogram of blank preparation of method precision study: 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
400
500
(E
ze
tim
ib
e)
(S
im
va
st
at
in
)
 
 
 
Chromatogram of standard preparation of method precision study: 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
400
500
Ez
et
im
ib
e
Si
m
va
st
at
in
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Prototype chromatogram of test preparation of method precision study: 
Minutes
0 2 4 6 8 10 12 14 16 18
m
A
U
0
100
200
300
400
500
E
ze
tim
ib
e
S
im
va
st
at
in
 
 
Acceptance criteria: 
%RSD of six replicate sets of method precision study for both analyte should be 
less than 2.0 
 
Results: 
%RSD of six replicate sets of method precision study is 0.42 for Ezetimibe and 
0.52 for Simvastatin. 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
5.5.5 System suitability study: 
 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
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Table 5: Summary for System suitability of method precision 
 
 
Acceptance criteria: 
1) RSD of peak area of five replicate standard preparations should be less 
than 2.0 %  
2) Theoretical plates of the analyte peak should be more than 5000 for 
standard preparation. 
3) Asymmetry of the analyte peak should be less than 2.0 for standard 
preparation.  
4) Resolution of the both analyte peak should be more than 20.0 in standard 
preparation. 
 
Result: 
1) RSD of peak area of five replicate standard preparations is found less than 
2.0 % for both analyte peak. 
2) Theoretical plates of the both analyte peak is found more than 5000 in 
standard preparation. 
3) Asymmetry of the both analyte peak is found less than 2.0 for standard 
preparation. 
4) Resolution of the both analyte peak is found more than 20.0 for standard 
preparation. 
 
System suitability  
parameters (In-house limit) 
% RSDa  
(NMTb 2.0) 
Theoretical plates 
(NLTc 5000) 
Asymmetry   
(NMTb 2.0) 
Resolution
(NLTc 20) 
     
Method Precision      
     Ezetimibe 0.41 6545 1.51 -- 
     Simvastatin 0.43 18746 1.05 33.0 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
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Conclusion: 
System suitability was found satisfactory during method precision. Hence, system 
is suitable for the same. 
 
5.5.6 Reporting of deviation 
The entire precision activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
5.5.7 Discussion and conclusion 
The observation and result obtained for precision and system suitability 
lies well with-in the acceptance criteria. Since, all the results are with-in the limit, 
the developed analytical method is considered as precise for assay quantification. 
 
 
 
5.6  Determination method of Ezetimibe, Atorvastatin and Fenofibrate  
 
 
5.6.1 Objective: 
To develop analytical method for the assay determination of Ezetimibe, 
Atorvastatin and Fenofibrate from combination dosage form  
 
5.6.2 Standard testing procedure: 
 
Aim:  
To determine assay of Ezetimibe, Atorvastatin and Fenofibrate from its 
combination dosage form (tablet) through High performance liquid 
chromatography 
 
Instrument:  
High performance liquid chromatograph (Shimadzu; LC-10ATvp) equipped with 
PDA detector (SPD-M10Avp) and connected to multi-instrument data-acquisition 
and  data-processing system (Class-VP 6.13 SP2) 
Section-5: Method development… 
 
                                                                    
243 
Reagents:  
Acetonitrile (HPLC grade) 
Methanol (HPLC grade) 
Orthophosphoric acid (GR grade) 
Water (HPLC grade) 
 
Chromatographic condition: 
Mobile phase :- 0.1% Orthophosphoric acid (v/v):Acetonitrile (35:65, v/v)   
Column :- Phenomenex Luna (2) C18, 4.6 x 250 mm, 5 µm 
Flow rate :- 1.0 ml/min 
Detection :-  232 nm 
Injection volume :- 20 µl 
Diluent :-  Acetonitrile:Methanol (70:30, v/v) 
 
Blank preparation:  
Use diluent as blank. 
 
Standard preparation: 
Solution-A: Weigh accurately about 50 mg Ezetimibe reference standard and 51.8 
Atorvastatin calcium reference standard (equivalent to 50 mg Atorvastatin) and 
transfer into 100 ml volumetric flask. Add 70 ml of diluent to dissolve the 
substance by sonication for one minute and then dilute to volume with diluent. 
The concentration obtained is 500 µg/ml of Ezetimibe and 500 µg/ml of 
Atorvastatin. 
 
Weigh accurately about 50 mg Fenofibrate working standard and transfer into 50 
ml volumetric flask. Add 35 ml of diluent to dissolve the substance by sonication 
for one minute. To this volumetric flask, add 5 ml of Solution-A and dilute to 
volume with diluent. The concentration obtained is 50 µg/ml of Ezetimibe, 50 
µg/ml of Atorvastatin and 1000 µg/ml of Fenofibrate.  
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Test Preparation: 
Weigh accurately 20 tablets and crush fine powder. Weigh accurately one average 
weight of powdered drug and transfer into 200 ml volumetric flask. Add 140 ml 
of diluent into the flask and sonicate of 30 minutes with normal hand-shaking. 
Cool the flask to room temperature and dilute to volume with diluent. Filter 10 ml 
of this solution through 0.45 µm nylon syringe filter. The concentration obtained 
is 50 µg/ml of Ezetimibe, 50 µg/ml of Atorvastatin and 1000 µg/ml of 
Fenofibrate. 
 
System suitability: 
• % RSD for replicate standard preparation should be less than 2.0 % for 
each analyte peak. 
• Asymmetry of the each analyte peak should be less than 2.0 in standard 
preparation. 
• Theoretical plates of the each analyte peak should be more than 4000 in 
standard preparation. 
• Resolution of between the peaks of Ezetimibe and Atorvastatin should be 
more than 1.5 in standard preparation. 
 
Procedure: 
• Inject the blank preparation and record the chromatogram.  
• Inject five replicate of standard preparation and check for the system 
suitability and record the chromatograms. 
• Inject test preparation in duplicate and record the chromatograms. 
• Calculate the % assay of the sample. 
 
Elution order: 
1. Ezetimibe 
2.   Atorvastatin 
3.   Fenofibrate 
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Calculation: 
Calculate the % assay of Ezetimibe, Atorvastatin and Fenofibrate in the sample 
using following formula. 
 
For Ezetimibe: 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
 
For Atorvastatin: 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
 
(Equivalency: 1155.36 mg of Atorvastatin calcium ≈ 1115.28 mg of Atorvastatin) 
Where by, 
AT2 = Average area of Atorvastatin obtained in test preparation 
AS2 = Average area of Atorvastatin obtained in standard preparation 
W3 = Weight taken of Atorvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Atorvastatin (mg) 
P2 = Potency of Atorvastatin calcium reference standard (%) 
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For Fenofibrate: 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
Where by, 
AT3 = Average area of Fenofibrate obtained in test preparation 
AS3 = Average area of Fenofibrate obtained in standard preparation 
W4 = Weight taken of Fenofibrate working standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC3 = Label claim of Fenofibrate (mg) 
P3 = Potency of Fenofibrate working standard (%) 
 
5.6.3 Product Information: 
Name  :- Ezetimibe, Atorvastatin and Fenofibrate tablet  
Label claim     :- 10 mg for Ezetimibe ; 10 mg for Atorvastatin ; 200 mg for      
Fenofibrate 
  
5.6.4  Method precision study: 
Method precision of the analytical method was determined by analyzing 
six sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard 
deviation and 95% confidence interval for the same was calculated.   
 
For method precision, blank, standard preparation and six sets of test preparations 
was prepared as per method as under: 
 
Blank preparation: 
Diluent was used as blank. 
 
Standard preparation: 
Solution-A: Accurately weighed about 50.8 mg Ezetimibe reference standard and  
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53.4 Atorvastatin calcium reference standard (equivalent to 51.5 mg Atorvastatin) 
were transferred into 100 ml volumetric flask. 70 ml of diluent was added into 
this volumetric flask to dissolve the substance by sonication of one minute and 
then diluted to volume with diluent. The concentration obtained is 508 µg/ml of 
Ezetimibe and 515 µg/ml of Atorvastatin. 
 
Accurately weighed 50.9 mg Fenofibrate working standard was 
transferred into 50 ml volumetric flask. 35 ml of diluent was added into this 
volumetric flask to dissolve the substance by sonication of one minute. To this 
volumetric flask, 5 ml of Solution-A was added and diluted to volume with 
diluent. The concentration obtained is 50.8 µg/ml of Ezetimibe, 51.5 µg/ml of 
Atorvastatin and 1018 µg/ml of Fenofibrate.  
 
Average weight of tablets: 
Average weight of tablets was performed on 20 tablets. 20 tablets are randomly 
selected and weighed (8364.0 mg) for the same. The average weight (418.2 mg) is 
calculated.  
 
Test Preparation (Set 1): 
20 Tablets were accurately weighed (420.0 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Test Preparation (Set 2): 
20 Tablets were accurately weighed (417.8 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
Section-5: Method development… 
 
                                                                    
248 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Test Preparation (Set 3): 
20 Tablets were accurately weighed (418.8 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Test Preparation (Set 4): 
20 Tablets were accurately weighed (418.4 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Test Preparation (Set 5): 
20 Tablets were accurately weighed (418.1 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
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The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Test Preparation (Set 6): 
20 Tablets were accurately weighed (419.2 mg) and crushed to fine powder. 
Accurately weighed one average weight of powdered drug was transferred into 
200 ml volumetric flask. 140 ml of diluent was added into the volumetric flask. 
The volumetric flask was proceed for sonication of 30 minutes with normal hand-
shaking. Then, the flask was cooled to room temperature and diluted to volume 
with diluent. 10 ml of this solution was filtered through 0.45 µm nylon syringe 
filter. The concentration obtained is 50 µg/ml of Ezetimibe, 50 µg/ml of 
Atorvastatin and 1000 µg/ml of Fenofibrate. 
 
Chromatographic sequence for Method precision study is represented through 
Table 1. 
 
Table 1: Sequence of Method precision study: 
Sr. No. Description Injection replicate 
1 Blank 1 
2 Standard preparation 5 
3 Test Preparation (Set 1) 2 
4 Test Preparation (Set 2) 2 
5 Test Preparation (Set 3) 2 
6 Test Preparation (Set 4) 2 
7 Test Preparation (Set 5) 2 
8 Test Preparation (Set 6) 2 
9 Bracketing standard 1 
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Observation, calculation and chromatograms: 
 
Table 2: Summary of method precision study for Ezetimibe 
 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 50.8 mg 
1 2745425  Standard potency 99.8 % 
2 2743143   
3 2769773   
4 2768061   
5 2769537   
Average 2759188   
Stdev 13644.93   
% RSD 0.49   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2704938 1 2 2704091 2704515 420.0 mg 
     
1 2701923 2 2 2704134 2703029 417.8 mg 
     
1 2704574 3 2 2701704 2703139 418.8 mg 
     
1 2704426 4 2 2706277 2705352 418.4 mg 
     
1 2701557 5 2 2702231 2701894 418.1 mg 
     
1 2698838 6 2 2698874 2698856 419.2 mg 
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% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
               = 8.99 
10
2.418
0.420
200
50
5
100
8.50
2759188
2704515 xxxxx  
               = 99.0 
 
For Set 2:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
               = 8.99 
10
2.418
8.417
200
50
5
100
8.50
2759188
2703029 xxxxx  
               = 99.4 
 
For Set 3:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
               = 8.99 
10
2.418
8.418
200
50
5
100
8.50
2759188
2703139 xxxxx  
               = 99.2 
 
For Set 4:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
               = 8.99 
10
2.418
4.418
200
50
5
100
8.50
2759188
2705352 xxxxx  
               = 99.4 
 
For Set 5:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
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               = 8.99 
10
2.418
1.418
200
50
5
100
8.50
2759188
2701894 xxxxx  
               = 99.3 
 
For Set 6:- 
% Assay = 1
12
1
1
1 200
50
5
100
xP
LC
AWx
W
xxWx
A
A
S
T  
               = 8.99 
10
2.418
2.419
200
50
5
100
8.50
2759188
2698856 xxxxx  
               = 98.9 
 
Where by, 
AT1 = Average area of Ezetimibe obtained in test preparation 
AS1 = Average area of Ezetimibe obtained in standard preparation 
W1 = Weight taken of Ezetimibe reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC1 = Label claim of Ezetimibe (mg) 
P1 = Potency of Ezetimibe reference standard (%) 
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Table 3: Summary of method precision study for Atorvastatin 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 53.4 mg 
1 2632443  Standard potency 99.2 % 
2 2598808   
3 2635844   
4 2607576   
5 2589781   
Average 2612890   
Stdev 20431.43   
% RSD 0.78   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 2554859 1 2 2511668 2533264 420.0 mg 
     
1 2538738 2 2 2511467 2525103 417.8 mg 
     
1 2596386 3 2 2569949 2583168 418.8 mg 
     
1 2541564 4 2 2513347 2527456 418.4 mg 
     
1 2551512 5 2 2523388 2537450 418.1 mg 
     
1 2532672 6 2 2516168 2524420 419.2 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
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               = 2.99
10
2.418
420.0
200
36.1155
28.1115
50
5
100
4.53
2612890
2533264 xxxxxx  
               = 98.7 
 
For Set 2:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
               = 2.99
10
2.418
417.8
200
36.1155
28.1115
50
5
100
4.53
2612890
2525103 xxxxxx  
               = 98.9 
 
For Set 3:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
               = 2.99
10
2.418
418.8
200
36.1155
28.1115
50
5
100
4.53
2612890
2583168 xxxxxx  
               = 101.0 
 
For Set 4:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
               = 2.99
10
2.418
418.4
200
36.1155
28.1115
50
5
100
4.53
2612890
2527456 xxxxxx  
               = 98.9 
 
For Set 5:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
               = 2.99
10
2.418
418.1
200
36.1155
28.1115
50
5
100
4.53
2612890
2537450 xxxxxx  
               = 99.3 
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For Set 6:- 
% Assay = 2
22
3
2
2 200
36.1155
28.1115
50
5
100
xP
LC
AWx
W
xxxWx
A
A
S
T  
               = 2.99
10
2.418
419.2
200
36.1155
28.1115
50
5
100
4.53
2612890
2524420 xxxxxx  
               = 98.6 
 
Where by, 
AT2 = Average area of Atorvastatin obtained in test preparation 
AS2 = Average area of Atorvastatin obtained in standard preparation 
W3 = Weight taken of Atorvastatin calcium reference standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC2 = Label claim of Atorvastatin (mg) 
P2 = Potency of Atorvastatin calcium reference standard (%) 
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Table 4: Summary of method precision study for Fenofibrate 
Observation  
 
Data for Standard preparation 
 
Replicate Area  Standard weight 50.9 mg 
1 30775385  Standard potency 99.9 % 
2 30755765   
3 31070302   
4 31033906   
5 31060293   
Average 30939130   
Stdev 159141.6   
% RSD 0.51   
 
Data for Test preparations 
 
Set No. Replicate Area Mean area Weight of the sample 
1 30184035 1 2 30172779 30178407 420.0 mg 
     
1 30197848 2 2 30165624 30181736 417.8 mg 
     
1 30210659 3 2 30184109 30197384 418.8 mg 
     
1 30228899 4 2 30194387 30211643 418.4 mg 
     
1 30184139 5 2 30231844 30207992 418.1 mg 
     
1 30182815 6 2 30160219 30171517 419.2 mg 
 
 
% Assay calculation for each set is as under: 
 
For Set 1:- 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
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               = 9.99 x
200
2.418
x
0.420
200
x
50
9.50
x
30939130
30178407
 
               = 98.8 
 
For Set 2:- 
% Assay = 3
32
4
3S
3T
xP
LC
AW
x
W
200
x
50
W
x
A
A
 
               = 9.99 x
200
2.418
x
8.417
200
x
50
9.50
x
30939130
30181736
 
               = 99.3 
 
For Set 3:- 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
               = 9.99 x
200
2.418
x
8.418
200
x
50
9.50
x
30939130
30197384
 
               = 99.1 
 
For Set 4:- 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
               = 9.99 x
200
2.418
x
4.418
200
x
50
9.50
x
30939130
30211643
 
               = 99.3 
 
For Set 5:- 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
               = 9.99 x
200
2.418
x
1.418
200
x
50
9.50
x
30939130
30207992
 
               = 99.3 
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For Set 6:- 
% Assay = 3
32
4
3
3 200
50
xP
LC
AWx
W
xWx
A
A
S
T  
               = 9.99 x
200
2.418
x
2.419
200
x
50
9.50
x
30939130
30171517
 
               = 98.9 
Where by, 
AT3 = Average area of Fenofibrate obtained in test preparation 
AS3 = Average area of Fenofibrate obtained in standard preparation 
W4 = Weight taken of Fenofibrate working standard (mg) 
W2 = Weight taken of test sample (mg) 
AW = Average weight of tablets (mg)  
LC3 = Label claim of Fenofibrate (mg) 
P3 = Potency of Fenofibrate working standard (%) 
 
Table 5: Summary of Method Precision study 
Analyte Set No. Assay (%) 
Mean 
Assay 
(%) 
Stdev RSD (%) 
95% 
Confidence 
Interval 
1 99.0 
2 99.4 
3 99.2 
4 99.4 
5 99.3 
Ezetimibe 
6 98.9 
99.2 0.21 0.21 0.22 
1 98.7 
2 98.9 
3 101.0 
4 98.9 
5 99.3 
Atorvastatin 
6 98.6 
99.2 0.90 0.91 0.94 
1 98.8 
2 99.3 
3 99.1 
4 99.3 
5 99.3 
Fenofibrate 
6 98.9 
99.1 0.22 0.22 0.23 
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Chromatogram of blank preparation of method precision study: 
Minutes
0 5 10 15 20 25 30 35
m
A
U
0
250
500
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1000
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Chromatogram of standard preparation of method precision study: 
Minutes
0 5 10 15 20 25 30 35
m
A
U
0
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Prototype chromatogram of test preparation of method precision study: 
Minutes
0 5 10 15 20 25 30 35
m
A
U
0
250
500
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1000
1250
E
ze
tim
ib
e
A
to
rv
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ta
tin
Fe
no
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ra
te
 
 
Acceptance criteria: 
%RSD of six replicate sets of method precision study for each analyte should be 
less than 2.0 
 
Results: 
%RSD of six replicate sets of method precision study is 0.21 for Ezetimibe,  0.91 
for Atorvastatin and 0.21 for Fenofibrate. 
 
Conclusion: 
All the results are well with-in the acceptance criteria. Hence, the analytical 
method is found precise. 
 
5.6.5 System suitability study: 
A system suitability test for the chromatographic system was performed 
before each validation parameter. Five replicate injections of standard preparation 
were injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
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Table 5: Summary for System suitability of method precision 
 
 
Acceptance criteria: 
1) % RSD for replicate standard preparation should be less than 2.0 % for each 
analyte peak. 
2) Asymmetry of the each analyte peak should be less than 2.0 in standard 
preparation. 
3) Theoretical plates of the each analyte peak should be more than 4000 in 
standard preparation. 
4) Resolution of between the peaks of Ezetimibe and Atorvastatin should be 
more than 1.5 in standard preparation. 
 
Result: 
1) RSD of peak area of five replicate standard preparations is found less than 2.0 
% for each analyte peak. 
2) Theoretical plates of each analyte peak is found more than 4000 in standard 
preparation. 
3) Asymmetry of the each analyte peak is found less than 2.0 for standard 
preparation. 
4) Resolution of between the peaks of Ezetimibe and Atorvastatin is found more 
than 1.5 for standard preparation. 
System suitability 
parameters (In-house limit) 
% RSDa   
(NMTb 2.0) 
Theoretical 
plates  
(NLTc 4000) 
Asymmetry   
(NMTb 2.0) 
Resolution 
(NLTc 1.5) 
     
Method Precision      
     Ezetimibe 0.49 5831 1.31 -- 
     Atorvastatin 0.78 7118 1.22 2.41 
     Fenofibrate 0.51 19648 1.19 43.48 
 
ªRelative standard deviation       
bNot more than 
cNot less than 
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Conclusion: 
System suitability was found satisfactory during method precision. Hence, system 
is suitable for the same. 
 
5.6.6 Reporting of deviation 
The entire precision activity was performed in accordance with the 
acceptance criteria and no deviation was observed. 
 
5.6.7 Discussion and conclusion 
The observation and result obtained for precision and system suitability 
lies well with-in the acceptance criteria. Since, all the results are with-in the limit, 
the developed analytical method is considered as precise for assay quantification. 
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6.0 Conclusion 
  
The analytical methods are successfully developed and validated for assay 
and content uniformity quantification of Ezetimibe from its pharmaceutical 
dosage form. Further, analytical methods are developed for the assay 
quantification of Ezetimibe from its combined pharmaceutical dosage form with 
Statins and Fibrate. The aim of work is full-fill according to its objective with pre-
defined acceptance criteria.  
 
The developed method for dosage form of Ezetimibe can also use for 
dissolution determination of drug by deliberate fine tune. The developed methods 
for combination dosage forms of Ezetimibe can also use for content uniformity 
and  dissolution determination of drugs for the same by deliberate fine tune. 
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